MUC1 polymorphism in relation to susceptibility to  Helicobacter pylori gastritis. by Santos Teixeira, A.S.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Year "^© crb  Name of Author
V A v  S
COPYRIGHT
This  is a thesis  accepted for a  Higher Degree of the  University of London.  It is  an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I  recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from  it or information derived from it may be published without the 
prior written consent of the author.
LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to  approved  libraries  within  the  United  Kingdom,  for  consultation  solely  on  the 
premises  of  those  libraries.  Application  should  be  made  to:  Inter-Library  Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from  the  Senate  House  Library.  Enquiries  should  be  addressed  to the 
Theses Section  of the  Library.  Regulations concerning  reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before  1962.  Permission granted only upon the prior written  consent of the
author.  (The Senate House Library will provide addresses where possible).
B.  1962- 1974.  In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C.  1975 - 1988.  Most theses may be copied  upon  completion  of a Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
This copy has been deposited in the Library of
□
This copy has  been  deposited  in the Senate  House  Library,  Senate  House, 
Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor\Local SettingsYTemporary Internet Files\OLK8\Copyright - thesis (2).doc iMUC1 polymorphism in relation to susceptibility to Helicobacter pylori gastritis
by
Ana Sofia Santos Teixeira
Submitted for the degree of Doctor of Philosophy
University College London 
September 2005
The Galton Laboratory 
Wolfson House 
4 Stephenson Way 
London NW1 2HEUMI Number: U592491
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592491
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346Esta tese e dedicada aos meus pais, Maria Teresa e Ramiro,
por todo o carinho e apoio incondicional que me deram durante estes quatro anos, 
mesmo estando a milhares de kildmetros de distancia.
Muito, muito obrigada... por tudo.
2Abstract
The gene MUC1 encodes a transmembrane mucin glycoprotein that is expressed on 
the apical surface of most epithelia and is aberrantly expressed in cancer.  MUC1  contains 
an  extended  domain  of tandemly repeated  (TR)  amino-acid  sequence,  which  acts  as  the 
backbone  for  a  large  amount  of O-linked  glycosylation,  and  which  varies  in  length  and 
sequence in different alleles. Previous studies on MUC1 tandem repeat variation in patients 
with  gastritis  (Vinall  et  al,  2002)  and  gastric  cancer  (Carvalho  et  al,  1997)  showed  an 
overrepresentation of short TR alleles in  the patient groups  when compared with normal 
controls. The major aim of this thesis is to pursue this observation further.
MUC1 allele and three locus haplotype frequencies were compared in 3 populations 
of different ancestry, from UK, Nigeria and Portugal, which show dramatic differences in 
gastric  disease  incidence;  in  patients  with  gastric  disease,  patients  with  other 
gastrointestinal disease; as well as associated controls. There were differences between the 
Nigerians and unselected European control groups, but there was no significant difference 
between the groups collected in London and Porto. Analysis of the gastric disease groups 
showed an o ver-representation o f a particular MUC1 haplotype.  A search was made, by 
sequencing  and  using  a  bioinformatics  approach,  for  additional  polymorphic  markers 
within and  surrounding the MUC1  gene,  that might act  as  convenient markers  for future 
disease association studies.  Patterns of Linkage Disequilibrium were established across a 
600Kb genomic region containing MUC1  using information in the HapMap resource and 
this information was used to assist in the selection of the single nucleotide polymorphisms 
(SNPs) within a 70Kb region to test on disease groups.
During the course of this thesis work, a second UK cohort of patients and controls 
was  collected  and  characterised  and  a replication  study attempted.  DNA  samples  from  a 
total  of 154 Northern  Europeans classified as H. pylori gastritis (n=33),  former H. pylori 
gastritis  (n=44),  No  H.  pylori  gastritis  (n=18)  and  normal  (n=59).  Examination  of the 
MUCl  polymorphisms failed to show over-representation, in the H.  pylori gastritis group, 
of t he s ame h aplotype found i n t he first g astritis c ohort. T he e xtended  70Kb h aplotypes 
showed  the  expected  association  in  the  first  cohort  but  no  significant  differences  in  the 
second cohort.  However,  in the population overall,  it was noteworthy that there is a very 
high  frequency haplogroup  containing long tandem repeat  arrays  and this  was  somewhat 
lower in frequency in both H. pylori gastritis groups.
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INTRODUCTIONThis thesis is concerned with a study of the variation of membrane associated 
mucin  MUCl  in  relation  to  gastric  disease.  This  introduction  gives  a  brief 
background  to  mucins,  a  more  detailed  account  of MUCl,  as  well  as  describing 
gastric disease, Helicobacter pylori, gastric disease risk.
1.1  Mucins
Mucins  are  heavily  glycosylated  glycoproteins  in  which  carbohydrate 
accounts for more than 50% of the molecular mass (Shimizu and Yamauchi,  1982). 
Glycosylation is O-linked through the hydroxyls on serines and threonines (Gendler, 
2001; Shimizu  and  Yamauchi,  1982).  They  are  highly  heterogeneous  molecules 
which  are  major  components  of mucus  and  the  mucous  layer  on  the  surface  of 
epithelia.  They are encoded by multiple genes which have been given the symbol 
MUC,  though  they  are  not  necessarily  closely  related.  The  major  secreted  gel 
forming mucins are encoded by a gene family located on chromosome  11, and there 
is a second family of genes that encodes mucins with a membrane anchor, which is 
located on chromosome 7 (MUC3A, MUC3B, MUCl 1/12 and MUC20).  However 
most of the other genes (including MUCl) do not show close sequence similarity to 
any other gene in the genome.  Mucins do however have some features in common. 
They contain large domains rich in serine and threonine which form the backbone for 
the  O-glycosylation  and  these  domains  usually  contain  repetitive  sequence. 
Variation  in  the  length  and  sequence  of these  repeat  arrays  has  come  to  be  the 
hallmark of mammalian mucins (Fowler et al., 2001;Gross et al., 1992;Nguyen et al., 
1990;Pigny et al., 1995;Swallow et al., 1987a;Vinall etal., 1998).
Mucins play a major role in protection of epithelial surfaces.  The secreted 
mucins are vital to the clearance of particulate matter from the airways; they act as 
lubricants; they protect against extreme acidity in the stomach, and they interact with 
bacteria.  Many  bacterial/carbohydrate  interactions  have  been  described,  and  the 
bacteria  which  colonise  the  mucous  layer  use  mucus  as  food  (Bry  et  al., 
1996;Roussel et al., 1988). They also play many roles at the epithelial surface, as will 
be  evident  from  the  more  detailed  description  of MUCl  below.  The  membrane 
mucins  for example play a role in signalling and the cytoplasmic domains interact 
with other proteins.
181.2  MUCl
1.2.1  MUCl from a historical perspective
MUCl  was the  first gene to be described that encodes one of this class of 
glycoproteins involved in the protection and lubrication of human mucosal surfaces. 
For  that  reason,  a  very  large  amount  of literature  is  available  in  relation  to  this 
particular gene and protein, yet there are a lot of unanswered questions.
In 1  982, Cartron et al (Cartron et al., 1  982),  in an attempt to describe the 
human  urine  components  that  carry  particular blood  group  antigens,  described  a 
glycoprotein of apparent Mr 340,000 that exhibited the red cell Sda antigen. It had a 
typical composition of a mucin, with low contents of cysteine and methionine and 
high content of serine, threonine, alanine and proline. In addition, the carbohydrate 
component did not show detectable amounts of mannose or fucose,  ruling out the 
possibility  of  this  being  the  Tamm-Horsfall  (T-H)  glycoprotein,  a  known 
glycoprotein that was a candidate at the beginning of the study.
The MUCl  polymorphism was described for the first time in  1983  as a family of 
glycoconjugates present not only in urine, but also in kidney and lung (Karlsson et 
al., 1983). These glycoconjugates were called PUM, ‘peanut-reactive urinary mucin’, 
given that they were first found in human urine samples and were able to bind peanut 
agglutinin, which was being used as a way of detecting glycoconjugates. The PUM 
molecules  had  different  mobilities  in  polyacrylamide  gels  in  urine  samples  from 
different individuals. Four codominant alleles were found, and the authors predicted 
that this was a genetically determined polymorphism encoded by an autosomal gene 
locus.
In  parallel  with  this,  several  different  authors  were  characterising  monoclonal 
antibodies  that,  in  the  context  of  their  studies  on  cancer,  might  be  useful 
diagnostically. These antibodies were raised against several tissues and body fluids, 
including breast cancer cell lines, human milk fat globule membrane (HMFG) and 
cervical carcinoma cell  lines.  It was quickly realised that most of these antibodies 
could  recognise  a  milk  glycoprotein  or  a  urinary  protein  (Ashall  et  al.,
191982;Bramwell et al., 1983;Bramwell et al., 1985;Burchell et al., 1983;Hilkens et al., 
1984;Kufe et al., 1984;Price et al., 1986;Taylor-Papadimitriou et al., 1981).
The recognition that this protein was encoded by the same gene as PUM came from 
Swallow  and  collaborators,  when  testing  several  of  the  monoclonal  antibodies 
available (Swallow et al.,  1986). In addition to the genetically determined variation, 
the authors found at least 3 distinct components of the different allelic forms of the 
glycoprotein  in  the  urine,  which  were  preferentially  detected  with  different 
agglutinins.  This  was  a  reflection  of  the  sialic  acid  content  of  the  different 
constituents, which altered the affinity to the lectins. Also, one antibody was shown 
to bind preferentially to more sialylated products (Ashall et al.,  1982), whereas the 
other  antibodies  bound  both  sialylated  and  desialylated  forms,  yet  showing 
differences  in  the  binding  affinities  (Bramwell  et  al.,  1983;Bramwell  et  al., 
1985;Burchell etal., 1983;Taylor-Papadimitriou etal., 1981).
The PUM  glycoprotein was also found to be present in other body fluids, such as 
milk,  as  well  as  in  several  epithelia and  in particular tumours  of epithelial  origin 
(Burchell  et  al.,  1983;Girling  et  al.,  1989;Griffiths  et  al.,  1988b;Griffiths  et  al., 
1988a;Karlsson et al., 1983).
The discovery that all the antigens recognised by the various antibodies were 
in  fact  all  variants  of the  same  protein,  and  that  at  least  some  of the  antibodies 
recognised a protein epitope, allowed Gendler et al (Gendler et al.,  1987;Gendler et 
al.,  1990)  to  use  an  antibody  to  obtain  cDNAs  from  an  expression  library  and 
consequently to obtain information on the DNA sequence and deduced amino acid 
composition.
Using  the  same  cDNA  clone  and  the  DNA  sequence  information,  the  PUM 
variability  was  established  to  be  a  genomic  polymorphism  (Swallow  et  al., 
1987a;Gendler et al., 1987) which could be detected using restriction fragment length 
polymorphism (RFLP) assay. Using the restriction endonuclease EcoRI, the authors 
found high variability between the DNA samples studied, with alleles ranging from 7 
to 12 Kb inherited in the family in a Mendelian fashion. This genomic polymorphism 
also  showed  correlation  with  the  mobility  (apparent  size)  differences  observed 
previously in the protein (Karlsson et al.,  1983).  Swallow et al also used the HinjI 
restriction endonuclease that cuts smaller fragments,  from 3  to 7 kb, displaying an 
even larger number of alleles, but with the same relative differences in size. This led 
them to suggest that the PUM locus had a tandem repeat area that showed a different
20size in different individuals due to variation in the number of repeats.  In the same 
year, this gene locus was assigned to the long arm of chromosome 1, more precisely 
in the region lq21 (Middleton-Price et al., 1988;Swallow et al., 1987b).
1.2.2  Constitution of MUCl: gene and protein
Several independent laboratories attempted to clone this gene, with several 
authors reporting partial or entire cDNA sequences (Gendler et al., 1987;Gendler et 
al.,  1990;Hareuveni et al.,  1990;Lan et al.,  1990;Siddiqui et al.,  1988;Wreschner et 
al.,  1990). The comprehensive MUCl gene structure and most of its gene sequence 
was  shown for the first time by Lancaster and colleagues (Lancaster et al.,  1990). 
MUCl is composed of 7 exons, spanning from 5 and 11 kb, depending on the tandem 
repeat size (between 20 and 125 repeats).
1.2.2.1  MUCl promoter and regulation of transcription
All  the  functional  elements  of  the  promoter  of MUCl  so  far  described  are 
localised in the small intergenic region that extends for less than 3kb upstream from 
the beginning of the gene (Sequence accession number: X69118). At position -2663 
from MUCl  transcription start site (TSS) is the polyadenylation signal (CATAAA) 
for the adjacent gene upstream, Thrombospondin 3 (THBS3).
In  1999,  a  group  of researchers  made  an  extensive  description  of potential 
binding sites and respective transcription factors found in a fragment of about 800bp 
immediately upstream MUCl using computational methods (Zaretsky et al.,  1999). 
Cis-elements  of  several  types  were  identified  in  this  sequence,  and  included 
ubiquitous  cis-transcription elements, as well as ones that are present in particular 
cell types,  such as mammary epithelial cells, haematopoietic cells, immunospecific 
cells, hepatocytes, muscle cells and even elements specific for viral promoters. From 
this wide variety, only a few elements have been studied and reported as functional 
in transcription of MUCl.
Experimentally, two DNAse I hypersensitive sites were identified in the promoter 
region. The one at -750bp from the beginning of the gene does not seem to correlate 
with MUCl  expression and is not tissue  specific, whereas the other, at -250bp,  is 
present  only  in  MUCl  expressing  tissues  and  correlates  with  the  transcriptional
21activity of the gene (Shiraga et al., 2002). Also, a 743bp fragment in the 3'-region of 
the promoter was shown to induce full expression of a reporter gene (Kovarik et al., 
1993).
The MUCl promoter has a TATA box 25 nucleotides upstream the transcription 
start site (TSS).  In MUCl, both gene and promoter region are very GC rich.  That 
high level of GC in the promoter accounts for the numerous GC boxes found, some 
of which act as cis-elements involved in the transcription of MUCL Two of these are 
known  to  be  functional  Spl  binding  sites  (“consensus”  binding  sequence: 
GGGCGG), one located at -99/-90 from the TSS  and the other much farther, at - 
5161-561  (Kovarik  et  al.,  1993;Kovarik  et  al.,  1996;Morris  and  Taylor- 
Papadimitriou, 2001). The -576A567 cis-element binds the Spl  transcription factor 
forming  a  complex  that  is  functional  in activating  the  transcription  of MUCl  in 
breast cancer cells. The other GC box at position -99/-90 also binds Spl, activating 
transcription  in  MUCl  expressing  cells,  but  the  way  in  which  this  element  is 
involved is rather more complex. Because of the AG nucleotides 5' to this Spl  site, 
this s equence  is a Iso a s ite for attachment of another D NA binding protein,  SpA, 
which by competing with Spl for binding, acts as a repressor of MUCl transcription. 
Interestingly, w hen i nactivating m utations a re i ntroduced i n t he sequence f or both 
Spl  and SpA, and consequently the binding of both is abolished, the non-expressing 
cells  show a dramatic increase in expression of the reporter gene (Kovarik etal., 
1996).
In  this  region  of the  promoter,  there  are  also  three  purine/pyrimidine  mirror 
repeat  elements  (M-PMR),  M-PMR1  (-641/-615),  M-PMR2  (-253A237)  and  M- 
PMR3(-133/-102). However, until now, no functional role was detected in M-PMR1 
and  M-PMR2,  despite  the  co-localisation  of the  later  with  one  of the  DNAse  I 
hypersensitive  sites  described  previously.  Conversely,  The  M-PMR3  element, 
localised just before the SpA binding site (-101/-90), seems to act as a repressor of 
transcription,  since deletion of this sequence results  in increased expression of the 
reporter gene in all cell types. When active, most probably when it is in the single 
stranded  state,  it  intervenes  in  the  binding  occurring  at  the  -101/-90  sequence, 
favouring SpA binding to the sequence as opposed to Spl.
Another cis-element in the MUCl promoter that seems to have a role in tissue- 
specific  transcription regulation is the sequence  fragment positioned at -84/-72.  It 
contains  two  copies  of the  consensus  E-box  sequence  (CANNTG)  that  together
22constitute  the  E-MUC1  enhancer  element.  Mutation  of  this  sequence,  which 
abolishes the binding of the transcription factor, leads to increased expression in non­
expressing c ells and reduced expression in epithelial  cells. Also, when this  site is 
mutated simultaneously with the proximal Spl  site, the non-expressing cells show a 
12-fold increase  in expression (Kovarik et al.,  1996),  indicating the presence of a 
synergistic  interaction between these  two  cis-elements  in  the  regulation of tissue- 
specific transcription. In this case, the induced transcription may be due to activation 
of the  distal  Spl  site,  together  with  other  elements,  possibly  another GC  box  at 
position -57/-44.
After  Ko  varik  and  collaborators  established  this  Spl-based  transcription 
mechanism  (Kovarik  et  al.,  1996),  another  group  of  investigators  aimed  to 
investigate  whether  this  mechanism  which  has  been  shown  to  be  functional  by 
reporter gene assays was also functional with the MUCl gene itself (Zaretsky et al., 
1999).  Using  mouse  DA3  cells  (mouse  mammary  epithelial  cells)  transiently 
transfected  with  human MUCl  and  the  743bp  of promoter  sequence,  the  authors 
demonstrated that human MUC1   protein was being produced in these cells, using a 
monoclonal antibody (mAb) specific for the MUC 1  protein isoforms containing the 
tandem repeat.  In the T47D breast carcinoma cell lines Zaretsky and collaborators 
found  using  RNase-protection  assay  three  new  transcription  start  sites  (TSSs) 
together with the major start site, all within a 70bp fragment from the first site. These 
cells have TGFp-receptors, and the fragment analysed contains two TGFp elements, 
the authors reported that treating these cells with TGFpl  lead to activation of two 
further TSSs (Zaretsky et al.,  1999). Indeed, deletion constructs of the 743bp MUCl 
promoter region in a reporter gene, demonstrated that according to the cell line used, 
this  fragment  has  promoter  function  in  the  3'  and  5'-parts  suggesting  a  dual 
promoter,  and  the  possibility  that  MUCl  transcription  may  occur  from  different 
transcription start sites. This could mean that these different TSSs found, and perhaps 
others  still  to  be  found,  can  be  used  alternatively  according  to  tissue-type  and 
transcription factors involved.
231.2.2.2  Gene
Exon 1, which is 126bp long, contains a 72bp of 5-untranslated region, followed 
by  the  ATG  initiation codon.  The ATG  area in MUCl-  CCACCATGA is  almost 
homologous to the Kozak consensus sequence- ACCATGG, the published sequence 
proved to be responsible for effective translation of DNA  sequences in eukaryotic 
cells (Kozak,  1987a;Kozak, 1987b).
Exon 2  is the largest and the most variable exon of the gene. Not only does it 
comprise  the  tandem repeat domain,  that accounts  for the  majority of the protein 
backbone, but can it vary in length by 27 nucleotides at the 5' end, due to a splicing 
event.  The  27  nucleotides  in  the  elongated  sequence  are  acquired  by  translating 
sequence that originally belonged to intron 1. This alternative splice event is thought, 
on  the  basis  of  association  in  15  samples,  to  be  due  to  a  single  nucleotide 
polymorphism (SNP), A to G transition, occurring 8 nucleotides after the beginning 
of exon 2 (Ligtenberg et al., 1991).  According to the authors, the nucleotide present 
in that position, A or G, determines the spliceoform. This conclusion is supported by 
the recent findings of Wendy Ng in the group.
The major source of variation in exon 2 is the tandem repeat domain, which is 
composed of a variable number of tandem repeats (VNTR) of 60 nucleotides each. 
The number of repeats is very variable, ranging from about 20 to  125 repeat units, 
and  displaying  a  bimodal  allele  length  distribution,  with  the  two  most  common 
alleles having approximately 40 and 80 repeat units. The repeat units also vary in 
sequence as will be discussed in detail later (Fowler et al., 2003).
The  region  that  follows,  between  intron  2  and  exon  6,  is  composed  of small 
exons intercalated with small introns, all no longer than 150 nucleotides long. Within 
this region, no sequence variability is known to date, though some reports describe 
some MUCl  protein iso forms that splice in this area (Baruch et al., 1999;Wreschner 
et al.,  1990).  This region, though not very big,  is also extremely important for the 
mature  form of the protein.  Part of exon 5  sequence codes  for the transmembrane 
domain of the protein, while exon 6 and part of exon 7 code for the cytoplasmic tail.
Between exon 6 and 7, lies a very big intron, about  1017 nucleotides long, 
that also contains a CA microsatellite that can have from 11 to 14 repeats (Pratt et al., 
1996). Exon 7, 378bp long, contains the final 72 translated nucleotides, followed by 
a  TAG  stop  codon  and  a  303bp  of  3-untranslated  region  (UTR)  with  a  single 
AATAAA polyadenylation signal.
24Figure 1.1: Schematic representation of MUCl  gene (AX mRNA (B) and mature glycosylated protein (C). (A) 
The gene has the 7 exons represented at scale, with the two UTR in diagonal stripes boxes and the TR domain in 
pale grey in exon 2. (B) MUCl mRNA with the TR domain in grey, TM domain coloured in dark lilac and the 
CT  in  paler  lilac.  The  same  colours  are  used  for  the  TM  and  CT  domains  of the  protein  (C),  and  the 
glycosylation in the EC domain  is shown as lilac circles.
1.2.23 MUCl Protein
MUC 1  protein is fairly ubiquitously expressed in epithelial cells. It is present 
at high levels in the gastro-intestinal tract, (particularly the stomach, but much less in 
the colon), respiratory tract and female reproductive tract. Being a transmembrane 
protein, MUCl  usually localises in the apical surfaces of the epithelial cells, in the 
interface between the organism and the extracellular environment.
The MUCl  protein sequence was deduced from several cDNA clones that 
were made available in the early 90’s. The first cDNA clone and respective protein 
sequence was published by Gendler et al (Gendler et al., 1990) showing a 474 amino 
acids  sequence  with  only  one  repeat  from  the  tandem  repeat  array  represented. 
Sequences  showing high  degree of identity  with this  sequence were published at 
about the same time (Lan et al., 1990;Ligtenberg et al., 1990;Wreschner et al., 1990),confirming the sequence of the non TR parts of the molecule. This original sequence 
constitutes the most commonly found form of the protein, and is made of translated 
sequence from the 7 exons, producing a final product that has the 3 components of 
the transmembrane mucin: the extracellular domain, that includes the tandem repeat 
region, the transmembrane domain and the cytoplasmic tail (see figure  1.1). Before 
reaching the cell surface, the protein is proteolytically cleaved in the area coded by 
exon 4 and undergoes subsequent reannealing forming heterodimers (Ligtenberg et 
al.,  1992).  Also, before the mature protein reaches the apical surface of the cell, it 
goes  through  a  process  of glycosylation  occurring  in  the  Golgi  apparatus,  where 
chains of carbohydrates O-link to threonine or serine in the protein backbone. The 
final product, the mature protein, is usually heavily glycosylated.
1.2.2.3.1  Protein sequence present in the databases
Despite the knowledge on the protein sequence of MUCl, no actual sequence 
was obtained from protein sequencing. Instead, all sequences available and published 
come  from  translation  of mRNA  fragments  obtained.  Nevertheless,  a  consensus 
sequence  for  MUCl  protein  is  available  at  http://us.exDasv.org/sDrot/  (Protein 
accession  number:  PI5941).  According  to  the  information  available  in  the  web- 
resources, MUCl  protein is made up of 1255 amino acids.  This sequence contains 
42 repeat units.
1.2.3  MUCl processing
1.2.3.1  Glycosylation and Biosynthesis
As mentioned at the beginning of the chapter, mucins are glycoproteins with 
a very high molecular weight. This high molecular weight is partly due to the heavy 
glycosylation  associated with the protein backbone.  The  glycosylation  of proteins 
occurs by attachment of the monosaccharide chains to specific amino acid residues. 
According to the type of link two different types of glycosylation can occur: N- type 
or O- type, the latter being the most common in mucins.
O-glycosylation adds carbohydrate side chains to the hydroxyl groups of the 
amino acids serine and threonine and initiates through the addition of galactosamine. 
Indeed  because  of the  TR  array,  which  constitutes  more  than half of the  protein
26backbone, according to allele length, serine and threonine residues that account for 
some 25% or more of the amino acid content of the protein.
N-glycans  in  general  constitute  a  small  portion  of the  total  carbohydrate 
chains  present  in  mucins.  N-glycosylation  initiates  on  asparagine  amino  acid 
residues, requiring the amino acid motif Asn-X-Ser/Thr to occur. The inner core is 
constituted by two GlcNAc residues followed by 3 mannose residues. This inner core 
can subsequently elongate to make diverse forms.
The  processing  of  the  MUCl  mucins  starts  shortly  after  the  initiation  of 
translation.
According  to  the  results  of Hilkens  et  al  (Hilkens  and  Buijs,  1988),  this 
oligomannose  glycan  addition  (N-glycosylation)  occurs  1   minute  after  the 
biosynthesis of the protein, within the endoplasmic reticulum (ER). O-glycosylation 
occurs  in  the  Golgi  apparatus,  after  the  proteolytic  cleavage,  and  mucins  are 
processed  through  the  cis,  midi  and  trans  Golgi,  acquiring  in  the  process  more 
complex and branched glycosylation (Figure  1.2) (Hanisch et al.,  1996;Hilkens and 
Buijs,  1988;Litvinov  and  Hilkens,  1993).  Figure  1.3  shows  the  5  potential 
glycosylation sites per repeat marked circles. The glycosylation of each repeat and of 
the e ntire repeat array i s tissue specific and i s dramatically changed i n n eoplasias 
(Burchell et al.,  2001;Hanisch et al., 1  996;Hanisch and Muller, 2000;Lloyd  et al., 
1996;Reis et al., 1998).
The N-glycans are likely to be in the extracellular domain, C-terminal to the 
tandem repeat array, where 5 potential N-glycosylation sites (Asp-X-Ser/Thr) can be 
observed (Ligtenberg et al., 1990).
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Figure  1.2: Schematic representation of MUCl  biosynthesis from the initial precursor protein backbone to the 
fully glycosylated mature protein.
281.2.3.2  MUCl Interactions and function roles
The full length mature MUCl  protein comprises an extracellular domain, a 
transmembrane  domain and  a cytoplasmic  tail.  The presence  of a  transmembrane 
domain makes this mucin a potential signal transmitter, transmitting messages from 
the extracellular (EC) environment into the cell. The cytoplasmic tail (CT) comprises 
74 amino acids (http://www.ncbi.nlm.nih.gov/ Protein Accession Number PI5941), 
which include 7 tyrosine residues, which are potential phosphorylation sites, and also 
contains  areas in the sequence  that are putative binding  sites for other molecules. 
There is reasonable evidence that about 4 of them can be phosphorylated, though not 
all  authors  agree  which  ones.  Recently,  Wang  and  colleagues  reported 
phosphorylation of Y1203, Y1212, Y1229 and Y1243 (Wang et al., 2003), while Zrihan- 
Licht and colleagues(Zrihan-Licht et al.,  1994a), using a human breast cancer cell 
line, had previously found evidence of phosphorylation in Y1229 and Y1243 and Y1218.
In  spite  of  this,  researchers  believe  MUCl  does  not  undergo  auto- 
phosphorylation(Zrihan-Licht  et  al.,  1994a).  It  has  recently  been  suggested  that 
proteolytic  cleavage  of  the  EC  domain  of  MUCl  contributes  to  the  CT 
phosphorylation (Baruch et al., 1999;Zrihan-Licht et al., 1994a). Proteolytic cleavage 
of MUCl  during processing was first reported by Hilkens et al (Hilkens and Buijs, 
1988) who observed MUCl precursors of much  smaller apparent size than the newly 
synthesised glycoprotein, Mr 250000 and 350000, instead of Mr 45000 and 650000. 
They hypothesised that this was due to a proteolytic cleavage event that occurs in the 
endoplasmic  reticulum  (ER),  and  they  were  able  to  narrow  down  the  region  of 
proteolytic cleavage to an 18 amino acid sequence in upstream of the transmembrane 
anchor  (see  below)  (IKFRPGSVWQLTLAFRE).  Because  two  bands  very  close 
together were observed in the immunoprecipitation assay,  it could not be ruled out 
that there were in fact two  instead of one proteolytic cleavage site.  However,  this 
second cleavage site was never confirmed in subsequent reports. Also, they observed 
in in vivo and in vitro experiments that the cleaved subunits could form a complex, 
possibly  by  the  annealing  of  the  C-terminal  and  N-terminal  domains,  i.e. 
heterodimers.  The  cleavage  site  was  finally  narrowed  to  a  precise  position: 
FRPGi 097/S 1098VW , 65 amino acids upstream the transmembrane domain (Parry et 
al., 2001).  Parry et al could not observe a second proteolytic cleavage site in their 
experiments.  Using  a  cell  line  transfected with a  construct of MUCl  lacking  the 
tandem repeat domain, they observed that the proteolytic cleavage also occurred at
29the same position, showing that the TR domain was not essential for proteolysis. It 
was  then  established  that  this  mechanism  of  cleavage  occurs  on  the  fully 
glycosylated MUCl, possibily still in the endoplasmic reticulum.
This  proteolytic  cleavage  site  is  located  in a region of MUCl  EC  domain 
downstream o f the TR in a domain k nown as the  SEA module (Bork and P atthy, 
1995;Wreschner  et  al.,  2002).  SEA  modules  usually  occur  in  membrane  docked 
proteins that undergo extensive post-translation modifications, in particular O-linked 
glycosylation.  Also,  the preservation of the structural fold of the  SEA sequence is 
crucial.  These  sequence  domains  contain  some  highly  conserved  motifs  across 
proteins and across species, in particular the GVSSS cleavage site.
Two other small sequence fragments are highly important in this module: one in 
the sequence Y1065YQEL, the other in the sequence LiossED, 39 and 32 amino acids 
upstream  the  cleavage  site,  respectively.  Without the presence  of at  least these  3 
pieces of sequence, the proteolytic cleavage does not occur.
Yet,  once  the  proteolytic  cleavage  occurs  inside  the  cell,  the  two  subunits 
reassociate subsequently and form heterodimers in the cell membrane. The authors 
speculate  that  these  “off’  and  “on”  reactions,  cleavage  and  reannealing,  lead  to 
conformational changes in the membrane associated unit, recruiting tyrosine kinases 
and  serine/threonine  kinases  that  will  phosphorylate  the  CT  domain,  this  way 
initiating a signalling cascade.
Evidently other factors must be involved in the signalling process, in particular 
bacterial adhesins with affinity to the MUCl ligands. It has been shown in a hamster 
tranfection model that Pseudomonas aeruginosa flagellin protein acts as an adhesin 
with  the  ability  to  regulate  phosphorylation  of  serine  and  tyrosine  amino  acid 
residues  of  the  Mucl  cytoplasmic  tail  (Lillehoj  et  al.,  2001;Lillehoj  et  al., 
2002;Lillehoj  et al., 2004). These phosphorylation/dephosphorylation events lead to 
a  signalling  cascade  Grb2-Sos-Ras-MEKl/2-ERKl/2,  initiating  an  inflammatory 
response.  Interestingly,  there  is  also  evidence  that  MUC 1   interacts  with  the 
bacterium Helicobacter pylori in the human gastric mucosa via the BabA adhesin 
(Linden et al., 2004). H. pylori binds to MUC1  under neutral pH conditions. Also, 
under the same conditions, the BabA adhesin from the bacteria binds other ‘mucin­
like’ components that do not react with anti-MUCl antibody, but react with H-type-1 
ligand  structure.  The a uthors  suggest t hat the B abA adhesion to  MUC 1   could  for 
example lead to detachment of the EC domain of the protein from the cell surface
30and subsequently induce a signalling pathway over the epithelial barrier enhancing 
the inflammatory response.
Another MUC1  interaction that seems to play an important role is the one that 
takes place with p-catenin.
This molecule has different functions according to its intracellular location; it has 
an  important  role  in  cell-cell  adhesion,  linking  to  the  cell  cytoskeleton  the 
cytoplasmic  tail  of the  adhesion  molecule  E-cadherin,  but  also  as  a  transcription 
factor if present in the nucleus. The MIJC1  CT has a peptide domain that interacts 
with P-catenin (SAGNGGSSLS) (Yamamoto et al.,  1997). This interaction depends 
on various factors, including the amount of MUC 1  present in the cell, the presence of 
E-cadherin and the phosphorylation state of MUC 1   CT (Carraway et al., 2003;Li et 
al., 1998;Ren et al., 2002;Wen et al., 2003;Yamamoto et al., 1997). Different kinases 
that  phophorylate  different  CT  amino  acids  may  have  either  an  enhancing  or 
inhibitory  effect  on  the  MUC1-  p-catenin  interaction  (Li  et  al.,  1998;Ren  et  al.,
2002). As a consequence of this complex formation, E-cadherin is no longer able to 
bind  p-catenin,  compromising  in  this  way  the  cell-cell  adhesion  mechanism.  In 
experiments in a cancer cell line, where MUC1  is not polarised, it has been shown 
that MUC1 can inhibit E-cadherin adhesion properties in a length dependent manner 
(Wesseling et al.,  1996).  Long MUC1  molecules inhibit adhesion by simple steric 
hindrance, while small MUC1  molecules only inhibit when sialylated which causes 
charge repulsion between cells.
If this MUC1  CT- P-catenin interaction occurs in the nucleus, this coupling will 
help to stabilise p-catenin and prevent its degradation by the APC protein, p-catenin 
accumulation  in  the  nucleus  will  therefore  result  in  activation  of  its  role  as 
transcription factor (Wen et al., 2003). MUC1 can in this way be seen as a modulator 
of nuclear activity of p-catenin.
311.2.4  MUC1 hypervariability:
In addition to variability of tandem repeat number and in contrast to the early 
view that most of the tandem repeats were identical in sequence it is now known that 
there  is  considerable  variability  from  repeat  unit  to  repeat  unit  and  that  these 
nucleotide  changes  also  differ  across  the  array  in  different  alleles  (Figure  1.3) 
(Engelmann  et  al.,  2001;Fowler  et  al.,  2003;Muller  et  al.,  1999;Siddiqui  et  al., 
1988;Wreschner et al.,  1990). Curiously a high proportion of the nucleotide changes 
lead to amino-acid changes.
The only well characterised single nucleotide polymorphism is the g/a SNP 
(G3506A,  with accession number rs4072037)  at the  beginning  of exon 2  that  is 
mentioned above.  As well as its relevance to splicing studies to show that this SNP 
is  tightly  associated  with  a microsatellite  polymorphism  in  intron  6  of the  gene 
provide  the  important  and  initially  unexpected  evidence  that  the  TR  variability 
cannot have been generated by unequal crossing over at meiosis, but is more likely to 
have been generated by non reciprocal exchanges (Pratt et al., 1996).
Consensus repeat acc  gee cec  cca  gee cac ggt gtc  acc  teg  gee ccg  gac  acc  agg  ccg gcc  ccg  ggc  tcc
Amino-acid ©   A P  P  A H G v   (t Xs) a P  D  (T )  R  P A  P  G (D
geg gc* gtg cgt ecc  tec g*g  *gc ccc
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Q
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Figure 13: Nucleotide and amino acid ‘consensus’  sequences of the MUC1  TR domain and reported changes. 
The  amino  acids  enclosed  in  circles  represent  the  5  potential  glycosylation  sites  of the  TR;  the  nucleotide 
sequence changes reported so far are show below the consensus sequence, as well as the amino acids encoded by 
those changes. The highlighted aminoacids (orange) are the change that were studied in our lab, in particular the 
DT to ES change.
321.2.5  Splice variants of MUC1
Despite  the  hypervariability of the  tandem  repeat  array  of MUC1  gene,  to 
date not many polymorphisms have been identified and confirmed in other regions of 
the gene.  However MUC1  does, as indicated undergo alternative splicing, and some 
of this is apparently under genetic control.
Soon after the first MUC1  protein sequence was available, several variants of 
the original  found  in a variety of cell  lines started to be reported,  all  generated  by 
alternative splicing events.
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SEC I
Figure  1.4:  Schematic representation of MUC  I  and the several spliceoforms  reported to date,  as  reported by 
Obermair et al. A more detailed description of each spliceoform is given in section 1.6.
The variant that corresponds to the  1255 amino acid protein is called variant 
B.  Three  other  isoforms  that  are  very  similar  to  this  have  also  been  described. 
Variant A, is very similar to variant B, except for 9 extra amino acids included in the 
protein. These amino acids are coded by 27 nucleotides in the 3' end of exon 2. This 
alternative  splice event  is believed to be due to an  A to G  transition  in nucleotide 
3506 (DNA  accession  number M61170),  8  nucleotides  from  the  start of exon 2 of 
variant  B  (Ligtenberg  et  al.,  1991)  in  which  the  G  allele  is  associated  with  the 
insertion.  Variants  C  and  D,  though  submitted  directly  to  Genbank  in  1992  by 
Buluwela  and  collaborators  (Genbank  accession  numbers:  Z17324  and  Z17325), 
were  only  formally  reported  in  2001  by  Obermair  and  collaborators  in  cervical 
carcinoma cell lines (Obermair et al., 2001). The two variants, C and D, correspond 
to  deletions  of 3  and  12  amino  acids,  respectively,  from  the  start  of exon  2  in
33
1comparison with variant B. Thus there must be 4 different splice acceptor sites in this 
area of the gene. The two main variants A and B have different signal peptides and 
after cleavage by signal peptidase have different amino-terminal ends. Variant C is 
predicted to end up like B, while D loses a cleavage site (see Chapter 7, figure 7.1). 
All four forms are thought to be the same with respect to the rest of the protein.
Other  splice  variants  lacking  large  exonic  regions  were  also  observed  by 
several authors. Zrihan-Licht and collaborators were the first to report a small MUC 1  
protein with an invariable size of 1.2Kb (Zrihan-Licht et al.,  1994b). This isoform, 
called  MUC 1  AT,  is  devoid  of  the  tandem  repeat  array,  as  well  as  the  exon  2 
sequences immediately upstream and downstream the array. It was found in human 
breast  cancer  cells,  and  since  then,  other  cancer  cell  lines  and  human  epithelial 
tissues have been shown to produce the same isoform (Baruch et al.,  1997;Hartman 
et al.,  1999;Obermair et al., 2001;Oosterkamp et al.,  1997;Schut et al., 2003). Also, 
this  short MUC1  protein was  shown  to  have  cytokine  receptor properties  and to 
enhance tumorigenicity in mouse mammary epithelial cells (Baruch et al., 1997) (see 
section  1.5). A similar splice event that converts B into A variant is observed with 
the M UC1/Y  iso form generating the MUC 1/Y  alt, with 27 extra nucleotides at the 
beginning of exon 2.
Two  different  groups  described  another  iso form  similar  to  MUC 1/Y 
simultaneously  and  named  it  differently:  MUC1/X  or  MUC1/Z  (Baruch  et  al., 
1997;Oosterkamp  et al.,  1997).  This  isoform  is similar to  MUC 1/Y,  but it uses a 
different  splice  acceptor  site  within  exon  2  that  is  54  nucleotides  upstream  the 
MUC 1/Y acceptor site. This leads to the formation of an identical protein with only 
18 extra amino acids in the extracellular domain of the protein. However, despite this 
high  degree  of  similarity,  it  is  not  yet  known  whether  this  form  has  the  same 
properties for the MUC 1/Y (see below). Because the MUC1/Z name is the one found 
in subsequent publications, this is the name given to this spliceoform in Figure 1.2.
MUC1  protein can also apparently exist as a soluble form. The spliceoform 
MUC 1/SEC was reported for the first time by Wreschner et al, when characterising 
the  MUC1  cDNAs  in  human  breast  cancer  tissue  (Wreschner  et  al.,  1990).  This 
isoform contains the translated sequence corresponding to exon 1 and 2, and a unique 
sequence  of  11  extra  amino  acids  coded  by  the  first  33  nucleotides  of intron  2 
(VSIGLSFPMLP),  where  it  encounters  a  STOP  codon.  This  mRNA  extends  the 
length  of  the  rest  of  the  genomic  DNA,  without  splicing  at  the  exon/intron
34boundaries, creating an mRNA with an extremely long 3'UTR. This molecule does 
not have a transmembrane domain and a cytoplasmic tail it is thought to be released 
as a soluble form, without attaching to the cell membrane at any stage. Nonetheless, 
it has been postulated to play an important role in the mechanism of cell interaction. 
In  in  vitro  experiments MUC 1/SEC  has been shown to be able  to bind MUC 1/Y 
isoform with high affinity, and to induce phosphorylation in the cytoplasmic tail of 
MUC 1/Y (Baruch et al.,  1999).  However, how this leads to recruitment of kinases 
inside the cell to induce phosphorylation is still not understood.
1.2.6 MUC1 homologies from other mammals:
The MUC1 gene and respective protein are known to be present in a variety 
of species, at least in mammals, where several species have the gene in their genome 
and are also able to produce the corresponding protein.
Spicer and collaborators constructed alignments between the MUC1  cDNA 
and protein of cow,  rabbit, golden hamster, guinea pig, mouse, gibbon and human 
(Spicer  et  al.,  1995).  cDNA  from  the  various  species  was  obtained  by  RT-PCR. 
Clones from cDNA libraries were isolated to obtain the tandem repeat domain, which 
is particularly difficult to amplify.
The  extracellular  domain  (EC)  of MUC1  was  generally  poorly  conserved 
across species. The MUC1  tandem repeat (TR) domain in particular seems to have 
diverged widely, which is perhaps not surprising in view of the high mutation rate of 
repetitive  sequences.  While  human,  gibbon  and  bovine  MUC1  have  a  variable 
number of tandem repeats (VNTR), rabbit MUC1  seem to have a non polymorphic 
tandem repeat array, with a fixed number of repeats in all individuals, a characteristic 
previously observed in the mouse (Spicer et al., 1991). Also, the tandem repeat array 
shows a high degree of diversity in nucleotide sequence and respective amino acid 
sequence,  from repeat to repeat. Though gibbon TR seems to be very similar to the 
human consensus TR sequence, the other species show several modifications in the 
nucleotide  sequence.  Nonetheless,  MUC1  tandem  repeat  does  maintain  some 
characteristics between species: it has an average length of 20 amino acids per repeat 
and  shows a high content of Serine/Threonine and Proline amino acids which are 
potential glycosylation sites in the protein.
35The EC proximal region of the TM domain is also poorly conserved, except 
for some very specific regions. The YYQEL sequence (amino acids  1065 to  1069, 
sequence accession number: PI5941) in present in all species, and is though to be 
involved in the apical sorting of MUC 1. This corroborates work by Pemberton et al 
who  found  that  the  extracellular domain  of MUC1,  excluding  the  tandem  repeat 
domain, i s  involved i n t he a pical  sorting of the m olecule, t ogether w ith the C QC 
sequence present in the C-terminal side of the transmembrane domain (Pemberton et 
al.,  1996).  The  KDEL  amino  acid  sequence  is  also  present  in  all  the  species 
compared, and is similar to a short sequence known to be involved in the retention 
and return of resident proteins in the ER (Pelham,  1996).  The cytoplasmic tail and 
the  transmembrane  domain  of  the  MUC1  protein  represented  the  most  highly 
conserved regions (Spicer et al., 1995). In the CT, 6 out of 7 tyrosine (Y) residues as 
well  as  the  T-X-R  sequence  are  conserved  across  all  species,  indicative  of the 
importance of the these potential phosphorylation sites in the protein.
1.3  Gastric disease
1.3.1  Gastrointestinal tract- stomach
The gastrointestinal tract is in direct contact with the external environment. It is 
colonised with many different sorts of bacteria. These range from “friendly” bacteria, 
that acquired the ability to live in a symbiotic relationship with us, helping to break 
down  certain  substances  that  the  gut  is  not  able  to  do  on  its  own,  to  ones  that 
acquired the skill to survive in the most inhospitable environment possible, and still 
produce damage.
After mastication in the mouth, the stomach is the first stopping point for foods 
and  other  ingested  materials.  It  is  a  major  digestive  organ,  which  is  particularly 
exposed to external factors.
1.3.1.1  Stomach: anatomy, histology and physiology:
The stomach is a dilated part of the digestive tract that is connected with the 
oesophagus in its upper region, and with the duodenum at the other side. It is divided 
into four main regions: fundus, body, antrum and pylorus. The fundus is the region in
36the upper side of the stomach that makes contact with the oesophagus through the 
cardia; it is here that the digestive gases are collected. The body is the major part; it 
is  responsible  for the  secretion of hydrochloric  acid  and pepsinogen.  The  antrum 
extends from the body to the pyloric region, and together they constitute the area 
where most of the mucous glands can be found. Together with the lower body, the 
antrum  is  also  the  region responsible  for the  strong peristaltic  movements  during 
digestion.
Despite  the  differences  between  the  regions  of  the  stomach,  the  basic 
histology is very similar. The stomach mucosa is made-up of gastric glands that open 
into the stomach lumen through the gastric pits.  The gastric pit is mainly made of 
mucus-secretor columnar cells,  and the pit narrows  into  the  deeper glands  of the 
stomach. Usually, in the body region the gastric pits tend to be short, and the gland 
long.  On  the  other hand,  in the antrum/pylorus  region,  deeper pits  are  seen with 
shorter glands.
Each gland comprises a variety of cells playing different roles, according to 
their secretions. On the base of the gland are numerous Chief cells (or Zymogenic 
cells) that secrete pepsinogen, an inactive precursor of the proteolytic enzyme pepsin, 
that i s able  to i nitiate the break d own o f proteins d uring d igestion; t he enzyme i s 
produced in an inactive state to prevent proteolytic damage of the gastric mucosa. In 
the middle region of the gland, the neck, several cells coexist. The most numerous 
cells  in  the  neck are  the mucous neck cells  that secrete mucus  lining the surface 
epithelium.  The  parietal  cells  (or  oxyntic  cells)  secrete  hydrochloric  acid  and 
intrinsic factor; the hydrochloric acid maintains a very acidic pH in the stomach, that 
activates pepsinogen into pepsin and helps creating a hostile environment to possible 
colonisers; intrinsic factor is a glycoprotein important in the intestinal absorption of 
vitamin  B12,  which  in  it  turn  is  an  important  enzyme  cofactor  crucial  in  the 
development of erythrocytes. The neck also hosts a number of endocrine cells that 
produce  several  hormones  involved  in  in  the  digestive  process.  Of the  endocrine 
cells, the G cells are noted for the production of gastrin, a hormone that is involved 
in  digestion  by  stimulating  the  production  of hydrochloric  acid,  pepsinogen  and 
intrinsic factor, and by increasing stomach motility by inducing the distension of the 
antrum. Finally, a large number of stem cells, situated mostly in the neck and isthmus 
(upper part of the gland) serve to replace the lost cells and renovate the epithelium.
371.3.2 Mucins in the normal stomach
As mentioned before, many of the cells in the stomach epithelium produce 
mucus, a layer that lines the epithelium, lubricating and protecting it from external 
agents. The mucus is composed mostly of water, minerals and high molecular weight 
glycoproteins, in particular mucins.
The  mucins  typically  expressed  in  the  stomach  are  MUC1,MUC5AC  and 
MUC6. In the normal stomach, MUC1 is typically expressed at the apical surface of 
the cells lining the gastric mucosa (Vinall et al., 2002). MUC5AC and MUC6 are the 
secreted gel-forming mucins that actively contribute to the viscous and elastic nature 
of the mucous.  While M UC5AC  is m ainly secreted by the  surface  foveolar cells, 
MUC6  is  secreted  by  the  neck  mucus  cells  deeper  in  the  glands.  Despite  this 
difference in the localisation of the secreting cells, these two mucins are expressed 
together throughout the gastric epithelium and glands, and are the major constituents 
of the gastric mucus. On rare occasions, some MUC2, MUC3 and MUC4 may occur 
in the normal stomach, exhibiting a patchy and weak expression. These three mucins, 
together with some MUC5B, have been also observed to be expressed in the stomach 
at  early  developmental  stages,  and  subsequently  downregulated  at  a  later  stage 
during fetal life (Buisine et al., 2000).
1.3.3 Gastric disease and environmental factors involved
Gastric disease, and in particular gastric cancer, is a major burden to - human 
healthcare across the world. According to the cancer global estimates for 2002 from 
the International Agency for Research on Cancer (LARC) gastric cancer is the fourth 
most  prevalent  cancer  in  the  world,  after  lung,  breast  and  colorectal  cancers. 
However,  stomach cancer is the second most common cause of death from cancer, 
after lung cancer (Parkin et al., 2005). In Europe specifically, stomach cancer ranks 
fifth in the most common cancers and third in death rates (Boyle and Ferlay, 2005). 
This high mortality rate associated with gastric cancer is probably due to the fact that 
it tends to be diagnosed at a late stage.
Despite some controversy on the definition of types of gastric cancer,  it is 
widely accepted that it can be divided in two major types: the ‘intestinal type’, that 
accounts for about 90% of the human gastric adenocarcinomas,  and ‘diffuse type’
38(LAUREN,  1965).  While  the  diffuse  gastric  cancer  does  not  have  a  defined 
aetiology, some of the causal agents for the ‘intestinal type’ are widely known.
This  thesis  focuses  on the  study of precancerous  lesions  that occur in the 
stomach prior to intestinal type cancer, and agents that may intervene in the process. 
Helicobacter pylori,  the  bacterium  that  colonise  the  human  stomach,  has  been 
accepted as a major causal agent for gastric disease, and ultimately cancer. In 1994, 
the  IARC  classified H. pylori as a human type I  carcinogen  (1994a; 1994b).  This 
bacterium,  and  the  role  played  in  gastric  carcinogenesis  will  be  address  in more 
detail later in this chapter. Other established agents that may be causal of intestinal 
type carcinoma consist mainly of lifestyle factors, in particular diet, alcohol intake 
and smoking habits.  There is suggestive evidence that certain foods, such as fried 
food, foods with high salt concentration (such as dried salted fish, cured and smoked 
meat) and fibrous vegetables all contribute to the chemical or mechanical damage of 
the gastric mucosa by breaking the mucous barrier. Also, nitrogen rich nutrients such 
as nitrites are converted in N-nitroso compounds, a potential mutagen and carcinogen 
(Correa et al.,  1975). On the other hand, consumption of fresh fruit and vegetables, 
and particularly vitamin C are effective in reducing gastric cancer risk. In contrast, 
the role of alcohol intake and smoking remains unclear.  Several studies focused on 
these two agents  showed a positive association of smoking and/or specific alcohol 
drinking  with  gastric  cancer.  The  association  were  usually  not  very  strong,  but 
significant, nonetheless. Specifically, an increased risk of gastric cancer was found in 
smokers that were infected with Helicobacter pylori (Tredaniel et al.,  1997;Zaridze 
et al., 2000).
In  summary,  despite  gastric  disease  being  undoubtedly  a 
multifactorial  disease,  Helicobacter pylori  does  play  a  major  role  in  the  gastric 
cancer and  the  process of gastric  carcinogenesis,  in the  development of intestinal 
type gastric cancer, rather than diffuse type (Parsonnet et al., 1991).
1.3.4  Gastric cancer precursor lesions
The intestinal type gastric cancer is the product of a long multiple sequential 
changes pathway, that usually takes several decades to reach neoplasia (Correa et al., 
1975;Correa, 2005). That sequential mechanism was has proposed originally in 1975 
by Correa and collaborators, with the multistep proposed model shown in figure 1.5.
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Figure 1.5: Multistep process of gastric cancer precursor lesions. (Adapted from Correa, 2005)
Usually  in  the  presence  of  Helicobacter  pylori,  the  stomach  develops 
gastritis, as an attempt to fight the infection. However, the fact that most bacteria do 
not  remain  attached  to  the  epithelial  cells,  leads  to  chronic  gastritis  with  large 
number  of  mononuclear  cells  in  the  inflammatory  infiltrate,  and  sometimes 
accompanied of acute inflammation (active chronic gastritis) marked by the presence 
of neutrophils (Dixon et al.,  1996). In some cases, the chronic gastritis develops not 
only in the antrum, where it is usually observed, but also in the body region of the 
stomach. This kind of gastritis tends to evolve to a stage characterised by the loss of 
gastric glands- atrophy, that frequently evolves to intestinal metaplasia (IM) (Dixon 
et al.,  1996).
The  intestinal metaplasia can be divided into 2 major groups: Complete IM, 
also know as Type I IM, characterised by a histological morphology typical of small 
intestine  and  presence  of sialomucins,  and  Incomplete  IM,  that can  be Type  II  or 
Type III, exhibiting a typical colon morphology, producing neutral and sialomucins 
in Type II and sulphomucins in Type III, but exhibiting a mix of gastric and colonic
40characteristics.  The  Incomplete  IM  Type  III  phenotype  is  considered  to  be  more 
unstable  and  therefore  a  more  severe  form  of the  disease  with  higher  chance  of 
developing  into  gastric  cancer  (Correa,  2005;Filipe  et  al.,  1994;Reis  et  al., 
1999;Rokkas et al., 1991;Silva et al., 1990).
1.3.5  Mucin expression in gastric disease
Mucin expression on gastric disease changes dramatically, sometimes with loss 
of expression of gastric mucins and de novo expression of other mucins.
Figure  1.6: MUC1  immunohistochemistry in normal antral type mucosa, with a typical apical staining (left hand 
side), and antral type mucosa with H. pylori gastritis (right hand side), where the gastric pits lose completely the 
apical staining and acquire a marked perinuclear staining. (Adapted from Vinall et al, 2002)
In  gastric  chronic  and  acute  inflammation,  there  is  a general  decrease  in the 
expression of the 3 main mucins, MUC1, MUC5AC and MUC6 (Ho et al.,  1995). It 
is  also  reported  loss  of the  typical  MUC1  apical  staining  and  a  more  prominent 
perinuclear staining is observed (Figure 1.6) (Vinall et al., 2002).
41As  the  process  of gastric  carcinogenesis  progresses,  the  pattern  of mucin 
expression changes.  In intestinal metaplasia, the gastric  mucins  not only decrease 
expression, but in some cases lose completely the gastric mucins and replaces them 
by intestinal  mucins  (Ho  et al.,  1995).  In Complete  IM,  the mucosa  loses  almost 
completely the  gastric  mucin expression  and  expresses de  novo  MUC2  and other 
small intestine mucins;  in the Incomplete IM, both type II  and III  seem to have a 
similar  mucins  expression  pattern,  with  a  mix  of gastric  and  colonic  mucins,  in 
particular MUC2 (Ho et al.,  1995;Reis et al.,  1999;Silva et al., 2002;Teixeira et al., 
2002).
1.3.6  Helicobacter pylori
1.3.6.1  Brief history of H. pylori and colonisation of the human mucosa
For a long time, investigators observed the presence of gram-negative bacilli in 
the stomach, in some cases detected in association with gastric disease. However, the 
presence of these bacteria was disregarded for more than 40 years, and observations 
of those  organisms  were  attributed  to  the  presence  of other  well  know  human 
colonisers, such as Pseudomonas, contaminating the gastric samples.
Just over 20 year ago, Marshall and Warren recognised for the first time these 
organisms as a novel species of bacteria, which they called “pyloric Campylobacter”, 
later  known  as  Helicobacter  pylori  (Marshall  and  Warren,  1984).  The  two 
investigators characterised the bacterium,  describing it as a gram-negative bacillus 
type bacteria that could acquire either an S-shape or curved rod appearance, usually 
exhibiting  four  sheathed  flagella  at  one  end.  It  was  better  cultured  in  a 
microaerophilic environment at 37°C. In the same report, in a study performed with a 
sample of 100 individuals, the authors found that bacterial colonisation was in close 
association with chronic gastritis, and was common in those individuals with peptic 
ulceration of the stomach and duodenum (Marshall and Warren, 1984). Furthermore, 
in the absence of inflammation the bacteria were rare, suggesting a possible role in 
the development of gastric disease.
Since then,  this bacterium has been exhaustively studied, mainly due to its 
unique characteristics; the bacteria are able to colonise the Hydrochloric Acid (HC1) 
rich environment of the human stomach for decades. This amazing ability to colonise 
such  inhospitable  environment  is  probably  the  result  from  an  extremely  high
42mutation rate, leading to an enormous sequence diversity that is about 50-fold greater 
than the one observed in humans (Falush et al., 2003). Because of this high mutation 
rate, only partial linkage disequilibrium (LD) is observed in the bacteria (Falush et 
al., 2003;Spratt, 2003).
1.3.6.2  H. pylori main features
Helicobacter pylori  is  a  gram-negative  bacillus  type  bacteria  with  unique 
mechanisms  that  enable  it  to  survive  in  the  human  stomach,  an  extremely 
inhospitable  environment,  as  well  as  virulence  factors  able  to  induce  disease  in 
humans.  The  main  barriers  to  overcome  in  the  stomach  are  the  extremely acidic 
environment together with the frequent peristaltic movements. H. pylori has evolved 
a mechanism to alter pH, by production of urease.
The Helicobacter pylori urease is a high molecular weight protein with a very 
high affinity for the substrate, urea, and produced in large amounts by the organism, 
due to the crucial role it plays in bacterial survival in the host (Mobley et al., 1988).
Despite the highly acidic pH of the human stomach, Helicobacter pylori is 
only  able  to  survive  under neutral  pH.  For that  purpose,  the  bacteria  created  an 
adaptation  mechanism  to  control  the  pH  in  the  cytoplasm  and  extracellular 
microenvironment  around  itself.  Urease  is  therefore  an  essential  enzyme  for  the 
successful c olonisation o f the human stomach by Helicobacter pylori. The urease 
gene cluster comprises seven genes that must be all expressed for the efficiency of 
the mechanism. The genes can be divided into two classes: the structural genes and 
the accessory genes. ureA and ureB encode the urease structural subunits, producing 
proteins of Mr 26,657 and Mr 60,473, respectively (Clayton et al.,  1989;Clayton et 
al.,  1990;Labigne  et  al.,  1991).  However,  although  there  are  only  two  genes 
contributing to the enzyme structure, their expression is not enough for the activity of 
the enzyme. For that, the bacterium needs to express the five accessory genes, ureB. 
ureE, ureF, ureG and ureH, that encode accessory proteins involved in assembly and 
insertion  of  Nickel  in  the  apoenzyme,  essential  for  the  occurrence  of  catalytic 
activity. Finally, the urel gene, also an accessory gene, codes for an inner membrane 
protein with six transmembrane segments with both the N- and C-termini located in
43the periplasm. This protein acts as a H+- gated urea channel to transfer urea into the 
cytoplasm (Weeks et al., 2000).
The  bacterium  regulates  the  pH  by  activating  the  urease  enzyme  in  the 
presence of urea, hydrolysing it into ammonia and carbon dioxide, and in this way 
lowering the pH of the bacteria microenvironment. To avoid extreme alkalinisation 
of  the  environment,  that  can  also  be  deleterious  to  the  bacteria,  the  organism 
developed a mechanism of preventing continuous urea uptake, thought to be through 
mRNA decay of the urel mRNA which then breaks  the pathway for further urea 
hydrolysis (Akada et al., 2000).
Each bacterium exhibits 3 to 6 unipolar sheathed flagella. Each flagellum is 
encoded by 2 distinct genes, JlaA and flaB, that share poor homology between them 
and are present in distinct areas in the H. pylori genome. Each gene encodes one of 
the two structural subunits that constitute the flagella; a subunit of Mr 53,000, FlaA 
that  is  the  major  constituent  and  FlaB,  the  Mr  54,000  subunit  that  is  the  minor 
constituent  (Kostrzynska  et  al.,  1991;Leying  et  al.,  1992;Suerbaum  et  al.,  1993). 
Together they encode a protein named flagellin, involved in the bacterial motility. 
The FlaB subunit, expressed in low amounts, assembles to the hook, and forms the 
basal  portion  of  the  filament,  and  the  FlaA  subunit,  expressed  at  high  levels, 
constitutes  the  distal  portion  of  the  flagellum.  The  flagellum  is  sheathed  in  a 
membrane-like  structure  containing  lipopolysaccharides  (Geis  et  al., 
1993;Kostrzynska  et  al.,  1991).  To  become  active,  the  flagellin  is  previously 
glycosylated, and contains mainly neuraminic Acid (NeuAc) (Josenhans et al., 2002).
1.3.6.2.1  Virulence factors
Given the numerous Helicobacter pylori strains known, reflected in the DNA 
sequence  diversity  observed  for  this  organism,  it  was  difficult  to  make  a  good 
correlation  between  strains  present  in  the  patients  stomach  and  disease  outcome. 
Xiang and collaborators looked at the expression of vacuolating cytotoxin (VacA) 
and the cytotoxin-associated gene A (CagA antigen), two known virulence markers, 
in  several  strains  of H.  pylori  and  divided  them  into  two  major types  of strains 
(Xiang  et  al.,  1995).  Type  I  bacteria have  the  cagA  gene  and  produce  the  CagA 
protein  and  the  vacuolating  cytotoxin,  and  are  considered  to  produce  the  most 
virulent phenotype in the patient’s stomach. Type II bacteria do not have the cagA
44gene and do not express the CagA protein or the vacuolating cytotoxin, inducing a 
less virulent phenotype in the patients. Also, the investigators observed presence of 
other intermediate phenotypes that either produced or had the gene for one of the two 
virulence factors, identifying them as subgroups in the type I bacteria.
The  cag pathogenicity island (PAI)  was at  first thought to  be only one  gene, 
named cagA expressing a protein with a Mr 180,000 molecular weight. This antigen 
was found to be highly immunogenic, and present in patients’ sera infected with H. 
pylori. The protein expression was found to be associated with the expression of the 
vacuolating cytotoxin, a virulence factor, and therefore considered a virulence factor 
itself (Covacci et al.,  1993). Later on, Censini et al found that type I strains contain 
not only the cagA gene, but also flanking it a 40kb insertion of foreign DNA that was 
called the eng region (Censini et al., 1996). The cag region is situated within the 
glutamate racemase gene, and is made up of 2 regions separated by a sequence also 
present in cag negative strains. Within these two sections of sequence lay the cagA 
gene, one of the 27 genes that compose this region (Lamarque and Peek, 2003). The 
genes encoded in these region present strong homologies to constituents of type IV 
secretion  systems.  This  observation is  consistent with the  fact  that these  proteins 
could be a mechanism of export the Vac  A cytotoxin into  the host epithelial cells 
(Censini et al., 1996;Lamarque and Peek, 2003).
The vacuolating properties of the vacuolating cytotoxin was first described by 
Leunk and collaborators, when in 1988 they observed intracellular vacuolisation of 
cultured cells in vitro in presence of Helicobacter pylori (Leunk et al.,  1988). The 
factor  producing this effect was then determined to be a Mr 87,000 protein, partially 
homologous to ion channel and transport proteins (Cover and Blaser, 1992).
1.3.7  Genes and gastric disease
It is clear from the studies described above that inflammatory disease of the 
stomach and gastric cancer are provoked by H. pylori infection and there are also 
other environmental risk factors, such as smoking and alcohol.  However it is clear 
that not all people get gastric cancer if infected and also that there is great variability 
in susceptibility to  infection and  inflammation. Such observations  implicate  inter­
45individual genetic differences.  There is increasing literature to suggest variation in 
the genes encoding proinflammatory cytokines/receptors such as IL-1|3 IL-1RN and 
TNF-a (El Omar et al., 2000;E1 Omar et al., 2001;E1 Omar,  2001;Machado et al., 
2001;Machado et al., 2003) alters disease risk.  The key role of MUC 1  at the gastric 
surface  led  to  the  consideration  of  this  gene  as  a  candidate  intervening  in  the 
development of gastric disease as will be described in more detail in Chapter 3, 4 and 
6. In this thesis variation in MUC1 is examined in case control studies.
In  undertaking  association  studies  it  is  important  to  appreciate  that  the 
genome  is  not  comprised  of sets  of totally  independent  genes.  Physical  linkage 
resulting  from  co-location  of loci  in  the  same  chromosomal  region  can  lead  to 
genetic linkage in families, and closely linked loci can remain associated over many 
generations, leading to so-called Linkage Disequilibrium.  Methods of determining 
LD are described in the Methods section (Chapter 2). It is now known that blocks of 
Linkage  Disequilibrium  exist  in  the  genome,  as  well  as  regions  known  as 
recombination  hotspots  (Jeffreys  et  al.,  2004;Jeffreys  et  al.,  2005;Stumpf  and 
Goldstein,  2003).  The  existence  of LD  can  aid  association  studies  since  fewer 
markers are required (Goldstein and Weale, 2001;Goldstein et al., 2003;Weale et al.,
2003), but on the other hand in large regions of association make it harder to find 
causal  elements.  LD  in  a  region  reduces  the  numbers  of  haplotypes  (allele 
combinations) seen in a population.  While haplotypes are most reliably determined 
by  study  of  several  generation  families,  many  algorithms  are  now  available  for 
inferring haplotypes from population data.  These are also described in the Chapter 2.
461.4  Aims
The aims of this thesis are to explore MUC1 gene diversity in the context of 
interpopulation differences  and disease  susceptibility,  in particular gastric disease. 
Two independent studies previously reported an over-representation of short MUC1 
tandem repeat alleles in patients with gastric cancer (Carvalho et al., 1997) and with 
Helicobacter pylori gastritis (Vinall et al., 2002) and when compared with controls. 
The overall aim of this thesis was to pursue this observation further.  The specific 
aims were:
-  To  characterise  intra  tandem  repeat  variability  a  the  first  small  cohort  of 
gastritis patients and controls available in the lab
-  To examine three locus haplotype distribution in this and other patient and 
control cohorts
To  characterise  the  distribution  of MUC1  polymorphisms  and  three  locus 
haplotypes in human populations of different ancestries
To determine the extent of linkage disequilibrium around the MUC1 gene
To search for new polymorphisms within the immediate vicinity of MU  Cl
To characterise suitable markers in the MUC  I gene and in the region around 
it  that  would  be  suitable  for  association  studies  and  further  haplotype 
characterisation.
To collect and characterise a new cohort of gastritis patients and controls, for 
a replication study.
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MATERIALS AND METHODS2.1 Human Samples
Fully informed consent was obtained for all samples collected and in the UK 
LREC or MREC ethical approval obtained.
•  First  gastritis  cohort:  “The  relationship  between  genetically  determined 
variations in the intestinal mucins and intestinal injuries”
Ethical committee: UCL/UCLH 95/3037
•  Second gastritis  cohort: “Genetic  hypervariability of the MUC1  membrane 
associated mucin in relation to gastritis and gastric cancer.
Ethical committee: UCL/UCLH 01/0237
•  MRC  National  Survey of Heath  and  Development:  “Ageing and  health in 
middle life in a MRC National Survey of Heath and Development
Ethical committee: MREC/98/2/121
2.1.1 Northern European origin samples
2.1.1.1  MRC National Survey of Health and Development
The  1946  cohort  was  initially  made  up  of  15000  individuals,  all  bom  in 
England, Scotland and Wales in the same week in March 1946, but was stratified by 
social class and reduced to  5362 individuals.  Lifestyle and other information have 
been  collected  at  intervals  since  then.  In  1999,  blood  and  buccal  samples  were 
collected  from  consenting  individuals,  and  about  3000  samples  from  the  original 
5000 were obtained.
Samples  were  obtained  from  across  Great  Britain  (England,  Scotland  and 
Wales), including 349 samples collected in the London area. These samples collected 
in London  were  the  ones  used  in this project,  as  a matched  geographical  control 
group for the two gastritis cohorts, also collected in London.
492.1.1.2  Gastrointestinal  Clinic  -   University  College  London  Hospitals 
samples
2.1.1.2.1 The first Gastritis cohort
These  samples  were  collected  in  collaboration  with  Dr.  Martin  Samer. 
Patients  undergoing  gastric  endoscopy  or  colonoscopy  were  approached  by  the 
researcher and invited to take part in the study. A questionnaire was completed and 
all patients signed a consent form agreeing to take part in the study. Each individual 
provided a blood sample, for DNA extraction, as well as two biopsies for research 
collected during the endoscopy procedure together with those required for routine 
histopathology.  Patients  also  gave  information  about  smoking  habits  and  ethnic 
origin. Sample collection took place between April 1996 and September 1997, from 
a total of 181  patients.  Some of these patients, for whom DNA was available, had 
undergone  upper  gastrointestinal  tract  endoscopy,  and  an  additional  biopsy  was 
collected  from  these  to  perform  a  Campylobacter-like  organism  test  (CLO-test) 
(Marshall et al.,  1987) and determine H. pylori infection status. Disease status was 
determined by histological examination conducted in collaboration with Dr. Marco 
Novelli, using as a scoring reference the updated Sydney system (Dixon et al., 1996). 
Helicobacter pylori  infection  status  was  determined  by  three  different  methods: 
CLO-test, performed using one of the biopsies from the patient, routine histology and 
Immunohistochemistry, performed with paraffin wax embedded biopsy sections and 
a monoclonal antibody specific for H. pylori.
The  individuals  were  divided  into  subgroups,  according  to  disease and H. 
pylori infection status.
The individuals from whom colonic biopsies were obtained together with one 
from w horn  a duodenal  sample was obtained were  included i n t he patient control 
group.
2.1.1.2.2 Second gastritis survey
This series of samples were collected in collaboration with Dr Steve Pereira 
and  the  work  of patient  recruitment  and  patient  data  categorisation  was  shared 
between myself and Dr Adil Elamin with the assistance of Prof. Marco Novelli for 
the histological evaluation.  All patients had been referred for upper GI endoscopy
50(n=239) and similar information was collected to that obtained for the first cohort. 
Histological slides were assessed by at least two investigators.
2.1.1.2.3  Oesophageal disease group
Samples from individuals with oesophageal disease (n=103) were collected at 
the  same hospital i n c ollaboration with Dr. L aurence  Lovat.  From e ach patient, a 
blood sample was collected as well as biopsies, for further disease diagnosis.  Dr. 
Laurence  Lovat  and  colleagues  (including  histopathologists)  made  the  disease 
categorisation and recorded ethnic origin of the samples. Patients were subdivided 
into  five  major  groups  according  to  disease  status:  squamous  cell  carcinoma, 
adenocarcinoma, mixed carcinoma (squamous cell carcinoma and adenocarcinoma), 
Barrett’s  oesophagus  (a  pre-cancerous  lesion)  and  oesophagitis,  an  inflammatory 
disease. However, in this thesis, the oesophageal disease group of patients is used in 
total as a control group for the gastritis study together with the colon disease patients.
2.1.2  Portuguese origin samples:
2.1.2.1 Control group
The Portuguese control group consists of 155 individuals, who were donors 
recruited from the blood bank of S. Joao Hospital in Porto, Portugal. The collection 
was made during two periods of time: during one month in 1993 and one month in 
1995.  Informed  consent  was  obtained  from  each  individual,  and  a  10  ml  blood 
sample was taken.  Samples were obtained in collaboration with Prof. Leonor David 
from the Mucin group in the Institute of Molecular Pathology and Immunology of 
the University of Porto (IPATIMUP), Portugal. No gastric disease information was 
available  from  this  control  group.  DNA  was  extracted  using  a  Salt-chloroform 
extraction  method  (Mullenbach  et  al.,  1989)  and  Southern  blot  data  for  MUC1 
tandem repeat was collected by Dr Filipa Carvalho in Porto.
2.1.2.2 Viana samples- Helicobacter pylori gastritis group
The  samples  were  part  of a  prospective  study  on  the  development  of gastric 
disease.  The  individuals  were  selected  from  the  workers  of a  Naval  Shipyard  in 
Viana do Castelo, North Portugal. This particular region was chosen due to the very
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informed consent of individuals presenting symptoms of dyspepsia. A blood sample 
was collected from each individual, as well as several gastric biopsies. Histological 
diagnosis  was  made  in  S.  Joao Hospital,  in the  Pathology  department,  where  the 
slides were assessed by several pathologists.
Only patients with lesions in the stomach were included in the study due to the 
very low number of individuals showing normal biopsies (n=3). Apart from these 3 
patients all others had evidence of gastritis with or without intestinal metaplasia. No 
individuals had stomach ulcer, dysplasia or gastric carcinoma.
2.1.2.3  Gastric cancer group
Samples  were  collected  from  individuals  suffering  from  gastric  cancer  and 
undergoing surgery. All patients gave informed consent and participated voluntarily 
in  the  study.  Samples  were  obtained  during  surgery  from  carcinoma  tissue  and 
adjacent non-neoplastic gastric mucosa. The latter was used to extract DNA, which 
was done using a Salt-chloroform extraction method (Mullenbach et al., 1989).
2.1.3  Nigerian origin samples:
In collaboration with Dr.  Rosemary Ekong,  a  sample  of 94  individuals of 
Nigerian ancestry was obtained. All individuals were asked to give a buccal sample 
by rubbing the inner cheek with cotton buds. Later, these buccal samples were used 
for DNA extraction (Freeman et al.,  1997). Although the samples were anonymised, 
family  relationships were recorded. Five individuals were thus withdrawn from the 
study  for population c omparison since they were  related to  other members  of the 
cohort.
The individuals belong to several ethnic groups:  85 individuals (90% of the 
total sample group) belong to the Ibibio tribe (one of them belonging to the Okobo 
tribe, closely related), 6 are Yoruba/Isekiri and 3 individuals are Igbo/Ikwere
522.2 Materials
2.2.1  Buffers and Solutions
Agarose gel loading buffer:
0.25%  Bromophenol  blue,  0.25%  Xylene  Cyanol  FF,  15%  Ficoll  (Type  400;
Pharmacia) in H2O
Formamide loading buffer:
1:3 parts of Blue Dextran (50mg/ml) and Deionised Formamide.
5x TBE:
0.44M Tris, 0.44M Boric Acid, 12.5mM EDTA, pH 8.2-8.4
20x SSC:
3M Sodium Cloride (NaCl), 0.3M Sodium Citrate (Na3C6Hs0 7.2H20), pH 7.0
lOOx Denhardts:
2% (w/v) Ficoll type 400, 2% (w/v) Bovine Serum Albumin (BSA), 2% (w/v) 
Polyvinylpyrrolidone (PVP), filtered sterilised with a 0.2pm membrane.
Jeffreys’ buffer:
11.  lx concentrated, adapted from Jeffreys et al (Jeffreys et al., 1990)
0.499M Tris-HCL (pH8.8), 0.112M Ammonium Sulphate ((NH^SC^), 0.050M 
Magnesium Chloride (MgCh), 0.074M 2-mercaptoethanol, 48.8pM EDTA,  11.1 mM 
of each dNTPs  (Amersham  Pharmacia biotech),  1.25pg/pl  Bovine Serum Albumin 
(BSA) (DNAse free, Amersham Pharmacia biotech)
PCR clean-up solution:
1M  of NaCl,  2mM  Tris-HCl,  0.2mM  EDTA,  40%  PEG-8000  (polyethylene 
glycol), 3.5mM MgCh. The solution is sterilized, aliquoted and kept in the fridge.
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200mM  Tri-HCl  pH  9,  5mM  MgCl2.  The  solution  is  filtered,  sterilized  and 
aliquoted and ffeezed.
Depurinating solution:
0.25M hydrochloric acid (HC1)
Denaturing solution:
1.5M Sodium Chloride (NaCl) 0.5M Sodium Hydroxide (NaOH)
Neutralising solution:
1.5M NaCl, 0.5M Tris HC1, 0.001M EDTA, pH7.2 
Denrobing solution:
0.1%  SDS solution, prepared by adding 990ml of distilled water to  10ml of 
10% filtered SDS.
Commercial buffers:
New England Biolabs:
NEBuffer 1: (lx)
lOmM  Bis  Tris  Propane-HCl,  lOmM  MgCl2,  ImM  dithiothreitol  (pH  7.0  at 
25°C)
NEBuffer 2: (lx)
lOmM  Tris-HCl,  lOmM  MgCl2,  50mM  NaCl,  ImM  dithiothreitol  (pH  7.9  at 
25°C)
NEBuffer 3: (lx)
50mM  Tris-HCl,  lOmM  MgCl2,  lOOmM NaCl, ImM  dithiothreitol  (pH  7.9  at 
25°C)
NEBuffer 4: (lx)
20mM Tris-acetate,  lOmM magnesium acetate, 50mM potassium acetate,  ImM 
dithiothreitol (pH 7.9 at 25°C)
54Boehringer Mannheim GmbH, now part of Roche Applied Science 
suRE/Cut Buffer B: (lx)
lOmM Tris-HCl, 5mM MgCl2,  lOOmM NaCl,  ImM 2-mercaptoethanol (pH 8.0 
at 37°C)
GIBCO BRL, now part of Invitrogen 
REact 3:
50mM Tris-HCl, lOmM MgCl2, lOOmM NaCl, (pH 8.0)
REact 4:
20mM Tris-HCl, 5mM MgCl2, 50mM KC1, (pH 7.4)
2.2.2  Equipment
Thermal cyclers:
Helena Biosciences Phoenix thermal cycler- Helena Biosciences, Sunderland, 
UK
GeneAmp-  PCR  System  9700-  PE  Applied  Biosystems,  Warrington, 
Cheshire UK
MJ  Research  PTC-200  Peltier  Thermal  Cycler-  Genetic  Research 
Instrumentation (GRI), Essex, UK
MJ  Research  PTC-225  Tetrad  PCR  Systems-  Genetic  Research 
Instrumentation (GRI), Essex, UK
Sequencers:
ALFexpress DNA sequencer- Amersham Pharmacia Biotech, Bucks, UK
-  ABI PRISM 377 DNA Sequencer- ABI, Applied Biosystems
-  ABI PRISM 3700 DNA Analyser- ABI, Applied Biosystems
Electrophoresis equipment:
CONSORT  Microcomputer  electrophoresis  power  supply-  Flowgen 
Bioscience Limited, Nottingham, UK
Power supply ECPS 3000/150- Amersham Pharmacia Biotech, Bucks, UK
55Mini  Gel  Electrophoresis  tank  10  x  7  cm-  Flowgen  Bioscience  Limited, 
Nottingham, UK
Electro-Fast Stretch gel systems, 96 wells plus 12 wells for marker- ABgene 
House, Epsom, UK.
Horizon 20.25 Horizontal Gel Electrophoresis Apparatus- Gibco BRL, Life 
Technologies, Inc, Paisley, UK.
Horizon  11.14 Horizontal Gel Electrophoresis Apparatus- Gibco BRL, Life 
Technologies, Inc, Paisley, UK.
Others:
Dark Reader DR45M- Clare Chemical Research, Inc. GRI, Essex, UK 
UV Transilluminator- Ultra Violet Products (UVP), Cambridge, UK 
PCR plates- Thermo-Fast 96 Semi-Skirted- ABgene House, Epsom, UK 
Adhesive PCR Film- ABgene House, Epsom, UK 
-  Fuji Medical X-Ray Film Super HR-E30- Fuji Photo Film Ltd, London, UK 
Fuji cassette FG-8- Fuji Photo Film Ltd, London, UK 
pH meter- Mettler-Toledo Gmbh, Beaumont Leys Leicester, UK
2.3  Methods
2.3.1  DNA Extraction
2.3.1.1 DNA extraction from whole blood
Blood was collected in tubes containing EDTA and stored at -70°C before DNA 
extraction. DNA was extracted from 3ml of blood using a PUREGENE kit (Gentra 
Systems,  supplied  by  Flowgen  Bioscience,  Wilford,  Nottingham,  UK)  and 
reconstituted  in  250pl  of  DNA  hydration  solution  (Tris  [hydroxymethyl] 
aminomethane  and  EDTA  (ethylenediaminetetracetic  acid),  Puregene).  Aliquots 
were stored at 4°C and -70°C.
2.3.1.2 DNA collection and extraction from buccal cells
One of the sets of samples from the MRC  1946 Longitudinal Cohort, (used for 
the  PCR based  tests) and  samples  from Nigeria were both collected using buccal
56cells as a source for DNA. Each individual was asked to rub the inner cheek with 10 
cotton buds, rubbing a different part of the inside of the mouth with each bud for 
about 20 seconds. The cotton swabs were placed in a previously prepared 15 ml tube 
containing 2.5ml of a solution of STE buffer (100 mM NaCl, lOmM Tris HC1 pH8.0, 
lOmM EDTA pH8.0), 0.2mg/ml of Proteinase K and 0.5% of SDS (Freeman et al., 
1997;Meulenbelt et al., 1995).
To extract the DNA the tubes were incubated in a waterbath at 65°C for 2 hours. 
The contents of the tubes were inverted and transferred into 50ml conical tubes, and 
spun at 647g for 10 minutes in a MSE Mistral 300E bench model centrifuge at room 
temperature.  The  swabs were drained and discarded,  and  the  liquid poured into  a 
15ml centrifuge tube. 300pl of Yeast Reagent 3 (YR3) (Autogen Bioclear, Wiltshire, 
UK) was added to the tube contents and after vigorously mixing for  1   minute the 
tubes  were  spun  for  25  min  in a  MSE-Europa  24M  centrifuge  at  7000rpm.  The 
supernatant was transferred into a clean  15ml tube and another 300pl of YR3 were 
added  plus  vigorously  mixed.  The  centrifugation  procedure  was  repeated.  The 
supernatant was then transferred into  a new  15ml  tube, and  1.8ml of isopropanol 
were added. A fter m ixing,  the contents w ere s pun down a 17 OOOrpm i n the MSE- 
Europa 24M centrifuge for 25 minutes. The supernatant was discarded and the pellets 
were washed with 70% ethanol (EtOH)  and centrifuged at the same speed for  10 
minutes using the same centrifuge. The EtOH was discarded and the pellets were air 
dried for  15  minutes. Finally, 400pl of DNA hydration buffer (TE) was added and 
left to ressuspend overnight at 4°C. The DNA was kept at 4°C or in some cases an 
extra aliquot stored at -70°C.
2.3.2  PCR general method
Polymerase  Chain  Reaction  (PCR)  was  performed  in  reaction  volumes 
ranging from  10pl to 25pl. The reaction mix was prepared as followed, unless stated 
otherwise.  The final concentration of the reagents in the mix was:  1:10 dilution of 
lOx buffer IV (containing MgCh) was added to 0.2pM of each dNTP, 0.5pM of each 
primer  and  0.025U/pl  of  Taq  DNA  polymerase.  All  products  were  supplied  by 
ABgene (Surrey, UK). Some PCR products required addition of 5% (v/v) glycerol or 
2%  Dimethyl  Sulfoxide  (DMSO)  (Finnzymes,  supplied  by  GRI,  Essex,  UK)  to 
increase PCR stringency and obtain specific PCR products.
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(Equipment  section)  and  subjected  to  electrophoresis  in  a  2%  agarose  gel  (unless 
stated otherwise), together with a PCR ladder.
2.3.3  M arker PCR
All the markers used in the agarose gels and in the ALF express were made in 
the  lab.  One antisense primer was used (Marker AS),  combined with several sense 
primers to  give  final products of specific  sizes:  100,  150, 210,  250,  300, 400,  501, 
600,  700,  800,  900,  1000,  1200  and  1400  base  pairs.  For  the  ALF  markers  an 
antisense Cy5 labelled primer was used. The PCR was carried out as described in the 
general PCR methods. All the primers used for these PCRs are listed in Table 2.1. 
Table 2.2 has a summary of the proportions of each reagent used in the PCR.
Prim er name Primer sequence from 5’ to 3’ Orientation
Marker AS CTCTCAGGTCTGGTGTCATCC antisense
100 CTGTTCTCTTAAGCTTACTACTGACAG sense
150 ACATGATTCAGTCTAATCAATGGAT sense
210 G AGGTT GAGTC AT  ACC  AAAT  AGT  G sense
250 T  GT  CT  A  ACC  ACTC  ACT  GTC  AT  G  A sense
300 GCCTTGTCCTATGGAAGGC sense
400 CTTCCATCCTCCAAGGCC sense
501 TGCCTGTTGCTGTCCCTG sense
600 C AGCT  AT GGG  AG  AGG  AAGC  A sense
700 CCCAGCAGGCCCAGAA sense
800 AAGCCTCACATATCTCCGTTT sense
900 ACTTCTGGAAAATGACTGAGGC sense
1000 GCCCAGTTTTGTGGCATCT sense
1200 CCTGTCTTGGAGTCCCCAA sense
1400 GATGTTTTCTCTGAGTCTCCCTT sense
Table 2.1:  List of primers for the marker PCRs. For each primer, the sequence is indicated from 5' to 3', as 
well as the primer orientation.
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Buffer 4 1
10 x dNTP's 1
Marker AS 1
Sense primer 1
Taq 0.05
dH20 4.95
DNA 1
Table  2.2:  List  of reagents  and  proportions  used  for  each  PCR  for  the  marker  PCR.  The  reagents  and 
concentrations are the same indicated in the PCR general method.
2.3.4  MUC1 Tandem Repeat Size determination
2.3.4.1 DNA digestion
To  determine  the  allele  sizes of the MUC1  tandem  repeat  (TR),  each genomic 
DNA sample was digested with the restriction enzyme Hinf I, which cuts the MUC1 
product  as  shown  in  figure  2.5.  For each  digestion,  12  pi  of genomic  DNA  (200- 
400ng/pl) were digested with a mix with a final mix concentration of lx NEB Buffer 
2  (New  England  Biolabs),  17  units  of restriction  enzyme  Hinf I  (New  England 
Biolabs,  Herts,  UK),  and  O.IM of Spermidine  (Promega,  Southampton,  UK).  The 
mixture was incubated overnight (ON) at 37°C.
2.3.4.2 Southern Blot
The digests were loaded into a 0.8% agarose (Sigma-Aldrich, Dorset, UK) 24cm 
(300ml) gel, and subjected to 2 V/cm for 24 hours.  15pl of Raoul Molecular Weight 
Marker (lOOpg/ml) (Qbiogene, Cambridge, UK) was loaded  into two wells and two 
digested  genomic  DNA  controls  containing  allelic  bands  of known  size  (the  first 
prepared  from  the  cell  line  Caco-2  and  the  second  a  mixture  of two  other  DNA 
samples) were also used to allow accurate sizing of the bands.
The  gel  was  subjected  to  ‘Southern  Blotting’,  using  aVacuGene  XL Vacuum 
Blotting  Unit  (Amersham  Pharmacia  Biotech).  The  DNA  bands  were  transferred 
onto  a  positively  charged  nylon  transfer  membrane  Hybond-N+  membrane 
(0.222mx0.222m) (Amersham Biosciences) as follows:
59The membrane was placed in the Vacuum Blot unit on a gel supporting screen 
and the gel placed on the top, applying 75 millibars of pressure. The blot was made 
by covering the top of the gel with depurinating solution for 30 min,  followed by 
denaturing  solution  for  30  min,  and  neutralising  solution  for  30  min.  The  DNA 
transfer was made with 20x SSC for 2 hours. The membrane was wrapped in 3mm 
filter paper and baked at 80°C for at least 2 hours.
2.3.4.3  Probing the membrane
Pre-hybridisation
The  membranes  were  firstly  pre-hybridised  in  a  solution  containing  5x 
Denhardts  (2%  Ficoll  400,  2%  Bovine  Serum  Albumin  (BSA),  2%
Polyvinylpyrrolidone (PVP)), 0.5% (w/v) SDS and 6x S SC.  The membranes were 
incubated at 65°C, with agitation, for at least 4 hours.
Probe labelling
The MUC1  cDNA probe (pum24p), produced in our lab (Yonezawa et al., 
1991),  was  labelled  with  32P  using  the  Megaprime  DNA  Labelling  System 
(Amersham Biosciences, Bucks, UK). The cDNA probe (30-60ng) was mixed with 
water and the random primer from the kit and denatured for 5 min at 95°C and put in 
ice. The kit reaction buffer was the added to this mix. The probe was labelled with 
a32P dCTP (ICN Biomedicals, Basingstoke, UK) using 2.22 MBq of label and 4 pi of 
Klenow enzyme (lU/pl), incubating at 37°C for at least 30 min. After the incubation, 
the  labelled  probe  was  purified,  by  separating  the  different  fractions  in  a  ‘Nick 
Column’  containing  DNA  Grade  Sephadex  G-50  (Pharmacia  Biotech,  Amersham 
Biosciences, Bucks, UK). The unlabelled probe was eluted by adding 400 pi of 3x 
SSC,  and the  labelled  probe was then recovered by adding a further 400 pi of 3x 
SSC.  The  incorporation  rate  was  measured  with  a  Geiger  counter  in  counts  per 
minute (cpm), using the following formula:
Incorporation rate (%) =_______________ cpm of the labelled probe_______________   x  100
cpm of the labelled probe + cpm remaining in the column
The probe was only used if an incorporation rate of over 50% was obtained, 
and stored at room temperature.
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Once the membranes were pre-hybridised the membranes were removed from 
the pre-hybridisation  solution.  50pl  of Sonicated  Herring  Sperm  DNA  (lOmg/ml) 
(Promega, Southampton, UK) were added to the labelled probe, to block non-specific 
hybridisation  of the  probe  to  the  membrane.  The  probe  was  boiled  for  5  min  to 
denature and added to the pre-hybridisation solution. The membranes were returned 
to the solution one by one, and incubated at 65°C with agitation overnight.
Membrane washing 
The membranes were washed with 3 solutions containing decreasing amounts 
of S SC,  to increase the stringency. All the solutions had 0.1% (w/v) of SDS, and 
decreasing amounts of SSC: 2%  SSC,  0.2% SSC and0.1% SSC. The incubations 
were carried out at 65°C, with agitation. The time with each washing solution was 
dependent on the number of counts read after each wash, monitored with the Geiger 
counter.
Membrane development 
The membranes were wrapped in cling film and placed overnight within a 
Fuji cassette FG-8 with Super HR-E30 Fuji medical X-ray film (Fuji film). The film 
was then developed using a Compact X2 Automatic X-ray Film Processor (Xograph 
Imaging Systems Ltd, Glos, UK). If necessary, longer or shorter exposures would be 
done, to obtain a better result.
2.3.4.4  Allele size determination
Once t he autoradiographs  are developed,  the alleles a re  sized by scanning the 
autorad  using  Grab-IT2.59  (for  Windows  95)  software,  taking  particular  care  in 
lining up the top of the filter in the image. After scan, the analysis was done using the 
computer  software  GelWorks  ID  Intermediate  v4.01  (both  from  Ultra-Violet 
Products, Cambridge, UK). With GelWorks, the size of each band is determined in 
relation to the size of the bands of the Raoul marker and the other controls, which 
bands have known sizes (Figure 2.3).
Because of the bimodal distribution of the alleles, and in order to simplify the 
analysis,  the  alleles  are  divided  into  two categories:  large  alleles  (L),  with bands 
bigger than 5 kb, and short alleles, comprising all the bands smaller than 5kb. This
61cut-point  was  defined  by  the  dip  between  the  two  peaks,  5Kb,  in  the  bimodal 
distribution (Vinall et al., 2002) (Figure 2.3).
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Figure  2.3:  Southern  Blot  obtained  with  samples  digested  with  the  Hinf /  restriction  enzyme.  The 
autoradiograph shows the Raoul molecular weight marker in each side of the gel and the bands size on the left 
side(M), and  the  size of the bands  in Kb.  The two  internal  controls,  positioned  below  the  arrows facing 
downwards, are the Hinf  I restriction products of a cell line, Caco-2, and a mixture of 2 DNA samples.
2.3.5 Long PCR across tandem repeat
Because most individuals are heterozygous for MUC1  TR size,  and in order to 
obtain haplotypic MVR maps,  the  first step for the MVR analysis was a long PCR 
across the entire TR array, using specific primers for the regions flanking the array. 
For this purpose DNA of good quality was necessary, because if the DNA is nicked 
it is not possible to obtain PCRs across the entire TR region, and therefore this does 
not produce good MVR starting material.
The  long  PCR was  made  in  a 25|il  reaction,  using 2  pi  (80-160ng/pl) of DNA 
diluted 1:5 from the stock. Together with the DNA, the final reaction mix contained 
lx ‘ Jeffreys buffer’ (composition  in the buffers  and  solution section), 0.9 units of 
DyNazyme  EXT  DNA  polymerase  (Finnzymes,  obtained  through GRI  Ltd,  Essex, 
UK),  2%  DMSO,  0.5  pM  of forward  primer  Exon2S  (Table  2.4)  and  0.5  pM  of 
reverse  primer  MUC1E2AS  (Table  2.4).  The  reaction  is  performed  in  a  Phoenix
62Thermocycler  (Helena  Biosciences),  with  1   step  of  lm30s  at  96°C  for  initial 
denaturation,  followed by 22  cycles of 40s at 96°C for denaturing,  30s at 60°C  for 
annealing and 4 min at 68°C for extension. One final step of 5 min at 68°C concluded 
the reaction.
Primer name Primer sequence from 5' to 3' Orientation
Number of 
nucleotides
M lproFl TGATCTGATGCGCTCCAAT sense 19
M lproRl GAGAGGACGTTGGAACGTG antisense 19
MlproF2 CGCATCTGCCTCTTAAGTACA sense 21
MlproR2 GCTGGATAATGAGTGGACTAGG antisense 22
MlproF3 ACAGGGAGCGGTTAGAAGG sense 19
MlproR3 CAGCCTCTGTCTGCAATTCTT antisense 21
MlproF4 CAGTCTCCTTTCTTCCTGCTG sense 21
MlproR4 TACGCTGCTGGTCATACTCAC antisense 21
Ml 3utrFl GGAGATGTGAGGAGGAGGTG sense 20
Ml 3utrRl CTGTGCTGGGTGTGGTAGG antisense 19
Exon2S AAGGAGACTTCGGCTACCCAG sense 21
Exon2AS CTGGGACCGAGGTGACATGG antisense 20
MUC1E2AS TGTGCACCAGAGTAGAAGCTGA antisense 22
1946- AGS CCT  AAACCCGC AAC  AGTT  GTT  AC sense 23
Cy5- Exon2AS ♦CTGGGACCGAGGTGACATCC antisense 20
1946- CAS AG  AG  AGTTT  AGTTTT  CTTGCTCC sense 23
Cy5- CAA ♦TCTTGGCTCTAATCAGCCC anti sense 19
Table  2.4:  List of primers for the MUCl  gene,  including the promoter region and the region  immediately 
downstream of the  gene.  For each primer,  the  sequence  is  indicated  from  5'  to  3',  as  well  as  the  primer 
orientation and nucleotide length. The labelling in the Cy5 primers in marked with an asterisk (*).
2.3.5.1  Allele separation
To separate the two alleles in the samples heterozygous for the TR size, the PCR 
products were loaded onto a 1% agarose (Sigma-Aldrich) 14cm (100ml) gel, and run 
at 2.1 V/cm for 19 hours. To improve the visualisation of the bands, the gel was post­
stained  for 30  min  in  the  dark with  SYBR Gold nucleic  acid gel  stain (Molecular 
Probes, Leiden, The Netherlands) diluted lOOOOx in TBE pH7-8.5.
Taking  as a  reference the Hinf /fragment  sizes  previously d etermined  for the 
same individuals, and subtracting  1.02kb from that value (corresponding to the size 
of the region between the cut sites and the beginning and end of the TR array) (see 
Figure 2.5), the expected sizes of the TR bands in the gel were calculated. The bands
63in the gel were visualised and excised using a Dark Reader transilluminator (Clare 
Chemical Research), to allow DNA visualisation without nicking the DNA. Because 
some of the bands were not visible, despite using SYBR Gold to stain the DNA, the 
flanking  lanes  in  the  gel  were  loaded  with  1   Kb  DNA  ladder  (Gibco  BRL, 
Invitrogen, Paisley, UK), to help determine the position in the gel from where the 
bands  should  be  extracted.  The  gel  slices  after  extraction  were  placed  in  an 
eppendorf,  together  with  50  pi  of water  with  lOng/pl  of Herring  Sperm  DNA 
(Promega), crushed with a tip and frozen and thawed 3 times, to release the DNA 
from the gel slice.
Wad
cagtgcttacaggtgaggggcacgaggtggggagtgggctgccctgcttaggtggtcttcgtggtctttctgtgggttttgctccctggcagatggcaccatgaa
gttaaggtaagaattgcagacagaggctgccctgtctgtgccagaaggagggagaggctaaggacaggctgagaagagrttgcccccaaccctgagagtgggtacc
aggggcaagcaaatgtcctgtagagaagtctagggggaagagagtagggagagggaaggcttaagaggggaagaaatgcaggggccatgagccaaggcctatggg
cAgagagaaggaggctgctgcagggaaggaggcttccaacccaggggttactgaggctgcccactccccagtcctcctggtattatttctctggtggccagagct
tatattttcttcttgctcttatttttccttcataaagacccaaccctatgactttaacttcttacagctaccacagcccctaaacccgcaacagttgttacaggt
3543  Fxo" K   3563
tctqqtcatacaaactctaccccagqtggaqaagaqqaqacttoqqctaccc*3aqaaqttcatrtqcccaqctctactgagaaqaatgctqtqacrtatqaccaqc
agcgtactctceagceacagccccggttcaggctcctccaccaetcagggacaggatgtcactctggccccggccacggaaccagettcaggttcagctgccacc
3821
tggggacaggatgtcacctcggtcccagtcaccaggccagccctgggctccaccaccccgccagcccacgatgtcacctcagccccggacaacaagccagqgojs 
Conserved Tandem repeat  3^
cccgggctccaccgcccccccagcccatggtgtcacctcggccccggac
4002  MUC1E2AS 
igfficaqc aacaqqcccqccttqqqctccaccqccccticcaqtccacaatqtcacctcqqcctcaqqctctqcatcaqqqtfcaqcttctactctqqtqcafojacqqcacctct:
gccagggctaccacaaccccagccagcaagagcactccattctcaattcccagccaccactctgatactcctaccacccttgccagccatagcaccaagactgat
gccagtagcactcaccatagcacggtacctcctctcacctcctccaatcacagcacttctccccagttgtctactggggtctctttctttttcctgtcttttcac
atttcaaacctccagtttaattcctctctggaagatcccagcaccgactactaccaagagctgcagagagacatttctgaaatggtgagtatcggcctttccttc
4405
cccatgctcccctgaagcagecatcagaactgtccacaccctttgcatcaagcccglGfctcctttccctctcaccccagtttttgcagatttataaacaaggggg
Hiafl
Figure 2.5: Nucleotide sequence of the MUC1  sequence surrounding the TR region (extracted from sequence 
with accession number M61170), with the nucleotide numbers displayed on the top of framed nucleotides. The 
conserved tandem repeat nucleotide sequence is typed in red and underlined and the Hinf  I sites are also marked 
in red. The two primers used in the ‘Long PCR across TR’ are shown in pink.
23.5.2  Gel slice check PCR
To make sure that the gel slice was removed from the correct part of the gel and 
therefore contained the right PCR product, and to determine the relative amount of 
PCR product present in the gel slice, a semi-quantitative PCR was performed. After 
spinning the gel slice in an Eppendorf tube for 2 min at 13000rpm,  lpl of gel slice 
PCR product was added to a final concentration of mix of lx buffer IV (with MgCb)
64(ABgene), together with 0.2pM of each dNTP (ABgene), 0.5pM of forward primer 
Exon2S, 0.5pM of reverse primer Exon2AS,  10% glycerol (v/v) (BDH Biomedical, 
Poole,  Dorset,  UK),  and  0.25U  of  Taq  DNA  polymerase  (ABgene),  in  a  final 
reaction  volume  of 10pl.  The  reaction  was  performed  in  a  Phoenix thermocycler 
(Helena Biosciences) with 27 cycles, each with 40s of denaturation at 96°C, 30s of 
annealing time at 66°C and 30s of extension time at 68°C.
The final PCR product was 205bp long, and run in a 2% agarose gel at 7.5 V/cm 
for 45 min. The intensity of the bands, due to the relatively low number of cycles, 
was assumed to be proportional to the amount of PCR product in the gel slice.
2.3.6  MVR analysis
The Minisatellite Variant Repeat technique  (MVR)  (Jeffreys  et al.,  1990)  is a 
technique that allows the analysis of specific nucleotide variants in Tandem repeat 
regions of genes. To analyse MUC1  in this way, a specific primer for each variant 
was  produced,  which  together with a flanking primer  for the TR,  created several 
products of different sizes, according to the nucleotide variant present in each repeat.
In this study,  two major variation sites in the TR were studied:  the nucleotide 
changes from gag to cac that lead to the amino acid changes PDTR to PESR, and the 
nucleotide changes in the codon cca that lead to the modification of a proline to a 
alanine (gca), glutamic acid (caa), or threonine (aca). Figure  1.3 (Chapter 1) shows 
the consensus nucleotide and amino acid sequence of the tandem repeat of MUC1 
and the nucleotide changes and respective amino acid changes described above.
The method used to characterise the map of variants in the tandem repeats was an 
adaptation  of  the  Minisatellite  Variant  Repeat  (MVR)  technique  developed  by 
Jeffreys et al (Jeffreys et al.,  1990;Jeffreys et al., 1991), and is described in detail in 
Fowler et al (Fowler et al., 2003), also available in appendix 3 of this thesis.
652.3.7  Analysis of the G3506A SNP in exon 2 and the CA microsatellite in intron 
6 of the MUC1 gene:
To  determine  the  genotypes  for  the  two  markers  flanking  the  TR  region,  a 
multiplex  PCR  was  used,  using  primers  to  amplify  the  2  regions  flanking  the 
polymorphisms:  a  SNP  in  exon  2  that  occurs  before  the  TR  (G3506A)  and  a 
microsatellite  in  intron  6  composed  of CA  dinucleotides  with  11  to  14  repeats 
(Figure 2.6). The reaction mix was prepared by adding  lpl of DNA (diluted l:20-ie 
approximately 15ng) to a final concentration of mix with 1:10 dilution of lOx Buffer 
IV (with 1.5mM of MgCb), 0.2 jiM of each dNTP, 0.2jjM of each primer, 1946-AGS, 
Cy5-Exon2AS,  1946-CAS  and Cy5-CAA,  2.5%  of glycerol  (v/v),  0.025U of Taq 
DNA polymerase and water up to a volume of 12pl. The PCR was prepared in 96 
well semi-skirted well (ABgene) and run in a GeneAmp- PCR System 9700 thermal 
cycler (PE, Applied Biosystems) with the following conditions: pre-denaturation at 
95°C for 5 min, followed by 32 cycles of 96°C for 30 sec, 62°C for 1  min and 72°C 
for 1  min and a final extension of 72°C for 5 min.
Both reverse primers were Cy5 labelled, a fluorescent marker recognised by the 
ALF express machine.
2.3.7.1  Restriction enzyme digestion
After amplifying the PCR products as described above, 5pi of the PCR product 
were digested with lUnit (U) of the restriction enzyme AlwN I with 1:10 dilution of 
NEB buffer 4 at 37°C overnight. This enzyme cuts the G3506A SNP PCR product 
whenever an adenine is present at the SNP position. The restriction site is abolished 
when the guanine is present.
The  final  product  was  composed  of  2  fragments  of  265bp  and  173-18lbp 
(depending on the number of repeats), corresponding to the G3506A SNP and CA 
microsatellite PCR products, respectively. If the nucleotide adenine is present in SNP 
position, the 265bp fragment is divided in 2 fragments of 28bp and 237bp.
The samples were stored frozen away from light, to avoid degradation of the Cy5 
dye. To prepare the samples for running in the ALF genotyper machine, 2pl of the 
PCR digest product  were  mixed  with  2pl  of Loading Dye  (Amersham  Pharmacia
66Biotech), 2|xl each of Cy5 labelled of 100 and 300 base pair marker, both prepared in 
our lab.
Exon 2  Intron 6
Figure 2.6: Schematic representation of the PCRs for the two MUC1 gene polymorphisms flanking the TR (grey 
box). The g/a SNP is present in exon 2 (.), just before the TR. The CA microsatellite is positioned in intron 6, 
spanning from 11 to 14 repeats.
23.7.2  Detection of the products
The samples were genotyped using an ALF express DNA Sequencer (Pharmacia 
Biotech),  designed  to  detect  fluorescently  labelled  DNA  molecules  separated  by 
electrophoresis on vertical polyacrylamide gels. Cy5  labelled DNA is detected by a 
laser positioned near the bottom of the gel.
Preparation of the gel
Before preparing the gel mixture, the plates, spacers and comb were thoroughly 
cleaned, first with tap water and with a non-scratch brush, and then with Isopropanol 
(AnalaR, BDH, Poole, Dorset, UK). To help with the formation of neat wells, Bind- 
Silane  (y-methacryloxy-propyl-trimethoxysilane)  (Amersham  Pharmacia  Biotech) 
was applied to the top 2cm of each of the plates and the excess removed by wiping 
with a tissue containing a small amount of isopropanol. Once all the pieces were dry, 
the spacers were placed on the sides of the bottom glass plate and covered with the 
top  glass plate  and the two clipped together,  making  sure that the  spacers  did  not 
move. Finally the comb was inserted between the top of the two plates and held in 
place with bulldog clips.
The gel was prepared  by pouring  into  a 50ml  cylinder, 40ml  of SequaGel-6,  a 
19:1  acrylamide/bis-acrylamide  solution,  and  10ml  of SequaGel  Complete  buffer 
Reagent,  containing  TBE  and  TEMED  (both  solution  are  from  National
67Diagnostics). The mixture was then transferred to a squeezy bottle and 400|il of 10% 
Ammonium  Persulfate  (AMPS)  (Bio-Rad,  Bio-Rad  House,  Hemel  Hempstead, 
Hertfordshire, UK) was added and mixed gently. The mixture was poured into the 
gap at the bottom of the plates using the squeezy bottle until  the gel reached the 
comb and filled all the gaps between the wells. Gentle pressure was applied to the 
comb area by adding bulldog clips and gel left to set for about two hours.
Electrophoresis
Once set, the gel was inserted into the ALFexpress machine, filling the top and 
bottom buffer tanks with lx TBE. The comb was removed and the wells rinsed with 
TBE using a syringe. Using the AM v3.0 software (Amersham Pharmacia Biotech) 
the  run  settings  were  adjusted  to  1500V,  38mA,  25W,  for  400  minutes  with  a 
sampling interval of 1   second. A pre run of approximately 10 minutes was used, to 
prewarm the gel to 45°C and to stabilise the laser value, ideally with a value above 
600.  During the pre-run, the samples were denatured for 5 min at 95°C, and were 
kept in ice during the loading of the gel to avoid reannealing.
After the pre-run, the program was paused and the wells were rinsed again with 
TBE. The samples were then loaded into the wells. A positive control containing a 
mix of 2 samples (with different genotypes) and the 100+300bp markers was loaded 
in the first well, to allow comparison of the genotypes with the control. After loading 
the samples the run was resumed.
2.3.7.3  Analysis of the data
Once  the  run  was  completed,  the  data  was  analysed  using  the  ‘Fragment 
Manager’  software  (Amersham  Pharmacia  Biotech).  The  100  and  300  base  pair 
markers allow the sequences to be aligned and therefore the alleles to be accurately 
sized,  despite  the  CA  microsatellite  alleles  differing  by  only  2bp.  Figure  2.7 
demonstrates an example of the output of an ALF run.
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Figure 2.7: Representation of the output File of an ALF express run using Fragment Manager software.  The first 
lane  shows  a  control  sample,  that  results  from  the  combination  of 2  samples  with  different  genotypes.  The 
second  and  third  lane  show  two  samples,  one  heterozygous  for  both  markers  (11,12  AG)  and  the  other 
homozygous for both markers (12,12 AA).
2.3.8  Sequencing
2.3.8.1 PCR-product clean-up
lOpl  of  PCR  reaction  product  was  mixed  in  a  1:1:2  ratio  of PCR  product: 
distilled  water:  lab-made  PCR  clean-up  solution  (composition  in  the  ‘Buffers and 
Solutions’  section) and left  for 1 0 minutes at room  temperature. The mixture was 
subsequently spun at  13000 rpm ( 13400g)  for 1 5 minutes  (MSE ( SANYO) Micro 
Centaur  benchtop  centrifuge),  the  supernatant  (SN)  discarded  with  a  pipette  and 
lOOpl of 100% ethanol added. The tube was spun again at  13000 rpm for 5 minutes 
and  supernatant  removed  with  a  pipette.  After  repeating  the  ethanol  precipitation 
procedure, the tubes were left to dry at 60°C for about 20 minutes. The pellets were 
resuspended in 10pl of distilled water and left overnight at 4°C.
2.3.8.2 Sequencing reaction
5pl of the purified PCR product was added to 2.4pmol of primer,  lpl of Big Dye 
Terminator mix v3.1  (PE Applied Biosystems),  lpl of lab-made  sequencing buffer 
(composition in the ‘Buffers and Solutions’  section) and water, to a total volume of
6915pl (per reaction).  The sequencing reaction was performed in a GeneAmp- PCR 
System 9700 thermal cycler, at 96°C for 45 seconds, 50°C for 30 seconds and 60°C 
for 4 minutes for 25 cycles.
2.3.8.3 Sequencing reaction clean-up:
The sequencing product was precipitated with a mixture of 30pl of 100% ethanol 
and 4.5pl of 3M Sodium Acetate (NaOAc) pH5.2 and left overnight at -70°C. The 
day after, the samples were centrifuged in the cold room at 13000rpm (13400g in a 
MSE (SANYO) Micro Centaur benchtop centrifuge), the supernatant removed and 
lOOpl of 70% ethanol added. The samples were centrifuged again at 13000 rpm for 
15 min in the cold room and supernatant removed. Samples were dried in a thermal 
cycler for 20 min at 60°C, and stored at -20°C protected from light until sequencing.
Just before sequencing, the samples were resuspended in a sequencing loading 
buffer containing deionised formamide and blue dextran, in a 3:1 ratio. The samples 
were kept in the dark wrapped with aluminium foil at 4°C.
2.3.8.4 Sequencing gel:
Before preparing the gel, the sequencing plates were washed with  1% Alconox 
(Alconox  powdered  precision  cleaner,  PC  International  Limited,  Abington, 
Cambridge, UK) and rinsed well, first with tap water and then with Millipore water. 
The  spacers  and  comb  were  carefully  cleaned  with  Millipore  water  using  damp 
tissue. Once dry, the plates and spacers were assembled.
The gel was prepared in a beaker by mixing  9g of Urea with 2.85ml of 40% 
Accugel 29:1  acrylamide: bisacrylamide (National Diagnostics, Hessle, East Riding 
of  Yorkshire,  UK),  0.25g  Amberlite  (PE  Applied  Biosystems)  and  12.5ml  of 
Millipore  water.  The  mixture  was  heated  until  the  urea  crystals  were  dissolved 
completely and then filtered through Whatman  1   cellulose filter paper (7 cm) in a 
vacuum system. The recovered product was transferred to a 25ml cylinder and 2.5ml 
of TBE was added and topped up with Millipore water to 25ml.  17.5pl of TEMED 
and  125pl of 10% Ammonium Persulphate (AMPS) were pipetted into the mixture, 
which was decanted back to the beaker and stirred quickly and gently. The mixture 
was quickly poured into the assembled plates with a syringe and the square side of 
the comb inserted straight afterwards and a weight put on the top of the plates near 
the comb area. The gel was left to set for at least two hours.
702.3.8.5 Electrophoresis:
Electrophoresis was  either performed in  an ABI PRISM  377  DNA  Sequencer 
(Applied Biosystems) using the Data collection software version 2.5 or on a capillary 
system as indicated below.
Before the run, the comb was removed from the polymerised gel and the area of 
the  gel  formed by the comb  cleaned carefully with distilled water to  remove any 
unset gel. The comb was then cleaned and replaced in the comb area with the 36 well 
‘shark’s-tooth’  side towards the gel and sunk about 2 mm into  it.  The area of the 
plates through which the laser passes was also thoroughly cleaned with ethanol to 
make sure no dust or dirt interfered with the laser readings. The plate was placed into 
the machine and the buffer tanks filled with lx TBE.
A plate check was performed using the software to check the level of background 
fluorescence  and  a  pre-run  was  performed  at  lKv  and  35  minutes  while  the 
sequencer reached 51°C. Meanwhile, the samples were denatured at 95°C. Once the 
plates had reached 51°C, the samples were loaded into the gel in every other well and 
then run into the gel for 2 minutes. The intervening wells were then loaded. Once all 
the samples were loaded the 7 hour run was started at 1.68Kv, 50mA at 51°C, with a 
laser detection of 1200 scans per hour.
Capillary System
Many  of the  samples  were  analysed  in  an  ABI  PRIMS  3700  DNA  Analyser 
(Applied Biosystems). The BigDye Terminator v 1.1 Cycle Sequencing Kit (Applied 
Biosystems) was used for the sequencing reaction.
2.3.8.6 Sequences analysis:
The  sequences  obtained  were  analysed  using  Sequence  Analysis  v  3.3  and 
Sequence  Navigator v  1.0.1,  software  programs  from  ABI  (Applied  Biosystems). 
Sequences  were  aligned  using  Sequencer  Navigator  and  exported  to  Sequence 
analysis  to  analyse  the  sequences  or using  Chromas  v2.0  and  ChromasPro  vl.3 
software (free trial version, http://www.techneIysium.com.au).
712.3.9  Other SNPs from database- markers flanking the gene
Single Nucleotide polymorphisms outside the Mt/C/gene were found using the 
NCBI  SNP  database  (NCBI  dbSNP,  http://www.ncbi.nlm.nih.gov/)  and  HapMap 
(http://www.hapmap.org/).  The strategies used are described in detail in Chapter 5. 8 
new  SNPs  were  selected  from  the  databases  and  assays  designed  to  type  the 
polymorphisms using restriction enzyme digestion.
The SNPs selected and respective rs accession numbers are:
-  THBS3 PI- rs2075571
-  THBS3 P2- rs2066981
-  PCR5 Taqal- rs2070803
-  PCR5 BsmF I- rs4971101
-  497- rs4971100
-  MTXlp- rs 1045253
-  KCP2- rs4971088
-  EFNA1- rs9297
2.3.9.1  PCR reaction
The PCRs for the SNPs selected were performed as previously described in PCR 
general methods, but with varying reaction volumes. All PCRs were done in 96 well 
plates, using the GeneAmp- PCR System 9700 or the MJ Research PTC-200 Peltier 
Thermal Cyclers. Table 2.8 shows a summary of the primer sequences used for each 
PCR, the reaction volume, annealing temperature, extension time, number of cycles, 
extra reagents and product size.
4pl of each PCR product was loaded onto a 96 well ‘stretch’ gel (Electro-fast 
Stretch gel systems, ABgene) with 3pl of loading buffer. Each row of the gel also 
contained a molecular weight marker to allow size comparison of the products (lab- 
made). The gel was run at 100V and 50mA and visualised under U.V. light.
722.3.9.2  Restriction enzyme digestion
Once the size o f the P CR p roducts w as c onfirmed,  the s amples w ere d igested 
with a restriction endonuclease following the company guidelines. Table 2.9 shows a 
summary of the restriction assays. The restriction enzyme digestions at 60°C or 65°C 
were carried out in a thermal cycler for 16 hours. An incubator maintained at 37°C 
was used for the rest of the digestions, and samples were left also for 16 hours.
73Primer name Primer sequence 5'-3'
Reaction
volume
Annealing
temperature
Extension
time
Number of 
cycles
Glycerol
50%(v/v)
Product
size
PCR5
Ml 3’utrFl GGAGATGTGAGGAGGAGGTG
25pl 64°C 1  min 30 1:20 711 bp
M l 3'utrRl CTGTGCTGGGTGTGGTAGG
THBS3 PI
THBS3AUF1 GGCTGACC AAG AGAT ACTGGTC
lOp-1 60°C 1  min 30 427 bp
THBS3revl GGTGAGAGCTTCTGAACATCC
THBS3 P2
THBS3for2 GAGGTCAGAGCCCAGAAGG
20pl 65°C 1  min 30 291 bp
THBS3rev2 CAACTGCCTTGTGCTCCTG
497
4971lOOFor CAACTCCCT ATTT AAC ACCCTC
\2\x\ 57°C 30 sec 30 223 bp
4971 lOORev AG AG AA AGG AT  GTTGGG A AG
KCP2
KCP2For TTTTTACCAGCTCTGCCCGA
12(0.1 57°C 30 sec 30 217 bp
KCP2Rev CAGGGAGCAAGGCCTTCA
EFNA1
EFNAlFor GGCTGAGAGCCAGTACAAATA
12(0.1 57°C 30 sec 30 205 bp
EFNAlRev CTTT  AAGGCCAGGTGTGGTA
Tabic 2.8:  Summary of the  PCR conditions  used  for the non MUCI  PCRs.  In the table the PCR  name and  respective primers are shown,  as well  as PCR reaction volume,  PCR cycling 
conditions, extra reagents and final PCR product size.
74Prodnet
size
Restriction
enzyme
Enzyme
units
Buffer
Extra
reagents
Amount of PCR 
product
Total
volume
Incubation
temperature
Nucleotide
change
Fragments generated
PCR5 711  bp Taq° 1(1) 0.5 U Buffer B — 2pl 10pl 65°C C/t 464bp/247bp
PCR5 711 bp Bsmf I(2) 1  U NEB4 1% BSA 2pl 10pl 65°C C/t 463bp/248bp/ 164bp/84bp
THBS3 PI 427 bp HinP1  l(2) 1  U NEB2 --------- 3pl 15pl 37°C a/G 261 bp/164bp/145bp/116bp
THBS3 P2 291  bp BstE  II(2) 5 U NEB3 --------- 3pl 15pl 60°C c/T 216bp/75bp
497 223 bp Dde I(3) 1  U REact3 --------- 2pl 10pl 37°C a/G 178bp/45bp
KCP2 217 bp EcoR V (2> 5 U NEB3 1% BSA 2(jl 10pl 37°C a/T 197bp/20bp
EFNA1 205 bp Acc I(2 > 1  U NEB4 --------- 2pl 10pl 37°C A/g 185bp/20bp
Table 2.9:  Summary of the restriction  enzyme digestion  conditions  used  for the  non MUCI  PCRs.  In  the  table  the  PCR  name  is shown  together with  the  endonucleases,  buffers,  extra 
reagents, assay volume and  incubation temperature.  The polymorphism  is also shown with the nucleotide that creates the restriction site marked in capital  letter in bold.  The  last column 
shows  the sizes  of the  possible  fragments  generated.  (1)  Boehringer  Mannheim  GmbH,  now  part of Roche  Applied  Science;  (2)  New  England  BioLabs;  (3)  GIBCO  BRL,  now part of 
Invitrogen.
752.4  Statistical analysis
2.4.1  Hardy Weinberg Equilibrium:
The  Hardy-Weinberg  Equilibrium  (HWE)  derives  from  a mathematical model 
that  predicts  that  gene  pool  frequencies  are  intrinsically  stable  throughout 
generations,  despite the constant occurrence of evolutionary pressure.  A deviation 
from  HWE  can  occur  under  several  conditions:  non-random  mating,  inbreeding, 
selection and genetic drift (that usually occurs due to small population size). In a 
specific research project, it may deviate  from equilibrium due to  sampling errors, 
population stratification,  technical problems  (genotyping errors)  and small sample 
sizes.
A population is said to be in Hardy-Weinberg Equilibrium for a particular locus 
when the genotypic frequencies observed in a given population are not significantly 
different from the expected frequencies.
p2 + q2 +  2pq = 1
The  equation  presented  in  the  box  above  represents  the  Hardy-Weinberg 
principle for a bi-allelic locus, where p2 represents the frequency of homozygous for 
one of the alleles, q2 represents the frequency of homozygous for the other allele and 
2pq represents the frequency of heterozygous, in a given population. Significance of 
deviation from HWE is usually determined using a chi-square test, but in this thesis a 
kind of exact test implemented in Arlequin was used.
2.4.2  Tests of independence (Non-parametric tests):
2.4.2.1  Chi-square (x2) test:
X 2 tests for goodness of fit, ie tests how well the observed frequency distribution 
fits the expected frequency distribution.
y2  ^ (Observed - Expected)2
A,  = 2 -----------------------------------------------
Expected
76The x2 significance is then determined in the Pearson x2 contingency table at 95% 
confidence interval with (r-l)(c-l) degrees of freedom, where r is the number of rows 
and c the number of columns of the distribution.
In the context of HWE it uses the observed genotype frequencies to calculate the 
allele frequencies of a certain locus and in a way calculate the expected frequencies 
for the genotype distribution.
2.4.2.2  Fisher’s exact test:
The Fisher’s exact test calculates an exact probability value for the relationship 
between 2 variables with 2 variants each, in a 2 by 2 contingency table.
Locus 2
alleles 1 2 Totals
1 A B A + B
2 C D C + D
Totals A + C B + D A+B+C+D=N
The p value is calculated:
(A + B)! (C + D)! (A + C)! (B + C)!
P=-------------------------------------------
N! A! B! CD!
The  exact probability is  calculated  for the  observed  table and all possible 
tables that deviate more from the expected than the one actually observed, and these 
are summed, as well as those tables that deviate in the opposite direction (for a two 
tailed  test).  The  table  is  said  to  be  significantly  deviated  from  expectation when 
p<0.05.
2.4.2.3  Mann-Whitney U test:
Mann  Whitney  tests  whether  two  independent  samples  come  from  identical 
populations or whether these populations have unequal distributions. It is started by 
calculation of the number of observation in each group, where:
- nl is the number of observation in the larger group
- n2 is the number of observations in the smaller group
77The two sample groups are ranked together in an increasing order of magnitude 
as  a  single  series.  After  the  ranking,  the  two  sample  groups  are  separated,  each 
observation maintaining the previously given rank. For each group, the sum of the 
ranks is made and a value assigned for each group:
- R1  is the sum of the ranks of population 1  with nl number of observations
- R2 is the sum of the ranks of population 2 with n2 number of observations
T  T —  nl n?- nl(nl+l)
-R1 U   111 11^*
2
or
TI—  nln?- n2(n2+l)
-R2 U   111 IlZi
2
Calculation of U statistics:
If U exceeds the critical value for U at the specified significance level, then the 
two groups are said to have distributions that are significantly different.
2.4.3  Haplotype prediction:
2.4.3.1  Expectation-maximisation algorithm (EM):
The  Expectation-maximisation  algorithm  (EM)  is  an  iterative  process  that 
estimates  haplotype  frequencies  through  successive  steps  (Excoffier  and  Slatkin, 
1995). It assumes that the observed genotypes are in HWE.
78Based on the observed genotype frequencies:
Marker B
< D
U rn
cd
Genotypes BB Bb bb
AA AA/BB AA/Bb AA/bb AA
Aa Aa/BB  | Aa/Bb Aa/bb Aa
aa aa/BB aa/Bb aa/bb aa
BB Bb bb N
it computes the haplotypes as follows:
Haplotypes BB
Marker B 
Bb bb
AA AB-AB AB-Ab Ab-Ab
Aa AB-aB
AB-ab/
Ab-aB
Ab-ab
aa aB-aB aB-ab ab-ab
o
cd
All  haplotype  frequencies  are  easily  calculated,  except  for  the  double 
heterozygous  AaBb  that  can  be  either  AB-ab  or  Ab-aB,  where  the  phase  is 
ambiguous.  In the  EM algorithm the first  step is  to  estimate  the  initial haplotype 
frequencies of the double heterozygotes based on the allele frequencies (expectation 
step).  The  initial  haplotype  frequencies  estimated  are  then  used  to  estimate  the 
proportion of AB-ab in the AB-ab/Ab-aB heterozygotes. Once this value is estimated 
it is used to re-estimate the AB-ab proportion in the heterozygotes and compute new 
haplotype  frequencies  (maximisation  step).  The  iterative process  repeats  until  the 
haplotype distribution stabilises.
The EM algorithm makes no assumption about linkage Disequilibrium between 
loci.
2.4.3.2  Bayesian algorithm (based on Bayes theorem):
The Bayesian algorithm to infer haplotype distribution is described in Stephens et 
al (Stephens et al., 2001).  It is an inference method that adjusts the estimates of a 
population parameter in light of prior knowledge.
79It  uses  a  variant  of the  Markov  chain-Monte  Carlo  (MCMC)  algorithm.  It 
estimates  all unambiguous  haplotypes  and then repeatedly chooses  an  ambiguous 
individual  and  estimates  the  probability  under  the  assumption  that  the  other 
haplotypes  are  correct.  This  process  is  repeated  until  the  haplotype  probabilities 
become stationary. It assumes the most simple relationship between the haplotypes.
2.4.4  Linkage Disequilibrium measurement:
Linkage Disequilibrium is the non-random association of alleles at linked loci. 
There are several coefficients used to measure LD:
2.4.4.1  D and D' coefficients:
D measures the observed frequency of co-occurrence of an allele Ai  of locus A 
and  an  allele  Bj  of  locus  B  on  the  same  chromosome  (Pn)  and  the  expected 
frequency of co-occurrence under Linkage Disequilibrium
D= P i i-piqi
where pi  and qi  are the allele frequencies of Ai  and Bi, respectively.  If D differs 
significantly from zero, the loci are in LD.
Because D is dependent on allele frequencies in the population,
its maximum value is Dm ax= min (piq2, p2qi) 
its minimum value is Dm in= max (piqi, P2q2)
and D can be scaled to
2.4.4.2 x2  and associated p value:
Determined as shown above for tests of independence.
802.4.5  Exact test of population differentiation (Goudet et al., 1996;Raymond and 
Rousset, 1995)
The Exact test of population differentiation produces a contingency table similar 
to Fisher’s exact test, but with a variable number of cell (columns and rows).  All 
potential contingency tables are generated using a Markov chain, and calculated the 
probability  of observing  each  table.  For  haplotypic  data,  the  table  is  built  using 
haplotype frequencies (Raymond and Rousset,  1995), and for genotypic data with 
unknown gametic phase, the table is built based on the genotype frequencies (Goudet 
et al., 1996).
2.4.6  Software packages
Alrequin: http://lgb.unige.ch/arlequin/. version 2.0 
PHASE2.0 and Phamily:
http://www.stat.washington.edu/stephens/phase.html 
http://archimedes.well.ox.ac.uk/cgi-bin/pise/phamilvl 
Websites no longer available.
GOLD: http://www.sph.umich.edu/csg/abecasis/GOLD/index.html
LDmax:  part of GOLD  software package- uses the EM to  estimate 
haplotype frequencies (Excoffier and Slatkin, 1995).
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MUCl  AND GASTRIC DISEASE IN UK 
-1996/1997 COHORT STUDY-Introduction
As described in detail in Chapter 1, there is evidence that mucins, as part of 
the gastric mucosa/external environment interface, play a role in the competence of 
Helicobacter pylori to establish in the stomach. Several groups reported interactions 
between the MUC5AC mucin and the bacteria and there was also involvement of 
another non-MUC5AC  mucin,  which was  almost  certainly  MUCl  (Linden  et al., 
2004). The blood group-related antigen Leb is also a ligand for H. pylori, and this is 
potentially  expressed  on  the  carbohydrate  chains  of MUCl  (Boren  et  al.,  1993). 
Furthermore, dramatic changes were observed in the pattern of expression of MUCl 
in H. pylori gastritis (Vinall et al., 2002).
Studies  in  our  lab  and  other  labs  reported  a  correlation  between  MUCl 
tandem repeat (TR) size and presence of gastric disease, namely H. pylori gastritis 
and gastric cancer (Carvalho et al., 1997;Silva et al., 2001;Silva et al., 2003;Vinall et 
al., 2002) in different populations. All reports include an over-representation of small 
alleles  in  the  disease  groups  when compared with  the  control  groups.  It was not 
however clear whether this was due to the length of the repeat domain itself, the 
internal sequence of the TR array or perhaps due to linked polymorphisms elsewhere 
in the gene which affect the properties of MUC1  or level of expression.
At  the  outset  of this  thesis  work,  data  was  available  for  3  polymorphic 
markers in the MUCl gene for the published gastritis group and controls (Vinall et 
al., 2002) and various other disease and control groups ( Joanna Fowler and Lynne 
Vinall, unpublished data), though some of this was incomplete, or unchecked, and 
not fully analysed; I contributed to this work by completing the data collection and 
furthering  the  analysis  by  studying  Linkage  Disequilibrium  (LD)  and  haplotype 
distribution.
833.1 Samples collected
3.1.1  First small gastritis cohort
During  the  period  between  1996  and  1997,  181  individuals  needing 
gastrointestinal  endoscopy  examination  in  the  Middlesex  hospital,  London,  were 
recruited for the first gastrointestinal study. All individuals filled in a questionnaire. 
Blood  samples  as  well  as  biopsies  (either  colon  or  stomach)  for histology  were 
collected from each individual.
Gastric  samples were  collected  from 59  individuals  of Northern  European 
extraction who had had upper gastrointestinal tract endoscopy examination and from 
whom  blood  samples  were  also  available.  DNA  was  extracted  from  the  blood 
samples,  and  biopsies  were  analysed  and  scored  for  possible  lesions  in  the 
gastrointestinal  tract,  specifically  in  the  stomach  antrum,  and  presence  of 
Helicobacter pylori. Only Northern European individuals were included, to avoid the 
problem of population stratification, which might mask significant results or produce 
false positives.
7 of the individuals had evidence of gastritis but no H. pylori infection and 
were excluded from the comparisons because of the small number of cases, and lack 
of knowledge  as  to  whether  or  not  those  individuals  had  H.  pylori  eradication 
treatment before.
3.1.2  Oesophageal cancer and other GI disease
51  colon  samples  from  Northern  European  individuals  who  had  had  a 
colonoscopy examination and were diagnosed according to presence or absence of 
colon disease  were used as part of a  control population c ollected  in the  same  GI 
clinic, Middlesex Hospital. The other group included in this category was a cohort of 
individuals  with  oesophageal  disease  (n=101),  collected  by  Dr  Laurence  Lovat. 
These 2 groups were pooled into the same category, named Middlesex hospital- other 
diseases,  and f or which no  gastritis  information and Helicobacter pylori  infection 
status is available. Each of the groups is characterised in the Material and Methods 
section. From this point onwards, this group will be denominated ‘Mdx- others’.
3.1.3  Non-hospital controls
Finally,  a fourth group of individuals included in this analysis as a control 
population belongs to the 1946 cohort, described in more detail in the Materials and 
Methods  section.  This  was  composed  of  349  DNA  samples  collected  from
84individuals living in the London area, from whom no information on gastric disease 
or Helicobacter pylori infection status is available. These are identified below as the 
‘London area’ group, representing a random London population.
3.1.4  Characterisation of the samples from the first small gastritis cohort
The table 3.1 summarises the number of females and males in each of the two 
subgroups, normal and H. pylori gastritis, independently of the category. The table 
shows  that  there  are  more  males  in  the  affected  group  and  more  females  in  the 
controls GI clinic controls.
Males Females
Number of 
individuals
% of
individuals
Number of 
individuals
% of
individuals
H. pylori gastritis 14 56 9 33
Normal 11 44 18 67
Total cohort 25 - 27 -
Table 3.1:  Distribution of males and females in each of the disease groups  and the  total cohort in terms of 
number of individuals and  percentages.  Though there are more  females o verall,  51.9%,  the majority of H. 
pylori gastritis population is male (60.9%). In the normal GI clinic controls the majority of the individuals are 
females (62.1%).
In relation to the mean age of the individuals in these two subgroups, there is 
not a significant difference between sexes, with the mean age of 53 for the H. pylori 
gastritis patients (ranging from 25  to 81  years old) and 46 for the normal controls 
(ranging from  17 to 75). The slightly older age of the gastritis patients may reflect 
the  age-related  occurrence  of  the  disease  where  prolonged  colonisation  of  the 
bacteria, together with other factors, triggers a series of mechanisms that over time 
will lead to gastritis, and symptoms severe enough to require a visit to the doctor.
853.2  MUCl genotype and haplotype distribution for the 3 polymorphic loci 
within the gene
G3506A SNP CA microsatellite
12 repeats
11 repeats
andem repeat region
Figure 3.2: Schematic representation of MUCl gene. Yellow boxes represent the 7 gene exons.  In exon 2 the 
grey  boxes  are  shown  with  different  lengths  to  illustrate  the  variable  number  of tandem  repeats  (VNTR) 
polymorphism, and the g/a SNP polymorphism is also shown in exon 2 marked with an asterisk (*). In intron 6, 
the CA microsatellite is marked with open arrowheads and two of the possible number of repeats, 11 and 12.
3.2.1  MUCl genotypes and allele distribution
Figure  3.2  shows  a  schematic  representation  of  the  MUCl  gene  and 
polymorphisms within it. One large domain composed of repeats arrayed in tandem 
makes up most of exon 2 and is flanked by a single nucleotide polymorphism (SNP) 
and a microsatellite.  The  TR array  has  an  extremely variable number of repeats, 
which in the European population exhibits a bimodal distribution (see Figure 4.2 in 
Chapter 4).
Figure 3.3 (A, B and C) shows the genotype distribution of the three MUCl 
markers: G3506A  SNP, tandem repeat polymorphism (TR) and CA microsatellite, 
respectively, in the Helicobacter pylori gastritis group and the three control groups: 
GI  clinic  controls,  Middlesex  Hospital-  other  diseases  and  London  area.  The 
corresponding allele frequencies of the groups are show in Table 3.4 A, B  and C 
respectively.
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Figure 33: Genotype frequencies for 3 MUCl markers: G3506A SNP (A), TR length polymorphism (B) and 
CA  microsatellite  (C).  Each  graph  displays  the  genotype  frequencies  for  each  of the  groups  studied: 
Helicobacter pylori gastritis (n=23), GI clinic controls (n=29), Mdx- others (n=152) and London area (n=349).
87A
H. pylori  gastritis GI clinic controls Mdx other diseases London areaO
A 0.50 0.53 0.56 0.54
G 0.50 0.47 0.44 0.46
B
H. pylori gastritis GI clinic controls Mdx other diseases London areaO
L 0.26 0.48 0.45 0.48
S 0.74 0.52 0.55 0.52
C
H. pylori  gastritis GI clinic controls Mdx other diseases London areaO
11 0.50 0.48 0.44 0.45
12 0.48 0.45 0.48 0.46
13 0.02 0.07 0.08 0.09
14 0.00 0.00 0.00 0.00
Table 3.4:  Allele frequencies for the 3 MUCl markers: G3506A SNP (A), TR length polymorphism (B) and 
CA microsatellite (C). Each table displays the allele frequencies for each of the studied groups: Helicobacter 
pylori gastritis (n=23), GI clinic controls (n=29), Mdx- others (n=152) and London area (n=349). Note that for 
the London area, the CA microsatellite shows an additional allele, with 14 CA repeats, that is not represented 
in  the  other  groups.  This  observation  can be  explained  by  the  low  frequency  of the  allele  in  the  general 
population allied to a small sample size in the other groups, lowering the probability of showing the allele just 
by chance.
For all the four populations included in this study, all loci were found to be in 
Hardy-Weinberg Equilibrium (HWE).
The genotype distribution shows a substantial over-representation of the SS 
genotype  in  the  Helicobacter pylori  gastritis  group  (Figure  3.3(B))  not  only  as 
compared  with  the GI  clinic  controls (Vinall  et al.,  2002)  but also  with all  other 
controls.  Contingency  tables  and  Fisher’s  exact  test  calculations  show  that  the 
tandem repeat allele distribution of the Helicobacter pylori gastritis group is not only 
significantly different from the GI clinic controls, but also from Mdx-other disease
88and the London area, with 2-tailed p-values of 0.026, 0.016 and 0.0036, respectively 
(see Table 3.4(B)).
On  the  other  hand,  other  markers  are  more  similar  between  the  groups, 
except  for a  small and non-significant  increase  in AG  heterozygous  for the  SNP 
polymorphism in the gastritis groups, when compared with the others.
The lack of difference between the flanking markers in the various groups in 
comparison  with  the  TR  repeat  length  suggested  that  an  examination  of  the 
haplotypic distribution would be worthwhile.
3.2.2  MUCl haplotypes
To follow these observations further, MUCl  haplotypes  for  the  3 
polymorphisms were inferred. Two different software packages were used; Arlequin, 
that uses  Expectation Maximisation EM  algorithm to  infer haplotype  frequencies, 
and  PHASE,  that uses  a Bayesian method (involving conditional probabilities)  to 
infer the haplotypes of individual people with associated probabilities (Stephens et 
al., 2001).
The haplotypes inferred using the two methods are displayed in figure 3.5 (A) 
and (B). Observing the two bar charts, it is easily seen that the two methods generate 
similar haplotypes and the respective frequencies are also similar.
Using  the  Arlequin  statistical package  which  gives  a  measure  of Linkage 
Disequilibrium (LD), it was also found that for most groups, the 3 markers are in LD 
with each other generating two major haplotypes, A S 12 and G L 11, which together 
account  for  nearly  80%  of  the  chromosomes  in  most  groups  (see  Figure  3.2). 
Interestingly, in the gastritis population the strong LD observed in the other groups is 
broken. Though the g/a SNP remains in LD with the Tandem Repeat domain and the 
CA microsatellite, the LD between the TR and the CA microsatellite is disrupted (see 
table 3.6).
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Figure 3.5: MUCl  haplotype distribution in 4 different groups: Helicobacter pylori gastritis, GI clinic controls, Mdx- others and  London area. The haplotypes were  inferred 
using 2 different statistical methods: (A) a Bayesian method and (B) a maximum-likelihood method, the EM algorithm.
90Helicobacter pylori 
gastritis
GI clinic controls Mdx- other diseases London area
G3506A SNP and 
TR domain
0.00485 0.0001 <0.000001 <0.000001
G3506A SNP and 
CA microsatellite
<0.000001 <0.000001 <0.000001 <0.000001
TR domain and 
CA microsatellite
0.51653 <0.000001 <0.000001 <0.000001
Table 3.6: Pairwise Linkage Disequilibrium between pairs of markers for the four populations. The values on 
the  table  correspond  to  the  p  values  calculated  using  the  Arlequin  software  package.  All  groups  show  a 
significant  LD  between  markers,  except  for  the  H.  pylori  gastritis  group,  for  which  the  LD  is  disrupted 
between the TR array and the CA microsatellite.
Pairwise comparisons using PHASE program showed that none of the control 
groups (the GI clinic controls, Mdx- others and London area) differ significantly in 
haplotype distributions from each other. However, the Helicobacter pylori gastritis 
group was significantly different from all the other groups (p<0.02). The ‘exact test 
of  population  differentiation’  in  Arlequin  software  package  confirms  this  basic 
finding in that Helicobacter pylori gastritis group is significantly different from the 
the two larger control groups (Mdx-others and London area) although the GI clinic 
control group did not show as significant, possibly due to the small size of the two 
data sets.
However, just by observation, it is very obvious that one haplotype is over­
represented in the Helicobacter pylori gastritis group while the control groups look 
very similar. A particular recombinant haplotype in the gastritis group- G S 11- that 
accounts  for  almost  25%  of the  total  number  of chromosomes  in  this  group,  is 
present  in  the  other  groups  at  a  much  lower  frequency.  This  high  frequency 
recombinant haplotype explains the much higher frequency of the S allele and also 
the  SS genotype  found  in the  gastritis group, as well as the disruption of 1  inkage 
between the TR and CA polymorphisms in this disease group.
913.3 MVR analysis
Previous  work  from  this  lab,  and  elsewhere,  has  described  considerable 
variability  between  repeat  sequence  variation  in  the  MUCl  tandem  repeats 
(Engelmann et al., 2001;Fowler et al., 2003). The main variation studied by us was 
the change in sequence which alters the more common peptide motif in the repeat 
unit from PDTR to PESR. The results of this study, which I contributed to by data 
completion,  haplotype  assignment  and data  analysis  are  published  (Fowler et  al., 
2003) and a copy of the paper which includes relevant methods is appended to this 
thesis.  Alleles  were  separated  by  PCR  amplification  across  the  TR  array  and 
electrophoresis to  separate the bands, then used separately for minisatellite variant 
repeat analysis (MVR).  Complete maps were obtained from 119 alleles as well as 30 
partial maps. The MVR maps of 90 short alleles and 29 long alleles were compared, 
even though the majority of the long alleles were incomplete maps. Because of this 
gap  in  the  MVR  data  for  the  long  alleles,  no  statistical  comparison  was  done. 
However,  the  analyses  suggested that there  were  more PESR repeats  in the  long 
alleles and that the block structure was a little different and less regular (Fowler et 
al.,  2003).  The  observation  of over-representation  of one haplotype  GS11  in  the 
gastritis cohort, which was subsequently also seen in the patients with gastric cancer 
(see Chapter 4) led us to consider whether these alleles (GS11) might differ from the 
standard AS 12 alleles and perhaps resemble long alleles in terms of block structure 
and also have a greater PESR content. To make comparison of block structure was 
not possible with the limited number of these variant alleles, but a simple comparison 
of the proportion of PESR content was attempted.
To do this, only Northern European chromosomes were tested, and the MUCl 
allele maps were classified into GS and GA haplotype by a combination of methods. 
In some cases haplotype assignment was unambiguous (ie where at least one of the 
two polymorphism was homozygous).  In some cases it was tested directly by allele 
specific  PCR  across  the  TR region  and in  a  few  cases  phase  was  inferred using 
haplotype  inference  software.  It was possible to  assign haplotype with reasonable 
certainty for a total of 80 NE chromosomes (70 AS and 10 GS).
The number of each type of repeat was counted for each allele and expressed 
as a proportion of the total repeat number. Comparison of the two groups of alleles
92shows  that  although  there  were  indeed  slightly  more  PESR  repeats  this  was  not 
statistically significant. It should be emphasised that only 38 alleles from patients 
with gastritis were fully mapped. Attempts to continue this work and to analyse other 
inter-repeat variation were unfortunately not successful.
Haplotype
Number of 
chromosomes
Av erage of PESR 
variant
Standard
Deviation
SA 70 0.2050 0.0348
SG 10 0.2283 0.0514
Table 3.7: Summary of the number of small TR MVR alleles from NE individuals. The average amount of the 
PESR variant is slightly higher in the SG chromosomes than in the SA chromosomes but this difference was 
not statistically significant p=0.1939 p- 2tail, p=0.969 p- 1  tail.
3.4  Discussion
The 4 populations studied were all collected in London, three of the groups in 
the same GI clinic, so that all groups would be comparable. The two GI clinic control 
groups and the ‘London area’ group showed genotypic and allelic frequencies similar 
to each other, but statistically different from the Helicobacter pylori gastritis group 
for  the  TR  distribution.  In  the  H.  pylori  gastritis  group  there  was  a  significant 
increase of S alleles and of the proportion of individuals carrying the SS genotype.
In  the  haplotype  prediction,  PHASE  software  program  generated  a  larger 
number of haplotypes than the Arlequin program. This is due to the fact that PHASE 
estimates  the  haplotype  frequencies  without  taking  into  account  the  number  of 
chromosomes in each population and thus predicts some rare haplotypes that would 
occur in  less  than  1   chromosome.  However,  the two  software packages produced 
extremely similar haplotype distributions. Again, the 3 control groups showed very 
similar  haplotype  distributions,  and  distinct  from  the  gastritis  group.  The  latter 
showed an over-representation of a particular recombinant allele, G S  11, that was 
represented at small proportions of the chromosomes in the other groups.
In preliminary i nspection o f the MVR patterns, it s eemed that t he G  S  11 
haplotype showed a distinct pattern, with larger blocks of PESR variants interspersed 
between the PDTR blocks rather like the large TR alleles which generally share the
93same flanking markers. However, the analyses of the proportion of PESR variant in 
SA and SG chromosomes showed that the small difference between the two was not 
statistically significant. This  may be in part due to  the very small number of SG 
chromosomes with available MVR maps.
Since a different haplotype distribution was observed in the gastritis patients, 
it was of interested to establish whether there are inter-population differences in the 
distribution of these haplotypes and whether a change in frequency was observed in 
other patients with gastric disease. This is considered in Chapters 4 and 6.
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MUCl HAPLOTYPE DISTRIBUTION IN POPULATIONS 
OF DIFFERENT ANCESTRY
PORTUGUESE POPULATION- STUDIES ON PATIENTS
95Introduction
As seen in a previous chapter, in Northern Europeans MUCl usually exhibits 
a bimodal distribution of TR lengths and very high Linkage Disequilibrium between 
the  S and L TR lengths and the 2  flanking polymorphisms in the gene. However, 
little was known about other populations, and whether the bimodality and LD were 
still maintained. In the first part of this chapter, 3 populations of different ancestries 
are compared, not only in terms of allele length and genotypic frequencies, but also 
haplotype distribution.
For  this  study,  samples  were  available  from  an  unselected  population  of 
Nigerian origin.  No previous analysis of the TR domain of MUC genes has been 
reported for Africans, partly because  of the  lack of availablility of suitable DNA 
samples. Normally this means using DNA from blood, but because of HIV and AIDS 
blood is rarely sent from Africa to the UK these days.  For this study an attempt was 
made to use buccal DNA. DNA was obtained from 10 buccal swabs from each donor 
as described in section 2. In some cases it was found necessary to reprecipitate and 
after  this  procedure  DNA  of adequate  quality  was  obtained  in  a  total  of 60/86 
samples  from  unrelated  individuals  (70%  of cases)  to  obtain  MUCl  TR  data  by 
Southern blot analysis (see Figure 4.1).
TR  data  and  DNA  were  also  available  from  unselected  Portuguese  blood
donors.
In addition, data and samples were available from Portuguese patient groups 
and they are considered in the second half of this chapter.
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Figure 4.1:  Southern Blot obtained using Nigerian samples digested with the Hinf I restriction enzyme. The 
autoradiograph shows the Raoul molecular weight marker in each side of the gel and the bands size on the 
left side. The * symbol marks the lane position of the internal positive control, digested DNA from the cell 
line Caco-2.
974.1  MUC1  genotype  and  haplotype  distribution  in  populations  of  different 
ancestry
4.1.1  Allele  distribution  of the  tandem  repeat  array  in  the  Northern 
European population and Nigerian population
In this section the lengths of tandem repeat alleles of the Nigerian population 
group were compared with those of Europeans from the UK. The data are displayed 
in  histograms  with  alleles  binned  in  0.5Kb  classes  (Figure  4.2).  The  Portuguese 
population was not compared here because the TR sizing was done in another lab, 
using a different restriction enzyme, and a different method to size the alleles (see 
section 4.1.2.1).
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Figure 4.2: Allele size distribution in a population of Northern European extraction, collected in London 
(A), and Nigerian population (B). The NE group shows a bimodal distribution, though the second peak show 
a  very  abrupt  decrease.  The  Nigerian  group  shows  a  trimodal  distribution,  never  observed  in  a  NE 
population, with an increase of large alleles near the cut-point area (5-5.5Kb).
98The histogram in figure 4.2 shows the distribution of the TR array size in the 
Nigerians  compared  with  UK  residents.  As  previously  reported,  the  Northern 
European population shows a bimodal distribution of the alleles with the dip between 
the peaks at about 5Kb length (Vinall et al., 2002). The distribution in the Nigerians 
in contrast was trimodal with 2 peaks above 5kb. Despite these differences, a Mann- 
Whitney  test  reveals  no  statistically  significant  difference  between  the  two 
populations (P (2-tailed)= 0.1978).
4.1.2  Comparison of t hree p opulations  of different a ncestry:  Northern 
European, Nigerian and Portuguese
As seen in the previous chapter, because of the bimodal distribution of the 
MUC1  TR in Europeans,  it  is possible  to bin the alleles  into two  major variants: 
small alleles (S), shorter than 5Kb and large alleles (L), 5Kb long or longer.  Despite 
the trimodal distribution in the Nigerians a 5Kb cut point was used to separate short 
and long alleles for this group as well.
Division into S and L alleles had also been done by the Porto lab.  However, 
since  these  data  were  obtained  from  another  lab  and  allele  assignment  made  by 
another method, it was necessary to compare methods and test some control samples 
on both systems to check comparability of data, as described below.
4.1.2.1  Tandem Repeat array- Different sizing methods
The method of TR sizing used in our laboratory, described in more detail in 
the methods section, calculates the size of the TR in Kb, attributing a precise size 
value to each allele and incorporates the same controls on all gels.  In the Porto lab 
the  size  of the  tandem  repeat  array  was  determined  by  doing  restriction enzyme 
digestion  with  EcoRI,  or  Alul  followed  by  Southern  Blotting  (Carvalho  et  al., 
1997;Silva  et  al.,  2001;Silva  et  al.,  2003).  The  scoring  of the  alleles  was  made 
analysing the autoradiograms visually. The bands were scored into 15 discrete allele 
classes according to the band position in relation to the molecular marker XHindlll 
and other samples. The bands ranged in size from 8.9Kb to  12.6Kb, and the alleles 
were assigned a number corresponding to the size, with allele 1  being the largest, and
99allele 15 the smaller in molecular weight. Though this sizing method is very different 
from the one used in our lab, where we use the actual size of the bands and treat it as 
a continuous variable, the cut-point between large (L) and small (S) alleles seems to 
coincide,  and  therefore the  L  and  S  terminology  used  by  the  Portuguese  groups 
seems to be the same (see Figures 4.3 and 4.4).
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Figure 4 3 : Schematic representation of the MU  Cl gene (long arrow at the top) and the relative positions of 
Hinfl and EcoRl cut sites to exon2 and Tandem Repeat region. The distance in base pair number from the 
enzyme cut sites to the TR domain is shown in die open boxes (blue for the EcoRl and purple for the Hinfl). 
The Alu I cut points are not marked here since this enzyme was not used in any of the analyses for this study.
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Figure 4.4: Southern Blot obtained using 5 different samples digested with the 3 restriction enzymes used in 
the lab in London, Hinf I, and the lab in Portugal, Eco RI and Alu I. The autoradiograph shows the Raoul 
molecular  weight  marker  in  each  side  of the  gel  and  the  bands  size  on  the  left  side.  The  dashed  lines 
correspond to the calculated cut points for each enzyme. It is easily observed that the three enzymes have a 
consistent  cut  pattern  for  each  sample.  This  figure  shows  the  results  are  reproducible  using  different 
restriction enzymes.
1014.1.2.2  Genotype and allele distribution
Comparisons  were  made  of genotype  and  allele  frequencies  for  the  2  flanking 
markers and the simplified TR alleles (figure 4.5, Table 4.6).
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Figure  4.5:  Genotype  frequencies  for  the  Tandem  Repeat  array  (A),  G3506A  SNP  (B)  and  CA 
microsatellite  (C)  for  the  three  studied  populations:  Nigerians  (n=60),  Northern  Europeans  (London) 
(n=349) and Portuguese blood donors (n=75).
102A
Nigerian
Portuguese blood 
donors
N orthern European 
London
L 0.63 0.45 0.48
S 0.37 0.55 0.52
B
Nigerian
Portuguese blood 
donors
N orthern European 
London
A 0.63 0.49 0.54
G 0.37 0.51 0.46
C
Nigerian
Portuguese blood 
donors
N orthern European 
London
11 0.37 0.51 0.45
12 0.60 0.43 0.46
13 0.03 0.07 0.09
14 0.00 0.00 0.00
Table 4.6: Allele frequencies for the Tandem Repeat array (A), G3506A SNP (B) and CA microsatellite (C) 
for the three studied populations: Nigerians (n=60), Northern Europeans (London) (n=349) and Portuguese 
blood donors (n=75).
The two European populations have a similar distribution of L/S genotypes, 
though  the  Portuguese  group  shows  a  slightly  higher  proportion  of  individuals 
carrying the SS genotype. In contrast, the Nigerians show many more LL individuals. 
In fact using the 5Kb cut point, about two-thirds of the alleles are classed as Large 
alleles (L) in the Nigerian population. However, this is mainly due to L alleles near 
the cut-point, in the 5 to 5.5Kb range (Figure 4.2).
For the  G3506A  SNP,  the  Portuguese  and Northern  European  populations 
have  a  similar  genotype  distribution  and  the  Nigerians  show  relatively  more 
homozygous AA individuals and fewer GG and higher frequency of A (0.63).
The differences in genotype distribution of the CA microsatellite are not so 
obvious due to the presence of multiple alleles. The most obvious observation is the 
very  high  proportion  of  the  12,12  genotype  and  12  allele  in  the  Nigerians, 
accompanied by a less obvious decrease in the frequency of the 11,11 genotype. 63% 
of the alleles in the CA microsatellite with  12/13 repeats. The other two populations 
show  no  significant  differences  in  the  genotype/allele  distribution,  despite  the
103presence of a minor allele with 14 repeats in the Northern European population that 
is not present in the others.  These  differences  in  allele  frequencies  between  the 
Nigerian population and the two European populations are statistically significant. A 
Fisher’s exact test using allele counts revealed 2-tailed p values of 0.0031  between 
the  Nigerians  and  Portuguese  blood  donors  and  a  p  value  of  0.0022  between 
Nigerians  and  Northern  Europeans.  The  two  European  populations  were  not 
significantly different from each other (p value= 0.4714).
4.1.2.3  Haplotype distribution for the 3 populations:
Haplotype distributions were inferred for the 3 populations using:  Arlequin 
and PHASE, as used previously in Chapter 3.
Goodness of fit to Hardy-Weinberg Equilibrium (HWE) was also tested using 
the Arlequin software package. The G3506A SNP and CA microsatellite showed no 
deviation from HWE for the three populations tested.  However, while the TR array 
L/S  genotype  distribution is  in HWE  in the Portuguese blood donors,  it shows  a 
significant  deviation  in  the  Northern  Europeans  and  Nigerians,  with  p  values  of 
0.03132 and 0.02705, respectively. This deviation from equilibrium is in both cases 
due to a lack of LS heterozygotes.
Figure  4.7  shows  the  haplotype  distribution  inferred  using  both  methods. 
From  direct  observation  it  is  obvious  that  Arlequin  (Figure  4.7.A)  and  PHASE 
(Figure 4.7.B) produce very similar haplotype distributions, giving consistency to the 
predictions.
For all three populations, the two major haplotypes are the same, A S 12 and 
G L 11  (See Figure 4.7). However, the A L 12 haplotype, which is relatively rare in 
the two populations of European extraction, is much more frequent in the Nigerians, 
accounting for more than 25% of the chromosomes in this group. Nonetheless, the 
high  LD  between  markers  previously  observed  in  the  Northern  Europeans  and 
responsible for the appearance of two major haplotypes, A S  12 and G L  11, is not 
disrupted in the Nigerians, with the LD p values calculated by the Arlequin software 
package lower than 0.0001.
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Figure 4.7: MUCl  haplotype distribution for the three studied populations:  Nigerians (n=60), Northern Europeans- London (n=349) and Portuguese blood donors (n=75). The 
haplotypes were inferred using 2 different statistical methods: (A) a maximum-likelihood method, the EM algorithm, and (B) a Bayesian method.
105Comparison using the  ‘Exact test of sample differentiation’  (performed by 
Arlequin)  shows  that  the  Nigerian  population  is  significantly  different  from  the 
Northern  European  London  cohort  and  the  Portuguese  blood  donors’  cohort 
(pO.OOOOl for both pairs of populations). Comparisons of pairs of populations using 
PHASE also found the two European populations to be significantly different from 
the Nigerians (p=0.01 for both cases), but not different from each other (p=0.07).
This difference is clearly a reflection of the high proportion of the A L  12 
haplotype observed in the Nigerians.
Since it seemed possible that this increase reflected the large number of L 
alleles  in  the  5  to  5.5Kb  region,  this was  examined  further.  A  file  generated by 
PHASE was used  displaying  the possible  haplotypes  for each  individual and  the 
associated probabilities for each case. The raw data used is available in appendix 1. 
Of the  30  chromosomes with tandem repeats  in the  5Kb  to  5.5Kb  range,  18  are 
associated with the A  12  haplotype and the  other 9 have a  50%  chance of being 
associated with the same haplotype.  Only 3  chromosomes in this  size range were 
definitely associated with non- A 12 haplotypes. Out of 31 A L 12 haplotypes only 4 
were greater than 5.5Kb in size. In summary, the majority of the 5kb to 5.5Kb TR 
alleles  are associated with the A  12 haplotype,  flanking markers more commonly 
found for S chromosomes.
4.1.2.4  Discussion
Although MUCl polymorphism was reported a long time ago in the Northern 
Europeans, little was known about its variability in other human populations. So far, 
MUCl TR size variation has been reported for Northern Europeans, mainly of British 
origin, Portuguese and Danish as well as a very small amount of data from Japanese 
(Ando  et  al.,  1998;Carvalho  et  al.,  1997;Carvalho  et  al.,  1999;Silva  et  al., 
2001;Vinall et al., 2002). Here, we report for the first time MUCl TR information in 
Africans (a Nigerian population), as well as data on the two flanking markers present 
in the gene in Portuguese and Africans.
The original Nigerian cohort of 86 unrelated individuals was reduced to 60 
individuals, for whom the DNA quality was good enough to obtain data for the TR
106allele sizes. The results obtained from those that were included were however clear 
(Figure 4.1).
The Nigerian population revealed a significantly different distribution of the 
TR  array  alleles,  which  seemed  to  be  trimodal,  due  to  a  large  number  of 
chromosomes  with  TR  in  the  5-5.5Kb  size  range.  This  was  accompanied  by  a 
decrease in the proportion of small alleles in the 3-3.5Kb class, though the overall 
range in size of TR alleles seemed similar to that in Europeans.
The slight deviation from HW Equilibrium of the TR genotypes in Nigerians 
and Northern Europeans was of possible concern.  However, it may not be of real 
significance because of the large number of comparisons made; it may also reflect an 
artefact of binning allele sizes.  The presence  of very small  alleles,  missed in our 
system is also a possible explanation, though rather unlikely. The loss of a few large 
alleles  in  the  Nigerians  is  conceivable  because  the  samples  collected  were  from 
buccal DNA and the DNA quality is not as good as blood, and results for the TR 
using  Southern Blotting are more difficult to obtain. However, nearly 80%  of the 
samples showed 2 different length alleles making nether of these likely. The same 
situation  applies  to  the  NE  population,  where  87%  of the  individuals  showed  2 
different alleles.
A noteworthy feature of the Nigerian data, however, was that the flanking 
markers were, as in Europe, highly associated, with no evidence of greater haplotypic 
diversity than in Europeans, Most studies indicate that there is more diversity and 
regions  of LD  tend  to  be  shorter  in  Africans  (Gabriel  et  al.,  2002;Hollox  et  al., 
2001;Tishkoff et al., 2000) but here is still limited information available as to inter 
group differences. . Using the European cut point for the length of the TR alleles, one 
haplotype class that is rare in Europeans was frequent. This haplotype is different 
from the one found frequently in the UK gastritis study. It could be attributable to a 
particular TR allele (length 5-5.5Kb) being at a particularly high frequency in the 
Nigerian population we tested.  It should be noted that most of these samples came 
from a single tribal group Ibibio (n=85  from the original group).  If suitable DNA 
becomes  available  it will  be  of interest  to  study  these  TR variations  in different 
groups and in different parts of Africa. In Nigeria, the Helicobacter pylori infection 
is  usually  associated  with  moderate  to  severe  chronic  gastritis  (Oluwasola  and
107Ogunbiyi, 2004). Despite the high incidence of H.  pylori infection in the Nigerian 
population (80 to  85%), the prevalence of atrophy or intestinal metaplasia is quite 
low  (Oluwasola  and  Ogunbiyi,  2003;01uwasola  and  Ogunbiyi,  2004).  This  may 
explain  the  very  low  incidences  of gastric  cancer  in  Nigeria,  about  1   case  per
100.000  individuals,  according to  the  2002  statistics  from  Globocan (http://www- 
dep.iarc.fr/globocan/database.htm).
4.2  Portuguese Population- Studies on patients 
Introduction
The  Portuguese  population  has  a  very  high  incidence  of gastric  disease, 
including  gastric  cancer.  The  gastric  cancer  rates  in  Portugal  are  the  highest  in 
Europe, and one of the highest in the world. According to Globocan 2002 database 
(http://www-dep.iarc.fr/globocan/database.htm),  the number of new cases per year 
per 100.000 individuals (Incidence Crude Rate) in Portugal is of 43.4 in males and 
25.9  in  females.  In  the  face  of these  facts,  it  has  been  interesting  to  study  the 
Portuguese  population  to  assess  whether  genetic  predisposition  could  play  an 
important role,  and  the  Portuguese  lab  considered MUCl  as  one  of the possible 
candidates (Carvalho et al., 1997).
The samples in this study were obtained in collaboration with Prof Leonor 
David  and  Dr  Raquel  Seruca,  from  the  Institute  of  Molecular  Pathology  and 
Immunology  of the  University  of Porto  (IPATIMUP),  Portugal.  Three  different 
groups of samples were studied:  a cohort of blood donors,  from  S.  Joao Hospital, 
Porto, from whom no gastric disease information is available, a cohort of individuals 
with gastritis and dyspepsia, collected in a naval shipyard in Viana do Castelo, North 
Portugal, and a cohort of gastric cancer samples collected also in S. Joao Hospital. 
The  sample  collection  and  DNA  extraction  was  done  in  Portugal,  and  MUCl 
Tandem  Repeat  size  information  was  also  produced  in  Portugal  by  Dr  Filipa 
Carvalho and Dr Luis Filipe Silva.
The  aim  of  this  part  of  the  work  was  to  determine  whether  a  disease 
associated haplotype could also be detected in this population.
1084.2.1  Blood donors and gastric cancer
In  the  first  analysis  the  blood  donors  and  gastric  cancer  samples  will  be 
analysed together since they were collected in the same hospital, and therefore more 
likely  to  be  representative  of 2  subgroups  of the  same  population.  The  ‘Viana’ 
samples were collected in a different region of Portugal, and the collection procedure 
was different and will be referred to later in this chapter.
A  previous  study  of  the  MUCl  Tandem  Repeat  (TR)  polymorphism 
involving the two populations in this particular study reported a significant difference 
on the  distribution of the TR alleles and genotypes,  showing  a  significant higher 
prevalence  of small  alleles  (S)  and  individuals  with  SS  genotypes  in  the  gastric 
cancer group in relation to the blood donors control group (Carvalho et al., 1997).
In our study, only a subset of each of the above-mentioned populations was 
used, rather than the entire group of individuals in the report, because most of the 
DNA samples were not available. They were either degraded or used up. As a result, 
data was  obtained  for a total of 75  samples  from  the  blood donors  group  of the 
original 166 and 43 samples from the gastric cancer cohort of the original 66.
The TR information that was already available for the individuals was used 
and  analysed  in  conjunction  with  the  two  MUCl  flanking  markers.  Allelic 
frequencies and genotypic frequencies are produced and the haplotype distribution 
inferred.
4.2.1.1  Genotype and allele distribution
Figure 4.8 shows the genotype distribution for each of the 3 MUCl markers 
for  blood  donors  and  gastric  cancer  patients.  Figure  4.8.A  shows  the  dramatic 
difference in Tandem Repeat genotype frequencies between the two groups. While 
the blood donors show a relatively balanced distribution of LL and SS genotypes and 
a higher proportion of LS heterozygotes, the gastric cancer group has a very similar 
percentage  of heterozygotes  LS,  but the  fraction of SS  homozygotes  is  markedly 
increased and the LL homozygotes amount declines dramatically, to about 7% of the 
total number of gastric cancer patients.
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Figure  4.8:  Genotype  frequencies  for  the  Tandem  Repeat  array  (A),  G3506A  SNP  (B)  and  CA 
microsatellite  (C)  for the  two  Portuguese  populations:  Blood  donors  (n=75)  and  Gastric  cancer patients 
(n=43).
110The two MUCl flanking markers do not show a distinct difference between 
the two groups. The gastric cancer group shows a slight increase in the number of 
individuals with AA genotype, and a consequent decrease in the other two genotypes 
(Figure  4.8.B).  However,  these  differences  are  not  statistically  significant.  In  the 
same way, there is an increase of the 12,12 genotype for the CA microsatellite in the 
gastric  cancer group,  and a decrease in the fraction of 11,12  heterozygotes,  when 
compared with the blood donors control group (Figure 4.8.C).
The increase in AA homozygous and 12,12 homozygous, figure 4.8 B and C, 
respectively, are in accordance with the large number of homozygous SS present in 
the  disease population.  This  corroborates  the  associations  previously observed  in 
other populations between the 3 markers: A with S and 12 and G with L and 11.
A
Blood donors Gastric cancer
L 0.45 0.28
S 0.55 0.72
B
Blood donors Gastric cancer
A 0.49 0.56
G 0.51 0.44
C
Blood donors Gastric cancer
11 0.51 0.45
12 0.43 0.47
13 0.07 0.07
14 0.00 0.01
Table 4.9: Allele frequencies for the Tandem Repeat array (A), G3506A SNP (B) and CA microsatellite (C) 
for the two Portuguese populations: Blood donors (n=75) and Gastric cancer patients (n=43).
IllTable 4.9  shows the allele frequencies for the blood donors  group and the 
cohort of gastric cancer patients. As is easily observed, the percentage of S alleles is 
much higher in the gastric cancer group than in the control group of blood donors 
(Table  4.9.A).  Despite  the  reduction  in the  number of individuals  in  each  group 
compared with the ones reported by Carvalho et al, the difference in L and S allele 
distribution  for the  TR polymorphisms  is  still  statistically  significant.  A  Fisher’s 
exact  test  revealed  a  2-tailed  p-value  of  0.0124.  However,  the  two  other 
polymorphisms  tested in our lab  seem to have  similar a llele  distribution,  with no 
significant difference between the two population groups (Tables 4.9.B and 4.9.C).
4.2.1.2  Haplotype distribution
Using the Arlequin  software package  and  PHASE program,  the haplotype 
distribution for the two populations was inferred. Once more, both programs reveal 
very  similar  haplotype  distributions,  as  shown  in  figure  4.10  (A  and  B).  It  is 
interesting to observe a substantial increase in the particular haplotype G S 11 in the 
gastric  cancer group,  where it accounts for about  16%  of the  chromosomes.  This 
haplotype is the same one shown to be over-represented in the Helicobacter pylori 
gastritis group in Northern Europeans (see chapter 3). However, the difference was 
not statistically significant, although comparison of two locus haplotypes (AG and 
SL) almost reached significance (p=0.068).
The  3  loci  were  in  HWE  in both populations,  and  were  in  tight  Linkage 
Disequilibrium. Unlike the gastritis group in the Northern Europeans, the MUCl loci 
in the Portuguese gastric cancer patients group remain in LD, even though there is an 
increase in the ‘recombinant’ GS11  haplotype.
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Figure 4.10: MUCl  haplotype distribution for the two Portuguese  populations:  Blood donors (n=75) and Gastric cancer patients (n=43). The haplotypes were inferred using 2 
different statistical methods: (A) a maximum-likelihood method, the EM algorithm, and (B) a Bayesian method.
1134.2.2  Naval  Shipyard  in  ‘Viana  do  Castelo’  (North  Portugal)-  A  patients 
“enriched” study
A screening study for gastric lesions was performed in a naval shipyard in 
Viana  do  Castelo,  North  Portugal,  where  the  incidence  of  gastric  disease  is 
particularly high. All individuals, presented with symptoms of dyspepsia. Biopsies 
from  all  the  individuals  were  analysed  and  characterised  for  gastric  lesions.  No 
peptic  ulcer,  dysplasia  or  gastric  cancer  was  found  but  all  but  three  showed 
Helicobacter pylori gastritis. This study consists of a total of 157 individuals, from 
whom TR data was already available (Silva et al., 2001). Because only 3 individuals 
had  a  normal  gastric  mucosa,  it  was  not  possible  to  make  a  gastritis/normal 
comparison.  The  remaining  samples,  all  with gastritis,  were  divided  according  to 
presence or absence of intestinal metaplasia (IM)  and the type  of IM  found.  The 
intestinal metaplasia can be divided into 2 major groups: Complete IM, also know as 
Type I IM, resembling phenotypically small intestine mucosa, and Incomplete IM, 
that can be Type II or Type III, that resembles colonic mucosa. The incomplete IM 
Type III has been associated with higher risk of developing gastric cancer.  A more 
detailed description of each type of IM and association with cancer is described in 
Chapter 1, section 1.3.4.
Because of this relative risk, all individuals with areas of both Complete and 
Incomplete IM were classified as Incomplete IM group, as part of the higher risk 
group.  The  population  was  divided  then  in  3  groups:  No  IM  group  (n=113), 
Complete IM group (n=12) and Incomplete IM group (n=32).
4.2.2.1  Genotype and allele distribution
The  genotypes  for the  3  markers  in  the  diverse  subgroups  of the  ‘Viana’ 
cohort are illustrated in the graphs in Figure 4.11. Some differences can be observed 
between the 3 sets of samples.
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Figure  4.11:  Genotype  frequencies  for  the  Tandem  Repeat  array  (A),  G3506A  SNP  (B)  and  CA 
microsatellite (C) for the three ‘Viana’ subgroups: No IM (n=113), Complete IM (n=12) and Incomplete IM
(n=32).
115The tandem repeat genotype  frequency is  somewhat different in each c ase 
(Figure  4.11.A).  Though  the  No  IM  group  and  the  Complete  IM  group  have  a 
predominance of LS heterozygotes, the individuals with Complete IM include more 
LL homozygotes as compared with the individuals with no IM (No IM), that include 
slightly more SS homozygotes. Unlike these two cases, the group of individuals with 
Incomplete  IM  includes  a  high proportion  of SS  homozygotes,  compared  to  the 
number of heterozygotes and LL homozygotes.
The G3506A SNP genotype distribution is more similar between groups, with 
the AG heterozygotes representing the majority of the individuals. The only remark 
to be made is the lack of AA homozygotes in the Complete IM group, balanced by an 
increase in the number of heterozygous individuals (Figure 4.1 l.B).
The  genotypes  of  the  microsatellite  polymorphism,  displayed  in  figure 
4.11.C,  are  similar  between  the  ‘Viana’  subgroups.  The  genotype  11,12  is  the 
predominant one for all the subgroups, followed by the two homozygous genotypes 
for the more frequent alleles,  11,11  and  12,12. The Complete IM subgroup shows 
fewer 12,12 homozygotes, balanced once more by an increase in the number of 11,12 
heterozygotes.
None of these differences were statistically significant.
The allele distributions for the 3 subsets in the ‘Viana’ cohort are presented in 
Table 4.12. The groups ‘No IM’ and ‘Incomplete IM’  show a slight tendency for a 
higher proportion of small alleles, as well as the A allele in the SNP and 12 or 13 CA 
repeats in the microsatellite. In contrast, the ‘Complete IM’ group shows a tendency 
for higher proportions of the opposite alleles: large TR alleles with the G allele in the 
SNP  and  11  CA  repeats  in  the  microsatellite.  However,  all  these  differences  are 
small, and not statistically significant.
One  new  allele  with  15  repeats  was  observed  in  one  individual,  more 
specifically in the ‘IM absent’ group (See table 4.12.C).
116A
No Intestinal 
Metaplasia
Complete Intestinal 
Metaplasia
Incomplete Intestinal 
Metaplasia
L 0.42 0.54 0.36
S 0.58 0.46 0.64
B
No Intestinal 
Metaplasia
Complete Intestinal 
Metaplasia
Incomplete Intestinal 
Metaplasia
A 0.54 0.42 0.52
G 0.46 0.58 0.48
C
No Intestinal 
Metaplasia
Complete Intestinal 
Metaplasia
Incomplete Intestinal 
Metaplasia
11 0.45 0.54 0.48
12 0.48 0.42 0.47
13 0.07 0.04 0.05
14 0.00 0.00 0.00
15 0.00 0.00 0.00
Table 4.12:  Allele frequencies  for the Tandem  Repeat  array (A),  G3506A  SNP  (B)  and CA  microsatellite 
(C) for the three ‘Viana’  subgroups: No IM (n=l 13), Complete IM (n-12) and Incomplete IM (n=32).
4.2.2.2  Haplotype distribution
Arlequin  and  PHASE  inferred  haplotypes  for  the  ‘Viana’  subgroups  are 
shown in figure 4.13, A and B, respectively. Despite the high degree of similarity 
between the results obtained with the two methods, PHASE predicts a broader range 
of haplotypes,  including several with low frequencies.  Doing a chromosome count, 
most of these  low  frequency haplotypes  represent chromosomes  with a predicted 
frequency of less than 1  chromosome.
Using  the  Arlequin  software  package,  the  goodness  of fit  to  HWE  was 
assessed as well as the LD between pairs of loci. All loci were found to be in HWE 
for the three subgroups.
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Figure 4.13: M U C l haplotype distribution for the three ‘Viana’  subgroups: No IM (n=l 13), Complete IM (n=12) and Incomplete IM (n=32). The haplotypes were inferred using 2 
different statistical methods: (A) a maximum-likelihood method, the EM algorithm, and (B) a Bayesian method.
118In the No  IM group and the Incomplete  IM group all  loci  were  in LD with 
each  other,  but  for  the  Complete  IM  group,  the  LD  was  disrupted  between  the 
Tandem  Repeat  and  the  two  flanking  markers.  This  analysis  was  also  confirmed 
using the LDmax program, part of GOLD interface software, which also uses the EM 
algorithm,  x2  values  indicate  a  lack of significant association  between  LS  and  the 
flanking markers in the Complete IM group. The results are displayed in tables 4.14 
A and B.
A VIANA SUBSETS
No IM Complete IM Incomplete IM
G3506A SNP and 
TR domain
<0.000001 0.05707 0.00001
G3506A SNP and 
CA microsatellite
<0.000001 0.00002 <0.000001
TR domain and 
CA microsatellite
<0.000001 0.13552 0.00002
B VIANA SUBSETS
No IM Complete IM Incomplete IM
G3506A SNP and 
TR domain
0.697 0.565 0.807
G3506A SNP and 
CA microsatellite
0.954 1.000 1.000
TR domain and 
CA microsatellite
0.712 0.528 0.818
Table  4.14:  Linkage  Disequilibrium  measure  between  the  3  pairs  of markers  for  r  the  three  ‘Viana’ 
subgroups:  No  IM  (n=113),  Complete  IM  (n-12)  and  Incomplete IM  (n=32).  The  LD  measurements  are 
shown as p values (A) and D' values (B).
119The A S  12 and G L 11 haplotypes account for most of the chromosomes, in 
all three groups.  However, while the groups with no IM and Incomplete IM have 
more A S 12 chromosomes than G L 11, the Complete IM group is the opposite. It is 
also interesting to observe that the haplotype over-represented in the Helicobacter 
pylori gastritis group in Northern Europeans, G  S  11,  is present in relatively high 
proportions in the three groups, showing an increase in frequency from the non-IM 
group (~7%) to the two groups with intestinal metaplasia. The highest frequency is 
found  in  the  Incomplete  IM  group  (16%),  the  group  with  highest  cancer  risk. 
Nevertheless,  the  differences  in  haplotype  distribution  were  not  statistically 
significant.
4.3  Discussion
The Portuguese population is of interest as the only European country with a 
high rate of gastric cancer. In fact, the incidence of gastric cancer in the Portuguese is 
one of the highest in the world, being only surpassed by Japan, North Korea, South 
Korea and some Eastern European counties (Globocan 2002 database- http://www- 
dep.iarc.fr/globocan/database.htrrO.  One  factor  that  plays  a  vital  role  in  the  high 
incidence of gastric disease is the very high incidence of infection by Helicobacter 
pylori.  It is estimated that the incidence of H. pylori in Portuguese individuals 50 
years  old  or  older  is  as  high  as  80%  (Lunet  and  Barros,  2003);  in  younger 
generations the infection rate declines, to about 50% of infection rate in individuals 
in their twenties (Prof. Fatima Cameiro, personal communication). Despite the high 
incidence of H. pylori, this factor alone does not explain such a high incidence of 
gastric disease, and in particular gastric cancer. It is therefore reasonable to assume 
that  in  combination  with  the  bacteria  infection,  environmental  factors  as  well  as 
genetic factors are key aspects in the disease aetiology.
Carvalho et al investigated the potential association of gastric cancer and the 
epithelial  mucin MUCl,  looking  at  the  length  of the  tandem  repeat  of the  gene 
(Carvalho  et  al.,  1997).  Their  observation  of a  significant  over-representation  of 
small MUCl tandem repeats in the gastric cancer patients when compared with blood
120donors controls led to the studies in London. The aim of this work was to determine 
whether the same haplotype that was over-represented in the UK g astritis patients 
was  also  frequent  in  the  Portuguese  patients  with  gastric  disease.  A  consistent 
increase of this haplotype was indeed found in the gastric cancer group as compared 
with the blood donors.  Even though not statistically significant, it was noteworthy 
that  this  haplotype,  G  S  11,  is  the  same  one  found  to  be  over-represented in the 
Northern European Helicobacter pylori gastritis population. It should also be taken 
into account that the blood donors’ group, treated here as the normal controls, were 
not  assessed  for gastric  disease  status  and because  of the  very high incidence  of 
gastric cancer and precursor lesions in the Portuguese population, it is reasonable to 
assume that some of those individuals will suffer from gastric disease, and therefore 
the effects of the genetic background for disease association may be underestimated. 
A similar increase was also found in the ‘Viana’ subsets, from the individuals with 
no IM to the ones with IM, and within these, from the individuals with Complete EM  
to Incomplete IM though also lacked statistical significance. It seemed that this could 
be the very small sample size for the two IM subgroups, with 12 individuals in the 
Complete  IM  subgroup  and  32  in  the  Incomplete  IM.  A  breakdown  of LD  was 
observed in the Complete IM group; however, that was not observed in any other 
Portuguese disease group, and could again be an artefact of such a small sample size. 
Bigger sample sizes would be required to access the question of whether or not the 
effect observed in Northern Europe reflects in the Portuguese population. Another 
point that could affect the analysis is the male: female ratio, that in the ‘Viana’ group 
is very high. Because the samples were collected in a Naval Shipyard, most of the 
workers were males. In fact, the proportion male: female in the samples is as high as 
8.8:1 and males have a higher gastric cancer incidence than females and there may be 
sex difference in the relative role of MUCl.  It is possible that other genes have a 
relatively larger effect in men than women.
In  conclusion,  the  clear  increase  of  the  recombinant  haplotype  G  S  11 
frequency  with  disease  severity  is  noteworthy.  It  is  possible  that  the  study  had 
insufficient power to show significance and also that other genes have a bigger effect 
in the Portuguese population.
121CHAPTER 5
IDENTIFICATION OF NEW POLYMORPHISMS IN THE 
MUCl GENE AND ITS VICINITY
122Introduction
The evidence developed so far suggested that a particular MU  Cl haplotype 
was associated with increased susceptibility to gastric disease. The aims of the work 
in this chapter were to determine how this haplotype fitted in with the general pattern 
of Linkage Disequilibrium in the vicinity of MUC1 and to search for other potential 
associated  markers  that  might  be  suitable  and  transposable  for  PCR  for  more 
extensive epidemiological studies.
This chapter describes the strategies used for searching polymorphisms,  in 
particular  single  nucleotide  polymorphisms  (SNPs),  both  in  the  gene  and  in  the 
vicinity of the gene. Both sequencing and bioinfoimatics approach were used.
5.1  MUC1 gene resequencing
Complete sequencing of the 5' end of MUC1 gene, the promoter region, exon 
1, intron 1   and the beginning of exon 2 was carried out with the help of Mari Wyn 
Burley. A schematic representation of the region and primers used is shown in figure 
5.1,  indicating  the  exons  location  and  position  of the  primers.  The  region  to  be 
sequenced was divided into 3 PCR products, around 700bp each.
The aim was to  sequence 8  samples, though a total of 12  individuals were 
used  (Table  5.2).  The  samples  were  chosen according to  their  genotypes  for the 
MUC1 TR and the two flanking markers, in order to obtain as diverse as possible set 
of  genotypes  and  haplotypes,  to  maximise  the  chances  of  picking  up  new 
polymorphisms associated with disease haplotypes.
A  comprehensive  list  of the  primers  used  and  sequencing  techniques  is 
described  in  the  materials  and methods,  section  sequencing.  The  sequences  were 
analysed using the ChromasPro software (Technelysium Pty Ltd).
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Figure 5.1: Sequencing strategy for the 5' end of MUC1  gene. The genomic region includes promoter region, exon  1, intron  1   and the beginning of exon 2 (exons represented  in 
purple boxes and promoter region and intron represented as a line). The forward and reverse primers for the initial PCRs are represented as blue lines and named F or R (for forward 
and reverse, respectively) followed by a number (2-4). The internal primers are represented as red lines and named FF or RR (for forward and reverse, respectively) followed by a 124 
number (2-4). These internal primers were used to amplify and sequence regions that were not easily read using only the flanking primers.Sample Disease status Genotypes Region 2 Region 3 Region 4
M22 H. pylori  gastritis GG SS 11,11 ✓
M44 H. pylori  gastritis GG ss 11,11 ✓ ✓ ✓
M l 89 normal AG SS 11,12 ✓
M205 normal AG LL 11,12 ✓ ✓
M230 n.d AG LS 12,12 ✓ ✓ ✓
M231 normal AA SS 12,12 ✓ ✓ ✓
M232 normal AG LS 11,12 ✓ ✓ ✓
M233 normal GG LL 11,11 ✓
M264 n.d AG SS 11,12 ✓ ✓
M266 n.d AG LS 12,12 ✓ ✓ ✓
M271 n.d AA LS 12,13 ✓
M293 normal GG SS 11,11 ✓ ✓
Table 5.2: Summary of the samples used for each sequenced region, showing information about disease status 
and genotype for each sample. The  1 /  mark marks which samples were sequenced for each region, 
n.d.- not determined
5.1.1  Results:
Comparisons of MUCl  gene sequences were made using as a reference the 
sequence  with  accession  number  M61170,  from  August  2001  (Lancaster  et  al., 
1990). An exhaustive analysis of both sense and antisense sequences was performed 
using the sequencing analysis programs, but no new polymorphisms were found.
An error in the sequence in the database was detected in the promoter region 
where  there  are  only  two  nucleotides  CC  in  positions  2444  and  2445  (sequence 
M61170)  and  should  be  instead 4  nucleotides,  CCCC  (Figure  5.3.A).  This  change 
was observed  in all sequenced samples, and presumably reflects a sequencing error 
in  the  sequence  submitted  to  the  database,  rather than  a  polymorphism.  The  only 
polymorphism  observed  in  the  sequences  analysed  is  the  exon  2  G3506A  SNP 
(Ligtenberg  et  al.,  1990),  studied  previously  by  our  group  (Pratt  et al.,  1996)  and 
tested  in  Chapters  3  and  4  (Figure  5.3.B),  accession  number  rs4072037.  The 
genotype  in  the  sequences  was  in  accordance  with  the  genotypic  information 
obtained previously by restriction enzyme digestion.
It is particularly noteworthy that no sequence changes were seen in intron  1. 
This  is  relevant because the  single exon  2  SNP (rs  4072037/G3506A)  was said to 
have affected splicing (Ligtenberg et al.,  1991)  in transfection constructs studies to 
explore  this  differential  splicing containing  intron  1.  Although  the  Hilkens’  group
125had claimed there was no difference in this region, this was a particularly difficult 
sequence and it was reassuring to obtain good sequence runs to confirm this.
B O 90
A
_________________
B
90
Figure 53:  Sequencing chromatograms obtained using ChromasPro software.  Figure A illustrates 3 
different samples showing 4 C nucleotides instead of the 2 Cs found in the database sequence M61170 
used as reference. Figure B shows an example of polymorphism in exon 2 detected  in the sequence  126
reaction in the antisense strand for 3 different samples and the 3 possible genotypes: CT, TT and CC, 
that correspond to the GA, AA and GG genotypes in the sense strand.5.2  Search of NCBI SNP database for MUC1 SNPs
In the NCBI  SNP database (http://www.ncbi.nlm.nih.gov/SNP/) there are a 
total of 3 0  Single Nucleotide P olymorphisms (SNP) entries for the human MUC1 
sequence  and  its  immediate  vicinity.  Table  5.4  presents  a  summary of the  SNPs 
reported there, as well as a characterisation of the SNP properties and frequency.
Six  of the reported  SNPs  (1,  2,  3,  4,  5  and 25) are  in fact within theTR 
region,  and  reflect  the  variation  observed  within  the  repeats  (Engelmann  et  al., 
2001;Fowler et al., 2003;Siddiqui et al., 1988). Since those variations are not unique 
in the gene, occurring several times along the TR array, they are not considered as 
Single  Nucleotide  Polymorphisms  (SNPs).  Several  other  SNPs  reported  have  no 
genotypic  or  allele  frequency  information,  and  entries  are  usually based  on  two 
chromosomes. All the remaining SNPs, apart from the one marked in bold, have very 
low frequencies for the minor allele and no homozygous individuals for the minor 
allele occur in any of the genotyped populations.
In summary, a more detailed look reveals that most of the polymorphisms are 
possibly sequencing errors due to artefacts inherent to the nature of the sequence, or 
if real, with an extremely low heterozygosity levels.
The remaining polymorphism, entered with the accession number rs4072037, 
the one marked in bold in table 5.4,  is the G3506A  SNP described by Pratt et al 
(Pratt et al.,  1996) and already used in the previous chapters. Consequently, no new 
SNP was added to the panel using this approach.
127Acession
number Polymorphism Validation status Location
Number of tested 
chromosomes
Number of tested 
populations
Minor allele frequency
Amino-acid
change
1 rs 12743084 C/G not validated TR domain 2 0 n.d
2 rsl 2742111 G/T not validated TR domain 2 0 n.d
3 rs 12737964 G/T not validated TR domain 2 0 n.d
4 rsl 2737963 G/T not validated TR domain 2 0 n.d
5 rsl2728535 G/T not validated TR domain 2 0 n.d
6 rsl 2566541 G/T not validated intron 6 2 0 n.d
7 rs 12411216 A/C not validated promoter region 2 0 n.d
8 rsl 1807598 G/T not validated promoter region 3 0 n.d
9 rsl 1590286 C/T not validated after 3'  UTR 2 0 n.d
10 rsl 1465211 A/G validated after 3'  UTR 178 1 0.006
11 rsl 1465210 A/G validated after 3'  UTR 178 1 0.006
12 rsl 1465209 C/T not validated exon 7 180 1 0.006
13 rsl 1465208 -/C validated intron 6 172 1 0.012
14 rsl 1465207 A/G validated exon 5 170 1 0.012 Asn>Ser
15 rsl 1465206 C/T not validated intron 2 166 1 0.006
16 rsl 1465205 A/G not validated exon 2 154 1 0.006 Ser> Gly
17 rsl 1465204 A/G validated promoter region 158 1 0.013
18 rsl 1465203 C/T validated promoter region 180 1 0.011
19 rsl 1465202 C/G not validated promoter region 178/90/88/120 4 0.006/0/0/0.025
20 rsl 1465201 A/C not validated promoter region 178 I 0.006
21 rs7365893 G/T not validated promoter/ intergenic region 15 0 n.d
22 rs7364559 C/G not validated promoter/ intergenic region 11 0 n.d
23 rs6664861 C/G not validated intergenic MUC1/THBS3 2 0 n.d
24 rs6427222 A/G not validated intergenic MUC1/THBS4 44/42/38 3 0/0.095/0
25 rs4971063 C/G not validated TR domain 2 0 n.d
26 rs4072037 A/G validated exon 2 114/90/88/120/136 5 0.421/0.200/0.0159/0.492/0.353
27 rs 1611773 CAT validated 3’ UTR 176/178/184 3 0.006/0.006/0.07
28 rs 16 11772 C/T validated 3' UTR 174/184/180 3 0.006/0.02/0.006
29 rsl611771 A/G not validated intron 5 180/184/170 3 0.006/0/0.006
30 rs 1611770 A/G validated exon 4 176/170/118/90/88 5 0.023/0.018/0/0/0 Met> Val
Table 5.4:  Summary of the SNPs reported in the NCBI dbSNP.  Each entry is  identified with the accession number from the database,  location in the gene, number of chromosomes 
genotyped, allele frequencies and amino-acid change. The G3506A SNP, used in the previous chapters, is marked in bold in entry number 26.5.3  Characterisation of the lOOkb genomic region housing MUC1:
At the onset of this project MUC1 was not present on the human genome 
sequence  despite the  fact that the  full  gene  structure had been known since  1990 
(Gendler et al.,  1990;Lan et al.,  1990;Lancaster et al.,  1990). Although the gaps in 
the  sequence  were  subsequently  filled  it  was  important  to  carefully  check  the 
genomic  region and  understand the  disposition of the  coding  exons  and  flanking 
sequences.  The  lOOkb region,  shown in detail in figure 5.5, is very rich in genes, 
containing a total 8 genes and 2 pseudogenes. These are summarised below.
EPGL1:
EPGL1, also known as LERK-1 or EFNA1 {EPGL1 being the accepted gene 
name according to HUGO nomenclature) is encoded by 5 exons. It encodes a protein 
with  MW  22,000  called  Ephrin-Al,  made  up  of  187  amino  acids  and  with  one 
potential N-glycosylation site. Ephrin-Al belongs to a subfamily of receptor protein- 
tyrosine kinases and was first described by Dixit et al (Dixit et al., 1990) as a novel 
TNF-induced gene in endothelial cells. It is induced by pro inflammatory agents and 
was show to play a role in angiogenesis (Holzman et al., 1990).
Ephrins can be divided in two subclasses. EFNA1  belongs to the ephrin-A 
class,  a  group  of  ligands  that  are  membrane  anchored  by  a 
glycosylphosphotidylinositol  (GPI)  linkage.  It  has  affinity  to  several  receptor 
tyrosine kinases from the EphA receptor family.
LOC55974:
The LOC55974 locus was initially found in a cDNA library (RefSeq in NCBI 
database:  NM_018845).  The  gene  and  intron/exon boundaries  were  electronically 
predicted and characterised as having 6 exons spanning a region of 3Kb. The gene 
was placed between EFNA1 and DPM3. It encodes a MW  19,000 protein with 167 
amino acids, and is predicted to be a membrane protein, called “stromal cell protein”. 
The  protein  has  conserved  domains  homologous  to  pfam03083,  a  saliva  protein 
family in drosophila.  However, the function of the protein encoded by LOC55974 
remains unknown.
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Figure 5.5:  100Kb genomic region surrounding MUC1 displaying the 8 genes and 2 pseudogenes and their approximate size and orientation of transcription. MUC1 is coloured in the middle 
of the figure in the blue box. The SNPs described in this chapter are represented as arrows facing downwards and coloured according to the way they were found: the blue arrow represents the 
only SNP known at the beginning of the project, and is located in exon 2 of MUC1\ the green arrows indicate SNPs found using the NCBI dbSNP database, described later in this chapter; the  130 
red arrows indicate the 4 SNPs chosen from the HapMap database, whose analysis and characterisation will also be presented later in this chapter.PPM3:
DPM3 is made up of one exon and can produce two isoforms, in which one 
has an alternate transcription site in the 5' coding region, using an initiating ATG site 
further downstream and consequently producing a shorter N-terminus (Manos et al., 
2001). This shorter form of the protein, which seems to be the most common variant, 
encodes for a Mr 8,000 protein with 92 amino acids and is called dolichol-phosphate 
mannosyltransferase polypeptide  3  (Maeda  et al.,  2000;Manos  et al.,  2001).  This 
protein is a subunit of Dolichol-phosphate-mannose (DPM) synthase, an enzyme that 
synthesises DPM from GDP-mannose and dolichol-phosphate a mechanism essential 
for donation of mannose residues to glycoproteins, a central mechanism in N-linked 
glycosylation. DPM synthase is made up of 3 subunits: DPMI, the catalytic subunit, 
DPM2,  an  ER  transmembrane protein  and  DPM3.  DPM3  is  localised  in  the  ER 
membrane  and  contains  2  putative  TM  domains  in  the  N-terminal  hydrophobic 
portion, made up of about 60 amino acids, that attaches to the TM subunit DPM2, 
and a C-terminal hydrophilic portion of about 30 amino acids that associates with 
DPMI.
KCP2:
KCP2 or the KRTCAP2 gene is made up of 5  exons and encodes a protein 
known as ‘keratinocyte associated protein 2’. Bonkobara and collaborators originally 
described a transcript from a cDNA library of human keratinocytes (Bonkobara et 
al.,  2003)  as  encoding  a  non-type  I  transmembrane  polypeptide  with  2  putative 
transmembrane domains.  It was expressed in a series of tissues,  showing different 
expression levels, the strongest being in pancreas (Bonkobara et al., 2003). Later on, 
Shibatani  and  colleagues  found  it  as  a  protein  within  the  three  types  of 
Oligosaccharyltransferase  Complexes  (OSTC),  OSTCi  OSTCn  and  OSTCm 
(Shibatani et al., 2005). The authors reported KCP2 as a 14,000 MW protein with 4 
predicted  transmembrane  domains  and  a  C-terminal  ER  localisation  motif.  Apart 
from knowing that the protein is  localised in the OST complexes,  involved in N- 
linked glycosylation and transfer of high mannose sugars to nascent peptides in the 
rough ER lumen, the specific function of KCP2 protein remains unknown.
131TR1M46:
TRIM46  gene  is  still  not  well  described,  though  its  cDNA  sequence  is 
available. The gene consists of 10 exons, and so far 4 isoforms have been reported 
(predicted  from  the  cDNA),  though  only one  is  confirmed.  The protein  is  called 
‘tripartite motif-containing 46’  and belongs to the TRIM/RBCC family containing 
several of the conserved elements characteristic of this family:  B-Box C-terminal 
domain,  RING-finger  containing  E3  ubiquitin  ligase,  B-Box-type  zinc  finger, 
fibronectin type 3 domain and a SPRY domain (NCBI database, refseq NM  025058, 
14th May, 2005). It is believed to be involved in protein ubiquitination with ligase 
activity within the ubiquitin ligase complex.
THBS3:
THBS3 is the gene located immediately upstream MUC1. It has 23 exons that 
span a 12kb region, most of it intronic sequence (Adolph et al.,  1995). The exons in 
the  gene  are  coded  as  letters  (from  A  to  F)  and  numbers  (from  11  to  22),  the 
numbered exons being homologous to exons in THBS1 and THBS2. The 5' UTR is 
relatively  small,  made  up  of only  21  nucleotides.  However,  no  TATA  box  was 
present in the region, suggesting that other transcription start sites (TSS) may occur. 
This hypothesis  was  confirmed later on by the  same group  in  1999  (Adolph and 
Bomstein,  1999), when they found mRNAs with transcription initiation sites in the 
THBS3/MTX1 intergenic region further5'  from thatpreviously identified.  Anew 
exon was found 2498bp upstream exon A and was named exon A'. This new exon is 
209bp long and 137bp away from the MTX1 TSS.
The protein Thrombospondin 3, encoded by THBS3, has 956 amino acids and 
is made up of a short hydrophobic region in the N-terminal signal peptide sequence 
and an extensive hydrophilic region (Adolph et al., 1995). It has 4 Type II (EGF-like) 
repeat domains and 7 Type III (Ca2+-binding) repeat domains. Interchain disulphide 
bonds are likely to form through the two cysteines, and glycosylation of the protein 
may also  occur via  linkage  to  asparagine  residues.  Though the  exact function  of 
THBS3  in not known,  it was hypothesised that it shares some function roles with
132THBS1  and  THBS2  in  aggregation  of  activated  platelets,  cell  proliferation, 
embryogenesis, morphogenesis and cell shape and movement, but possibly plays a 
more specialised role in cell-extracellular matrix interactions (Adolph et al., 1995).
MTX1:
MTX1 is localised immediately upstream the THBS3 gene, but in the opposite 
orientation,  therefore  sharing a common upstream region.  MTX1  is  made up of 8 
exons, and is approximately 6kb long, with the translation initiation codon just 1374 
nucleotides away from the ATG of THBS3.  Adolph and colleagues,  failed to find 
alternative transcripts at the 5'end of MTX1, suggesting that the initiation site for this 
gene is not variable (Adolph et al., 1995). Alignment of the longer transcripts for the 
2  genes,  THBS3 and MTX1,  showed overlap  of about 90bp between the  5'  ends, 
suggesting  that  if in that  area  some  important transcriptional  regulatory  elements 
were present, that c ould h ave implications for t issue s pecific 1  evels of expression, 
where the 2 genes would co-regulate each other.
The encoded protein, Metaxin 1  is 317 amino acids long and a mitochondrial 
outer  membrane  protein  that  functions  as  an  import  receptor  for  mitochondrial 
preproteins  (Armstrong  et al.,  1997).  Studies  with Mxtl  in mouse  show  that this 
seems to be an essential protein,  since a knockout mouse exhibit embryo lethality 
phenotype (Bomstein et al.,  1995). Also, mutations in MTX1 have been reported to 
be associated with Gaucher disease, although the enzyme deficient in these patients 
being glucocerebrosidase, encoded by the GBA gene, immediately adjacent to MTX1 
(LaMarca et al., 2004).
GBA:
The p-glucocerebrosidase protein is encoded by GBA, a gene that contains 11 
exons and is 7kb long (Horowitz et al.,  1989;Reiner et al.,  1988). The gene encodes 
an enzyme protein found in the lysosomal membrane responsible for cleavage of the 
P-glucosidic linkage of glycosylceramides (Grabowski et al.,  1990).  GBA has been 
widely studied  due to  its  relationship with a  lysosomal  storage  disorder,  Gaucher 
disease,  particularly  frequent  in  the  Ashkenazi  Jewish  population.  Numerous
133mutations including point mutations, insertions, deletions and splicing mutations are 
described for the several types of the disease (Beutler, 1993;Stone et al., 2000).
Pseudogenes:
In the genomic area between GBA and MTX1 there are two pseudogenes that 
arose  as  duplications  of those  two  genes  and  were  named  GBAP  and  MTX1P, 
respectively  (Long  et  al.,  1996;Winfield  et  al.,  1997).  This  duplication event  is 
estimated to have occurred 40 million years ago (Winfield et al.,  1997). The genes 
and respective pseudogenes are displayed as shown in figure 5.5. The 3'  end of the 
duplication is within the MTX1P region and corresponds to exon 2 of the MTX1 gene 
and is followed by a 5.5kb region homologous to the region immediately upstream 
GBA. However, the GBAP gene is separated from MTXP1P by a fragment of 11.8kb, 
corresponding  to  the  5.5kb  region  upstream  GBA  with  a  6kb  insert  included 
containing 8 complete Alu sequences and several partial Alu sequences (Winfield et 
al., 1997).
Despite  the  high  degree  of homology  between  the  genes  and  respective 
pseudogenes, unlike GBAP pseudogene, MTX1P does not seem to be transcribed, or 
if so, at very low levels (Long et al., 1996).
5.4  Search of databases for other SNPs in the 100Kb region
5.4.1  NCBI database- flanking markers
5.4.1.1  THBS3
Two  polymorphisms  were  reported  as  characterised  and  validated  for  the 
THBS3 gene sequence. The first SNP, entered with accession number rs2075571, is 
an A to G transition in intron 4 of the gene.  It had, according to  the database, an 
average estimated heterozygosity of 0.306 and a minor allele frequency (allele G) of 
0.188. The second SNP, with accession number rs2066981, is a T to C transition in 
intron  8.  The  estimated  average  heterozygosity  was  0.431  and  the  minor  allele 
frequency (allele C) was 0.315.
134Assays  were  developed  for these  two  polymorphisms  based  on  PCR  and 
restriction  enzyme  digest,  described  in  detail  in  Chapter  2.  In  figure  5.6  the 
localisation of each SNP is shown.
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Figure  5.6:  Schematic  representation  of THBS3  gene and  localisation  of the 2  polymorphisms  described, 
rs2075571 and rs2066981, in introns 4 and 8, respectively.
5.4.1.2  SNPs downstream of MUC1
Two  SNPs  located  in  the  intergenic  region  between  MUC1  and  TRIM46 
genes were reported as characterised and validated in the database (see figure 5.5). 
The SNP with accession number rs4971101 is a C to T transition and the two alleles 
have frequencies of about 0.5 and average heterozygosity of 0.499. The other SNP, 
rs2070803, is also a C to T transition. The estimated heterozygosity is reported as 
0.500, and again the two alleles frequencies are close to 0.5.
These two polymorphisms, that are 81  nucleotides apart, can be typed using 
the same PCR product and two different restriction enzymes. The protocol developed 
to genotype the SNPs is described in detail in Chapter 2.
5.4.2  HapMap  database-  Selection  of  more  distant  markers  using 
patterns of LD
The  international  HapMap Project (www.hapmap.org)  is  a database which
main goal  is to  develop  a haplotype  map  of the  human genome.  In this  project,
several countries around the world are involved, namely Japan, UK, Canada, China,
Nigeria  and  USA,  collaborating  not  only  in  the  sequencing  process  but  also  in
sample collection. The task of assembly and analysis of all the data is responsibility
of several labs  in UK and USA,  sponsored by the multinational SNP consortium,
135“National Institutes of Health” (NIH) and “The Wellcome Trust”. The aim of this 
project is  to  compile  SNP  information for the entire human  genome  and make  it 
freely available to the research community.  For this purpose, several thousands of 
SNPs are described in this database, including genotyped SNPs and others that are 
found in other databases.
Phase I from the HapMap project was completed in March 2005, where the 
major aim was to genotype  1  SNP approximately every 5kb in 4  different human 
populations accounting for a total of 270 individuals: 90 Utah CEPH (Centre d'Etude 
du Polymorphisme Humain) individuals composed of in 30 family trios, considered 
representative of a Northern and Western European population (CEU), 45 unrelated 
Han  Chinese  individuals  collected  in  Beijing  (HCB),  45  unrelated  Japanese 
individuals collected in Tokyo (JPT), and 90 Yoruba individuals organised  in family 
trios collected in Ibadan, Nigeria (YRI).
For each genotyped SNP frequency data as well as individual data for each 
individual are freely available.
5.4.2.1  HapMap in chromosome 1
For this project, HapMap was used to characterise the patterns of LD in the 
genomic area around MUC1  and search for suitable polymorphisms to test.  In the 
present study, only individuals from the CEPH cohort were used, because this work 
was done before  the other 3  populations were included  in the  HapMap  database. 
Also, the population for which this study was conducted, and that will be presented 
in Chapter 6,  is of Northern European extraction, and therefore comparable to the 
Utah-CEPHs  used  in  HapMap,  thought  to  be  originally  from Northern  European 
origin.
SNP data was retrieved from HapMap from an area of 2Mb, approximately 
1Mb each side of MUC1, comprising a total of 175 SNPs, shown in figure 5.7. From 
these, 38 SNPs were excluded from the analysis: 20 SNPs were not polymorphic, at 
least for this population,  10 SNPs had a minor allele frequency of 0.03% or lower 
and  8  SNPs  were  repeated  in  the  database  and  therefore  one  of the  copies  was 
excluded. The remaining 137 SNPs were used for the analysis.
136Tandem  Repeat  size  data  produced  previously  in  our  laboratory  by  Ms 
Wendy Pratt was available for some of the CEPH families and integrated with the 
SNP data to improve the analysis. Because only 21 families in this study had this TR 
information available, the other 9 families were not used. Also, there was an apparent 
typing  error  in  one  of  the  remaining  families  for  one  of  the  markers,  and 
consequently was excluded.
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Figure 5.7: HapMap database adaptation from the 2Mb region flanking the MU  Cl  gene. The figure represents 
all the genotyped SNPs for the area and respective rs number. The G3506A SNP, present in MUC1 is marked in 
a box for better recognition.
The final database analysed was comprised of 138 markers (137 SNPs plus 
the TR array) typed for 60 individuals, 20 Utah-CEPH family trios.
137Data was arranged in a pedigree format and run in the LDmax program, part 
of  GOLD  statistical  software  package
(http://www.sph.umich.edu/csg/abecasis/GOLD/index.html)  to  determine  the 
Linkage  Disequilibrium  between  the  markers  in  the  region.  LDmax  infers  the 
haplotype frequencies in the population based on the genotypes from the founders 
using  the  EM  algorithm  (Excoffier  and  Slatkin,  1995)  and  uses  these  to  run  a 
pairwise  comparison  between  markers  and  produces  a  table  of  Linkage 
Disequilibrium measurements: Chi-square (%  ) and respective p-value, Delta-square 
(D2) and D-prime (D') for each pair. Using the p value and D'  value, 2 by 2 tables 
were  constructed  for each  element (see  tables  5.8.B  and  5.9.B)  and  analysed  for 
positive  associations  with both markers within MUC1,  the G3506A  SNP  and the 
tandem repeat (TR) polymorphism. Figure 5.8 shows the Gold graphical interface of 
the  Chi-squared p-values  calculated with LDmax  for the  2Mb  region (5.8.A)  and 
below the table with the markers found to have a positive LD based on the p-value 
shaded in blue (5.8.B). The two MUC1 markers are bordered by a black frame. The 
same 2Mb area is represented in figure 5.9, with the Gold graphical interface of the 
D'  value  calculated  with  LDmax  (5.9.A)  and  the  respective  table  representing 
possible positive association (D'> 0.4) in the shaded blue cells (5.9.B). This genomic 
area  on chromosome  1   which includes markers  with positive LD  values with the 
MUC1 TR contains 40 markers and extends for more than 600kb.
Once the Linkage Disequilibrium was established in this area, the genotype 
of the 40 markers for the 20 family trios was used again to predict haplotype pairs  in 
each  person  from  the  population  using  the  Phase-Phamily  software 
(http://archimedes.well.ox.ac.uk/pise/phamilv-simple.htmn.  All  3  individuals  of a 
trio are used in the analysis (entered as a pedigree format), to infer the haplotypes 
from the parents, who can be considered as a non-related group of individuals. The 
children are used in this program as a way of improving the haplotype prediction of 
the parents. The program predicted 52 different haplotypes,  some differing only in 
one or very few markers. To improve the analysis, the haplotypes were sorted for the 
MUCl markers, first by TR array and then by the G3506A SNP, as shown in figure 
5.10, in an attempt to  find markers that would correlate with the TR array or the 
G3506A SNP.
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Figure 5.8:  A.  Chi-square p value diagram  for significant LD  between  markers  using GOLD graphical  interface.  The  region  within the  lilac box  is represented  in detail  in figure B, with 
significant associations between markers highlighted also in lilac. The 2  M U C 1 markers are surrounded by a black frame.
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Figure 5.9:  A.  LDmax D'  value  diagram  for significant  LD  between  markers  using GOLD  graphical  interface.  The  region  within the  lilac box  is  represented  in  detail  in  figure B, with 
significant associations between markers highlighted also in lilac. The 2  M U C 1 markers are surrounded by a black frame.MU ilftl
5
Figure 5.10: List of haplotypes predicted using Phase-Phamily software. The first 40 columns represent the 40 markers showing association with MUC1  TR array and G3506A SNP. 
right-hand column shows the number of chromosomes predicted for each haplotype. The cells are coloured showing blocks of LD present in this region. MUC1  markers are shaded in grey 
and sorted by TR size and G3506A SNP.Markers were chosen from the haplotype table (figure 5.10) to subdivide the 
simple  2  locus  haplotypes  (L  A,  L  G,  S  A  and  S  G)  and  to  include  one  which 
appeared to associate better with LS than does G3506A SNP.
The 4 markers chosen from both sides of the MUC1 gene are the ones marked 
in  the  first  row  in  red  in  figure  5.10,  covering  an  area  of nearly  lOOkb  and  are 
described in more detail in table 5.11.
SNP reference 
number
Gene
Genomic
region
Distance from 
MUC1 TR array
Alleles
rs9297 EFNA1 - ephrin-A 1 3 'untranslated -55kb A/G
rs4971088
KCP2 - keratinocyte 
associated protein 2
intronic -19kb an
rs4971100
TRIM46 - tripartite motif- 
containing 46
intronic -6kb A/G
rsl 045253
MTX1P- me  taxi n 1  
pseudogene
not determined +40kb C/T
Table 5.11: Chromosome  1   markers chosen from the HapMap study to be genotyped.  The table also displays 
the gene in the SNP area, genomic region in relation to the gene, distance from MUC1 TR array and the two 
possible variants (alleles).
All  new  SNPs  were  typed  using  PCR  followed  by  restriction  enzyme 
digestion. The protocols used are described in detail  in the methods chapter. Figure 
5.12  illustrates  as  examples  some  of the  PCR  digests  for  the  first  three  markers 
(rs9297, rs4971088 and rs4971100).
142M   AA  AA  AG  AA  GG
M AT TT AA M  GG AG AA
Figure  5.12:  Photographs  of agarose  gels  under  UV  light.  The  images  illustrate  the  restriction  enzyme 
digestion of the PCR products from the polymorphisms rs9297 (A), rs4971088 (B) and rs47971100 (C). All 
gels  have  a  molecular  weight  marker  on  the  left  hand  column,  marked  with  a  M.  Figure  A  shows  the 
genotypes of 5 different samples, containing the 3 possible variants, AA, AG or GG; figure B displays the 3 
possible genotypes for the SNP rs4971088, AA, AT and TT; figure C also shows the 3 samples with the  3 
possible variants for the polymorphism, AA, AG and GG.
5.5 Discussion:
It is clear from observation of the Linkage Disequilibrium maps (figures 5.8 
and 5.9) that there is statistically significant positive association between the MUC1 
markers and other markers at a distance of about 300Kb each side.
Taking  a  closer  look,  and  specifically  analysing  the  possible  haplotypes 
inferred with Phase-Phamily, blocks of haplotypes from between the markers that are
143in  the  range  of -90Kb  to  +118Kb  reflect  strong  association  between  groups  of 
markers (see figure 5.10).
It is noteworthy that the MUC1 gene region shows long LD blocks like many 
other regions of the genome, despite the existence of the potentially destabilising TR 
array.  More  markers  are  positively  associated  with  G3506A  than  LS  suggesting 
perhaps not surprisingly that much of the variability of the TR domain was generated 
by non-reciprocal events after the main haplotypes were established. Inspection of 
the  different  MUC1  haplotype  chromosomes  show  that  the  majority  of  the  L 
chromosomes are rather similar to  each other, with  14 being identical at all  SNP 
sites, although the three A L chromosomes are rather different. There are also three 
common groups of A S chromosomes in this population. The 6 G S chromosomes, 
fall into two haplotype groups.
In Chapter 4 it has been shown that the two markers flanking the TR repeat 
domain are associated with each other in the Nigerians that were tested, suggesting 
LD blocks across this region also in an African group. Now that HapMap data are 
available for Nigerians it will be of interest to determine the pattern of LD blocks in 
this population. It should however be noted that the HapMap samples were taken 
from Yoruba,  a different tribal  group  from  the  one  available  in our lab,  that are 
mainly Ibibio.
In  examining  these  extended  regions  of  LD  in  the  context  of  disease 
association studies it is important to consider other genes in the vicinity particularly 
in such a dense region. Functionally significant variations in these genes are likely to 
be  or  have  been  under  selection  and  this  will  affect  gene  frequencies  of whole 
haplotype blocks.  It  is noteworthy in this  context that GBA  allele frequencies are 
likely to be different in Ashkenazi Jewish populations where frequency for Gaucher 
disease is high and where these alleles may have been under selection. Such selection 
may have influenced MUC1 allele frequencies.
One of the objectives of this analysis was to find markers that would highly 
correlate with the L/S variation of the MUC1 TR array or with the recombinant G S 
haplotype. The other aim was to find markers to expand the haplotype analysis in the
144Northern European gastritis cohort. For that, the new SNPs to be tested were chosen 
from within these LD block areas.
The first aim, choosing markers preferentially correlated with the TR was not 
successful, since all the SNPs in the area associated better with the G3506A SNP, 
even choosing a set of markers in both sides of MUC1.
The second aim, to  select a suitable set of markers  for extended haplotype 
analysis  was  successful,  apart  for  one  of the  markers.  The  SNP  with  accession 
number rsl045253, located in the MTX1P pseudogene, was not used because the area 
where the variation occurred was 100% identical to the equivalent in the MTX1 gene. 
In addition, the MTX1 gene was not polymorphic in this site, making impossible to 
distinguish homozygous CC, the variant for which the restriction enzyme would cut, 
from the heterozygous CT.
145CHAPTER 6
HELICOBACTER PYLORI GASTRITIS STUDY 
A NEW COHORT FIVE YEARS AFTER THE ORIGINAL
STUDY
146Introduction
Results of previous studies showed that short alleles for the MUC1 TR were 
more  frequent in disease populations.  Although not  statistically  significant in all 
groups there was in each case an increase in a particular MUC1 haplotype: G S  11. 
The  aim  of this work was  to  see  if these  observations  could be  replicated in  an 
independent study.
6.1 Characterisation of the samples
Volunteers were recruited over a period of 3 years, from 2002 to 2004, at the 
gastrointestinal  clinic  of Middlesex  Hospital,  part  of University  College  London 
Hospitals. Volunteers were patients who had been referred for upper GI endoscopy 
for  a  variety  of  reasons,  which  included  suspected  gastritis/ulcer,  oesophageal 
problems and less frequently for small intestinal complaints. P atients awaiting the 
procedure were approached and the project was explained to  them, and they then 
gave written consent.  A  simple questionnaire was completed which covered age, 
sex, ancestry of parents/grandparents, smoking habit.  In each case a blood sample 
was taken for the preparation of DNA and a series of biopsies was taken.  According 
to  the  clinical needs  of the patient,  and the  current circumstances  in the  clinic  a 
variable number of biopsies were taken. These were used for conducting a CLO test 
(Marshall et al.,  1987) which measures the amount of urease enzyme produced on a 
mounted gel pellet containing urea for routine histology, or frozen for future use for 
RNA.
6.1.1 Categorisation of the samples:
A total of 237 patients agreed to participate in the study, but of these 54 were 
not included in this part of the work because they were of non-Northem European 
ancestry. A further 29 were excluded because there was either no DNA (n=3) or no 
histology results (n=20) or for inconsistency in the collection of patients data.
Routine histology was used to determine gastritis status. A modified Sydney 
scoring  method  was  used  (Dixon  et  al.,  1996),  which  assesses  evidence  of 
inflammation, atrophy and the occurrence of intestinal metaplasia. An illustration of 
the histological classification for the various disease groups is show in figure 6.1.
147The presence of Helicobacter pylori was determined by routine histology, and 
where  needed  for confirmation,  or  in  many  cases  where  apparently  negative,  by 
immunohistology.  Figure  6.2  shows  gastric  mucosa  sections  stained  by 
immunohistochemistry  for Helicobacter pylori.  Figure  6.2  A  shows a antral  type 
mucosa with no Helicobacter pylori infection and figures 6.2 (B) show an example 
of a gastric mucosa positive for H. pylori infection, and a magnification of a gastric 
gland showing the bacilli very distinctly (C).
Patients were categorised into 4 groups, according to the histology report and 
Helicobacter pylori infection status. Individuals were assessed initially for H. pylori 
infection byCLO  test and/or immunohistochemistry and considered as positive if 
positive for one or other test. In 4 cases there was a positive CLO test and H. pylori 
were not detected histologically.  These slides were reviewed again and in one case a 
few organisms were detected.
The patients with Helicobacter pylori infection (n=34) all  showed signs of 
gastric disease; 27 individuals with at least mild chronic inflammation also showed 
presence of atrophy and/or acute inflammation; presence of intestinal metaplasia was 
also recorded and scored, but all cases with IM (n=8) also had chronic inflammation 
and  atrophy  and/or  acute  inflammation  of the  stomach.  Individuals  with  chronic 
inflammation  and  one  of the  other  changes  were  considered  in  the  same  group, 
named ‘//. pylori gastritis’.
Patients  showing  the  presence  of no  more  than  a  few  mononuclear cells 
(scored as mild, following the updated Sydney system) and negative for neutrophils, 
atrophy,  intestinal metaplasia a nd H. pylori were  considered normal.  However,  to 
eliminate the possibility of previous eradication therapy, most volunteers were also 
asked  by  telephone  or  in  the  clinic  whether  they  had  had  previous  antibiotic 
treatment.  Those without current H. pylori who  did not recall eradication therapy 
were considered as normal.
Seven people who had had previous eradication therapy were still positive for 
H. pylori and included in the H. pylori gastritis group.  Those who had previously 
received eradication therapy and were free of H. pylori were considered as a separate 
group. It is noteworthy that 16 of this group of 44 individuals showed some evidence 
of gastritis, atrophy or intestinal metaplasia.
148One  patient  had  gastric  cancer  and  H.  pylori  infection  and  was  therefore 
included with the H. pylori gastritis disease group.
In summary, 59 were classified as normal, 33 as H. pylori gastritis, 44 as H. 
pylori eradicated and 18 as the fourth group, Gastritis with no H. pylori infection.
Figure 6.1:  Haematoxylin-Eosin (HE) staining of human gastric mucosa showing progressive stages of gastric 
disease.  (A)  Antral  type  mucosa  with  mild  reactive  features  but  no  inflammation,  which  was  classified  as 
normal. (B) Antral type mucosa exhibiting moderate chronic inflammation and moderate atrophy, classified as 
non-active  chronic  gastritis.  (C)  Antral  type  mucosa  with  acute  chronic  gastritis,  with  a  large  number  of 
neutrophils  marked  with  arrows.  (D)  Gastric  mucosa  with  Intestinal  Metaplasia  (IM).  exhibiting  a  colonic 
phenotype with a large number of goblet cells. Original magnification: xlOO (A), xlOO (B). x400 (C), x200 (D).
149Figure  6.2:  Human  gastric  mucosa  stained  by  immunohistochemistry'  with  a  specific  antibody  against 
Helicobacter pylori.  Figure A shows antral  type mucosa negative  for presence of H. pylori.  Figures  B  and C 
show antral  type mucosa exhibiting Helicobacter pylori organisms  in gastric pits.  Two Helicobacter pylori S- 
shaped bacilli are clearly shown by the arrows in the magnified gland in figure C. Original magnification: x200 
(A) x200 (B) and x400 (C).
1506.1.2  Characterisation of the patients within the groups
Table 6.3 summarises some of the patients’ data on gender, age and smoking
status.
Gender Age Smoking status
Male Female Minimum Maximum Mean Current Ever Never
H.pylori gastritis 0.55 0.45 26 84 59.72 0.52 0.09 0.39
Former H. pylori gastritis 0.52 0.48 18 88 52.14 0.37 0.12 0.51
Gastritis no H. pylori 0.56 0.44 25 80 54.71 0.33 0.00 0.67
Normal 0.49 0.51 18 79 52.22 0.41 0.05 0.53
Table 6.3:  Summary of gender,  age range and smoking status  for the four groups:  H. pylori gastritis (n=33), 
Former H. pylori gastritis (n=44), Gastritis no H. pylori (n=18) and Normal (n=59). For the smoking status, data 
was not available for 1   individual in the Former H. pylori gastritis and  1   individual in the Normal; Age was not 
available for 1  individual in the H. pylori gastritis group and 1  individual in the No H. pylori gastritis group.
For this study, the 3 disease groups show a slightly higher proportion of men, 
whereas in the Normal group, the proportion of men and women is very similar. The 
smoking status however,  seems more variable, with the H. pylori group containing 
more smokers and almost  10% of ex-smokers. However, a Chi-square test revealed 
no significant differences between groups for the 2 variables. The H. pylori gastritis 
group  showed a significant difference in age distribution from the Normal controls 
and  Former H. pylori  gastritis  groups  (T-test  2-tailed  p=  0.0212  and  p=  0.04463, 
respectively).  The raw genetic data for each individual included in the 4 groups is 
shown in Appendix 2.
1516.2 Tandem repeat array allele size distribution
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Figure 6.4: Tandem repeat array allele size distribution for the entire cohort, exhibiting a bimodal distribution of 
the alleles.
Figure 2.3 (Chapter 2) shows a representative Southern blot and Figure 6.4 
shows the tandem repeat array allele size distribution for the whole cohort (n=154), 
which exhibits the typical bimodal  distribution,  observed in the previous gastritis 
cohort, and other European populations. There is a pronounced peak on the 3.5-4Kb 
range for the small alleles, and also a second peak with a mode of the 6-6.5Kb allele 
length and with quite a large number of alleles in the 5-6Kb range. Despite not being 
very obvious by observation of this chart, there are slightly more large alleles than 
small alleles in the cohort, partly a reflection of the high number of alleles binned in 
the 5 to 6Kb range.
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Figure 6.5: Tandem repeat array allele size distribution for each the four groups: (A) H. pylori gastritis, (B) 
Former H. pylori gastritis, (C) Gastritis no H. pylori and (D) Normal.
153A closer examination of the TR distribution in the different subgroups of this 
cohort  fails  to  show  an  increase  in  small  alleles  in  the  H.  pylori  groups  but 
nevertheless reveals  some differences between groups.  The//, pylori gastritis and 
Former H. pylori gastritis groups show a distribution which is similar to that of the 
entire cohort, both with a considerable number of alleles in the 5 to 6 Kb range. The 
gastritis no H. pylori group and the Normal groups show two clear modal peaks with 
fewer alleles in the neighbouring allele ranges. But it is the Normal control group 
that shows the largest number of small modal TR alleles.
The  absolute  TR  length  (ie  unbinned)  allele  distribution  was  compared 
between  groups,  using  the  Mann-Whitney  Rank  test.  There  were  no  significant 
differences between any of the groups.
6.3  MUC1 markers analysis
6.3.1  Genotype and allele distributions:
Genotype frequencies for the two flanking markers (see figure 2.7 (Chapter 
2) for a typical gel result) and the TR alleles binned as S and L for the four groups 
are represented in the histograms (A), (B) and (C) in figure 6.6. All four groups seem 
to  have  a  similar genotype  distribution  for the  3  markers.  The  small  differences 
observed  occur  in  the  Former  H.  pylori  gastritis  group,  with  less  SS  genotype 
individuals in the group, but a slight increase in the percentage of heterozygotes LS. 
There is also a slight increase in the 12,12 genotype for the H. pylori gastritis and No 
H.  pylori  gastritis  group.  However,  none  of these  small  differences  seem  to  be 
significant.
The allele frequencies for the three markers are shown in table 6.7 (A), (B) 
and (C).  Fisher’s exact tests based on chromosome counts revealed no statistically 
significant differences between any of the groups.
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Figure 6.6: Genotype frequencies for the Tandem Repeat array (A), G3506A SNP (B) and CA microsatellite (C) 
for the four groups: H. pylori gastritis (n=33), Former H. pylori gastritis (n=44), Gastritis no H. pylori (n=18) 
and Normal control (n=59).
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H. pylori  gastritis
Form er H. pylori 
gastritis
G astritis No 
H. pylori
Normal
L 0.52 0.53 0.53 0.48
S 0.48 0.47 0.47 0.52
B
H. pylori  gastritis
Form er //. pylori 
gastritis
Gastritis No 
H. pylori
Normal
A 0.55 0.50 0.53 0.53
G 0.45 0.50 0.47 0.47
C
H. pylori  gastritis
Form er H. pylori 
gastritis
G astritis No 
H. pylori
Normal
11 0.45 0.49 0.47 0.47
12 0.48 0.42 0.44 0.42
13 0.06 0.09 0.08 0.11
Table 6.7: Allele frequencies for the Tandem Repeat array (A), G3506A SNP (B) and CA microsatellite (C) for 
the four groups: H. pylori gastritis (n=33  individuals), Former H. pylori gastritis (n=44), Gastritis no H. pylori 
(n=18) and Normal control (n=59).
6.3.2  Haplotype distribution based on the 3 MUC1 markers:
Figure  6.8  shows  the  haplotype  distribution  for  the  3  markers  in  MUC1, 
inferred using Arlequin (A) and PHASE (B). As previously shown, the two programs 
infer similar haplotype distributions, despite the different methods used (see chapter
3).
Goodness of fit to Hardy-Weinberg Equilibrium and Linkage Disequilibrium 
between markers were also calculated by the Arlequin software package.  All 3  loci 
for all the groups of samples were in HWE, and all pairs of markers were in strong 
LD.
156Haplotype distribution in the new Northern European gastritis cohort inferred using Arlequin
B HLO Gastritis 
■ Former HLO Gastritis 
□ No HLO Gastritis 
□Normal
B 50 
45
8  40
S  35 
I  30
I 2 5 ■5  20
3 “
10
5
0
.  .  J Q u -t   t   Y   _________
Haplotype distribution in the new Northern European gastritis cohort inferred using PHASE
BHLO Gastritis 
B Former HLO Gastritis 
□No HLO Gastritis 
□Normal
V
G > o
Figure 6.8: MUC1 haplotype distribution for the four populations studied: H. pylori gastritis (n=33), Former H. pylori gastritis (n=44), Gastritis no H. pylori (n=18) and Normal 
control (n=59). The haplotypes were inferred using 2 different statistical methods: (A) a maximum-likelihood method, the EM algorithm, and (B) a Bayesian method.
157Examining figure 6.8, it is notable that all four populations have very similar 
haplotype distributions, with no particular haplotypes over-represented in any group. 
Comparisons  between  pairs  of populations  using  the  “Exact  test  of population 
differentiation”  (part  of  Arlequin  package),  revealed  no  significant  differences 
between  groups.  Likewise,  the  differentiation  test  performed  by  PHASE,  that 
computes the significant differences between haplotypes distribution did not reveal 
any significant differences.
Because  there was an apparent increase  in alleles of 5  to  5.5kb  in the H. 
pylori gastritis groups it was of interest to determine their haplotypes with respect to 
the flanking markers, or expressed another way, it seemed possible that there was an 
over-representation of relatively short G L 11  alleles.  This was examined by using 
PHASE to determine the individual haplotypes and then comparing the lengths of all 
the G carrying chromosomes in the H. pylori groups and normals. The lengths were 
compared using both a Rank test and a students T test and there was no significant 
difference between the groups (data not shown).
Thus in conclusion, this study failed to replicate the previous observations of 
an increase in short alleles or an increase in G S 11 haplotype.
6.4  lOOkb region markers analysis
Six additional markers were also tested on this and the earlier UK cohort and 
it had originally been intended, under the supposition that a disease associated G S 
11  haplotype would be found again, that the data of the two cohorts would then be 
pooled so that the extended G S 11 haplotype could be examined further.  Since this 
did not happen the two cohorts were analysed separately as presented below.
The  six  new markers  added  to  the  analyses are  localised  at both  sides  of 
MUC1,  in a  100Kb region as shown in figure 5.5  (see Chapter 5).  Of the 9  SNPs 
shown  in  figure  5.5,  SNP  rs4072037,  marked  in  blue,  is  that  (G3506A)  already 
included in previous analyses (Chapters 3 and 4).  SNP rs4971101, marked in green 
in figure 5.5 is one of the SNPs found in the NCBI dbSNP, was genotyped for the old 
gastritis cohort. It was found to be 100% associated with SNP rs2070803, localised 
81  nucleotides apart (Data not shown). Because no extra variability was added by
158including the rs4971101  SNP, it was not genotyped for the second cohort, and is 
therefore  not  included  in  the  analyses.  Finally,  the  SNP  with  accession  number 
rs 1045253, was not possible to genotype because it is included in a pseudogene, 
MTX1P that highly resembles MTX1. The PCR amplified products of both genes, and 
the homologous region in MTX1 does not contain the polymorphism.
Both gastritis cohorts were genotyped for the remaining 6 SNP by PCR and 
restriction  enzyme  digestion.  Figure  5.12  (Chapter  5)  shows  some  examples  of 
restriction enzyme digestions run in agarose gels. The markers shown in figure 5.12 
are the ones selected from HapMap: rs9297 (A), rs4971088 (B) and rs4971100 (C).
6.4.1  Extended  haplotype  distribution  in  the  old  and  new  gastritis 
cohorts
Figure 6.9 shows the 9 markers used for the extended haplotypes in a scheme 
of the genomic region.
100Kb haplotype region
CA microsatellite
TR
domain
Figure  6.9:  Schematic  representation  of the  100Kb  genomic  region  and  the  markers  genotyped  for  the 
construction of the extended haplotypes. The MU  Cl markers previously studied are shown in blue boxes, while 
the new markers are shown in green boxes (NCBI dbSNP) and red boxes (HapMap SNPs). MUC1 size is only a 
rough approximation because of the polymorphic TR domain that can alter dramatically the size of MUC1.
The inferred extended 9 marker haplotypes for the two gastritis cohorts are 
shown in figure 6.11. In this figure, the new gastritis cohort only shows data for 2 
groups: the H. pylori gastritis group and the normal controls. These two groups are
159the ones more comparable to the groups in the old gastritis cohort. Figure 6.12 shows 
the full data set for the new cohort.
The haplotypes for the old gastritis cohort (Figure 6.11 A) and new gastritis 
cohort (Figure 6.11 B) were both generated by Arlequin software package. Arlequin 
also calculates the goodness of fit to Hardy Weinberg equilibrium for the genotype 
frequencies for each locus. All loci were in Hardy-Weinberg Equilibrium, both in the 
old and in the new cohort.
Arlequin also runs a pairwise Linkage Disequilibrium test (LD) between pairs 
of markers. All pairs of markers were in LD in the new gastritis cohort, though the 
association between TR array and SNP rs4971088 (in KCP2, see figure 6.9) was of 
borderline  significance  (p=0.0457).  However,  in  the  old  gastritis  cohort,  the  LD 
breaks between several markers in the H. pylori gastritis group. In was previously 
shown in chapter 3 that the CA microsatellite in intron 6 is not in LD with the TR 
domain. In the 9 markers analyses the breakage extends further; the TR domain is not 
in LD with the CA microsatellite (as observed previously), the rs2075571  SNP and 
rs9297. The rs2075571 and rs4971088 markers also show lack of LD between them. 
The LD breakdowns in the H. pylori gastritis group in cohort 1   are summarised in 
Figure 6.10.
CA microsatellite
Figure 6.10: Schematic representation of the genomic region and markers genotyped for the extended haplotype, 
for H. pylori gastritis group from cohort 1. The lines in lilac connect pairs of markers for which LD is broken.
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Figure 6.11: Extended haplotype distribution for the two gastritis cohorts, the old cohort, collected in 1996/1997 and the new cohort collected 2002/2004.  The haplotypes were inferred using a 
maximum-likelyhood method, the EM algorithm.
161The haplotype distribution for each cohort was generated in independent runs 
of  Arlequin.  Firstly,  the  ‘Old  gastritis  cohort’  (Cohort  1),  was  plotted  into  a 
histogram sorting out the haplotypes a ccording to  their frequencies.  The  first two 
haplotypes correspond to the two most frequent haplotypes observed in the 3-marker 
analysis. The other haplotypes appear in a descending order of frequency. The ‘New 
gastritis cohort’ (Cohort 2) was done in a similar way, using the haplotype patterns 
predicted for the first cohort and adding further haplotypes that appeared in this new 
study.
As a consequence of larger samples sizes in the groups of the second cohort, 
the number of inferred haplotypes is greater as might be expected.
The haplotype frequencies seem somewhat different in the two studies.
In the ‘Old gastritis study’, the two major MUC1 haplotypes, A S 12 and G L 
11  are much less frequent in the disease group than in the controls.  It appears the 
core haplotypes w ere broken down into o ther low f requency haplotypes, which is 
consistent with the  decrease  in LD  observed in this  specific  group.  On the  other 
hand, the G S  11 haplotype, shown to be over-represented in the H. pylori gastritis 
group (see chapter 3), does not breakdown. In the original 3-marker haplotypes, G S 
11  accounted  for about 24%  of the chromosomes  in  the  gastritis  group,  and  that 
proportion is essentially maintained.  There is just one other very low frequency G S 
11 haplotype(G C G S 11 TGAG).
The haplotype distribution observed for the new study tells a different story. 
The two major haplotypes, containing A S 12 and G L 11 as core haplotypes, remain 
a very high frequency, not differing much from the original 3-markers analysis (see 
figure 6.8). However, it is noteworthy that the major G L 11 haplotype remains at a 
lower frequency in the gastritis group when compared with the controls, as in the 
three locus haplotypes.  This haplotype is also less frequent in the gastritis group of 
the old gastritis cohort, though the difference is not so dramatic.  The main G S  11 
haplotype  is  at relatively low  frequency,  and both H.  pylori  gastritis  and  control 
groups.  As before, this core h aplotype a gain is not broken down into  several low 
frequency haplotypes.  Interestingly in this new gastritis cohort there is a different 
haplotype  at elevated  frequency in the  gastritis  group:  ‘G  T  A  L  12  T  G  A A’, 
carrying the other ‘recombinant’ haplotype for the MUC1 markers (in bold).
162Despite  these  observations,  the  ‘Exact  test  of population  differentiation’, 
performed by Arlequin, did not find any significant differences between the groups 
in  either  study.  The  haplotype  differentiation  test  run  by  PHASE  software  did 
however find the difference between the two groups in the ‘Old gastritis cohort’ to be 
almost significant (p=0.052).
Inspection of the bar charts of the total population of patients and controls 
shows several noteworthy features. A large number of the G L 11 chromosomes are 
nearly identical for haplotype across the whole region.  This concurs with what can 
be seen for this region of the CEPH chromosomes in Figure 5.10 (Chapter 5) that can 
be seen in a simplified table containing only the genotyped markers (Figure 6.13). 
The  S chromosomes in contrast are more diverse, suggesting more recombination 
(Figure 6.13).  Interestingly most of the G S 11 chromosomes are the same as G L 11 
with respect to the flanking markers in both the London and CEPH cohorts.
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Figure 6.12: Extended haplotype distribution for the four populations studied: H. pylori gastritis (n=33), Former H. pylori gastritis (n=44), Gastritis no H. pylori (n=18) and Normal 
control (n=59). The haplotypes were inferred using) a maximum-likelihood method, the EM algorithm.
164A/G A/T A/G US A/G C/T Haplotypes
Number of CEPH 
chromosomes
A A G L A T AAGLAT 1
G A G L A T GAGLAT 4
T G L G C ATGLGC 28
T A S A C ATASAC 7
G A A s A C GAASAC 17
G A A s A T GAASAT 10
A A s A T AAASAT 3
A G s A T AAGSAT 3
T A s A T ATASAT 2
A G s G C GACSGC 2
...  J G s G C ATGSGC 4
Figure 6.13: Tabulated results obtained from the analysis of CEPH genotypes in HapMap. In this figure, only 
the selected markers (in red) and the MUC1 markers are included. It is noteworthy the larger diversity of S A 
haplotypes when compared with the L G, that is only represented in one haplogroup.
6.5  Discussion
A  major  aim  of this  part  of the  work  was  to  collect  samples  from  and 
characterise a new cohort of patients in the same GI clinic as the previous cohort. 
Despite the fact that this work was shared between two of us this proved slow.
There was greater than anticipated difficulty in collecting H. pylori gastritis 
cases of UK origin. This was strongly suggestive of a reduction in the UK population 
disease frequency, (in contrast there were many cases of non-UK origin).  During the 
course of collection it became apparent that many people had previously been treated 
with antibiotics although there was not necessarily a record of this in the hospital 
notes. Thus we relied on asking the patients. There was therefore more difficulty in 
obtaining an accurate record of this than for the first cohort where prior treatment 
was much rarer.
The numbers of clear H. pylori gastritis cases were many fewer than we had 
hoped and the small numbers did not allow matching for sex, age and smoking status 
as might have been desirable.  However every effort was made to group the patients 
rationally and to include only those of northern European origin, (152 individuals 
from UK and 2 individuals from Germany).
165Unfortunately  it  was  not  possible  to  replicate  the  original  finding  of an 
increase in S alleles and of a specific haplotype in H. pylori gastritis.  This will be 
discussed in more detail in the next Chapter, Chapter 7.
Determination of extended haplotypes did however provide some interesting 
insights.  In particular the very high frequency lOOkb G L haplotype was noteworthy. 
It implies that the majority of long alleles originate from a single progenitor and that 
more recent slippages, gene conversions or other mutations have led to subsequent 
TR length diversity, but the existence of this  ‘haplogroup’  at such high frequency 
suggests it might have been favoured by selection.  Interestingly the most common G 
S  11 haplotype is identical with respect to the flanking markers, but the TR array is 
much shorter. Inspection of the precise allele lengths of the G S 11 alleles shows that 
they are quite variable in length (data not shown). This suggests perhaps that these 
alleles arose  from  several  large  deletions  of common  L alleles.  As mentioned  in 
Chapter  3  there  was  indication  that  the  TR  array  of these  alleles  more  closely 
resembles L alleles, which is consistent with this suggested origin. The long A L 12 
alleles in contrast have a different haplotypic background.  It will be of interest in the 
future to examine the more extended haplotypes in the Nigerians and other Africans 
as well as the Portuguese and other individuals of non-UK origin.  From such studies 
it should be possible to chart the genealogy of the stretch of DNA more precisely. 
Examination of Ashkenazi Jewish populations will be of particular interest because 
of the location of GBA, the Gaucher gene, in this stretch of DNA (see Chapter 5 for 
discussion of this).
166CHAPTER 7
DISCUSSION, CONCLUSIONS AND FUTURE 
PERSPECTIVES
167At the outset of this project there was evidence for the involvement of MUCl 
in gastric  disease.  There  was  suggestive  evidence,  now  published,  that H.  pylori 
binds MUC1  (Linden et al., 2004) and there was clear evidence for a change in the 
pattern of MUC1 glycoprotein expression in H. pylori gastritis (Vinall et al., 2002). 
This  was  complemented by  early  studies  that  showed  evidence  of association  of 
MUCl allele length in gastric cancer (Carvalho et al.,  1997) and the finding of the 
same pattern of association in a small UK H. pylori gastritis cohort collected in this 
laboratory (Vinall et al., 2002).
Since preliminary studies by Jo Fowler (PhD thesis, University of London, 
2002)  suggested  that  the  markers  flanking  the  TR  domain  were  not  disease 
associated, despite the fact that these markers had been shown to be associated with 
each other and TR array length in other cohorts, one of the first aims of my work was 
to test these markers in all the patient material available and examine the pattern of 
haplotype distribution in control and disease groups.  This led to the observation that 
one particular haplotype (GS11) was over-represented in gastric disease patients or 
increased in frequency in parallel with disease severity, even though this was not 
statistically significant in the Portuguese patients.
The original aim of my work was to examine TR sequence variability in the 
context  of gastric  disease.  The  technique  involved proved  too  cumbersome  and 
required  very high quality  DNA,  but preliminary  examination  suggested  that the 
GS11 haplotype resembled long TR alleles in terms of repeat sequence array rather 
than short alleles (see Chapter 3).
In order to  pursue  these  observations  further,  two  approaches  were  taken. 
One was to determine the extent of linkage disequilibrium across the MUCl  gene 
region and identify SNPs to examine the patterns of disease association over a larger 
genomic region.  The other was to collect and characterise (together with Dr Adil 
Elamin) a new cohort of patients as a replication study.  Despite the existence of the 
potentially destabilising TR array in the middle of MUCl, a region of LD of 600Kb 
was found.  SNPs were selected to maximise haplotype diversity and with the hopes 
of providing particular association with the putative disease haplotype.  Analysis of
168these markers in the first UK cohort still showed a clear disease haplotype but no 
single SNP associated better with disease than the original L/S variation.
DNA samples from a new cohort of 237 people were successfully collected 
and characterised. Of these  154 could be included in the subsequent analyses. The 
collection of samples from H. pylori positive individuals of UK origin proved to be a 
difficult task. In the early stages of the collection, and with a view to not showing 
discrimination, samples were collected from individuals regardless of their ancestry. 
Many individuals collected at that period were of non-Northem European ancestry, 
and many of these had H. pylori infection and gastritis. To maximise our chances of 
getting  as  many  UK  patients  as  possible,  in  the  subsequent  collection,  UK  or 
Northern  European  origin  individuals  and  certain  classes  of  patients  were 
preferentially targeted. However in the 154 UK/Northern European samples, only 34 
individuals had H. pylori infection.  This proportion seems low when one considers 
that this was a selected population and, according to Vyse et al estimates, in 1996 
14%  of the  England  and  Wales  population  was  infected,  though  most  of those 
individuals were bom in the 1940s or pre-1940s (Vyse et al., 2002). However their 
data also suggests that H. pylori infection is becoming less frequent each decade, a 
possible  explanation  for  the  increased  difficulty  in  collecting  H.  pylori  positive 
samples  from  UK  patients  since  the  last  gastritis  cohort  study,  collected  in 
1996/1997. Other possible explanations for the decrease in the number of individuals 
infected is the rise in number of individuals treated with antibiotics to eradicate H. 
pylori infection
Using this new cohort the original observation of over-representation of the G 
S  11  and  associated  haplotypes  found  in  the  first  even  smaller  cohort  was  not 
replicated.  It is possible that the original associations were spurious resulting from 
small data sets in the first place (Cardon and Palmer, 2003;Tabor et al., 2002).  It 
could also have resulted from population stratification which is very difficult indeed 
to avoid completely (Cardon and Palmer, 2003).  We selected volunteers of northern 
European/UK ancestry but it was very clear that H. pylori is much more prevalent in 
people of non UK ancestry, possibly attributable to both cultural and genetic reasons 
(Vyse  et al.,  2002).  The population of London is  very mixed  and there could be 
geographic differences in Helicobacter pylori frequency as well as different bacterial
169strains present at the population and individual level, that affect the disease outcome 
(Figueiredo et al., 2001;Nogueira et al., 2001).  Particular strains, such as the ones 
carrying Cag PAI and VacA+ phenotype are particularly aggressive (Figueiredo et 
al., 2001). Kauser et al reported presence of less virulent strains as predominant, but 
also some strains that were typical of Asian populations (Kauser et al., 2005).
The p resence of a g eographically m ixed population in London could also 
lead  to  independent  differences  in  MUCl  allele  frequency.  This  however  was 
considered to be an unlikely explanation because no significant difference in MUCl 
haplotype  frequency  was  found across  the  UK  (Vinall,  Fowler unpublished).  It 
should  however  be  noted  that  one  potential  confounder  could  be  difference  in 
representation of patients of Ashkenazi Jewish extraction, who might possibly have 
different MUCl  haplotype  distribution due  to  selection  (see  Chapter 5  and  6  for 
discussion about GBA). The Portuguese gastric cancer study was likely on the other 
hand to  have been better because the  blood donors  came  from  S.  Joao  Hospital, 
Porto,  the  same hospital as the cancer patients.  The  gastritis patients came f rom 
Viana do Castelo, a city in the far North of Portugal, where gastric cancer incidence 
(and consequently gastric disease in general) is known to be particularly high (Lunet 
and Barros, 2003) but it was not possible to make direct comparisons between these 
two groups.
Despite  the  negative  findings,  there  were  several  curious  features  of the 
results which should be noted.  There was an apparent increase in the currently and 
formerly H. pylori infected groups of alleles just above the 5kb cut point, a category 
that is rare in the population as a whole.  Also, and perhaps more significant there 
was,  in both gastritis  cohorts,  an increase  in  low  frequency haplotypes  in the H. 
pylori gastritis group (albeit non-significant in the second cohort).  In each case there 
was a corresponding decrease in one extended haplotype (G C G L 11 T G T A) the 
one which is so frequent in the northern European population as a whole.  The high 
frequency of this haplotype had suggested that this haplotype has, or has had in the 
past, a selective advantage (see Chapter 6).  Perhaps this group of long MUCl alleles 
is protective against H. pylori colonisation?
Recent studies from the Hanisch group show that there is indeed likely to be a 
functional difference indifferent tandem repeat variants  (Mensdorff-Pouilly etal., 
2005).  PESR repeats, which seem to be relatively more frequent in long TR alleles,
170show  increased  flexibility  and  possible  reduced  glycosylation.  This  comes  from 
indirect evidence, showing that the PESR repeats were usually found in association 
with the A variant of the PAQT change  site  (Figure  1.3,  Chapter  1), which was 
shown  to  have  a  reduced  glycosylation  density  and  even  a  negative  effect  on 
GalNAc-Transferase  activity,  affecting  also  some  distant  glycosylation  sites 
(Mensdorff-Pouilly et al., 2005).
It should also be noted that the exon 2 GA SNP, like the TR array variation 
causes a functionally relevant change in MUCl.  Presence of G at this position leads 
to the insertion of 27 nucleotides in the MUCl transcript.  This leads to alteration of 
the signal sequence and abolition of one of the known proteolytic cleavage sites at 
the N-terminal end as depicted in Figure 7.1 and probable introduction of a new one 
(green arrow) (Parry et al., 2001), which  leads to an extended N-terminal end as 
described in Hilkens and Buijs for the A splice variant (Hilkens and Buijs, 1988).
MVCl B
Signal sequence
Figure  7.1:  Schematic representation of MUCl  alternative splicing event occurring  in the 5'  end of exon 2. 
MUCl  A  and  B  spliceoforms are  associated  with  a SNP,  G3506A, with  spliceoform  A associated  with the 
presence of G nucleotide, and spliceoform B associated with the A nucleotide. This SNP causes a change in the 
proteolytic cleavage site as show by the red and green arrows. Adapted from diagram kindly supplied by Wendy 
Ng.
Although  it is  hard to predict what effect this extension will  have  on the 
molecule it is not unreasonable to suppose that it may affect intra-cellular transport. 
It is also worth noting that the B variant contains a peptide in its signal sequence 
which  is  absent in variant A,  which has  been shown  in a cell  culture  system to 
provoke MUCl  specific cytotoxic T cells (Bohnenkamp, oral communication at 8th 
International  Workshop  on  Carcinoma-associated  Mucins,  Mucins  in  Health  and
MVCl A
171Disease, Cambridge, 2005).  Furthermore, preliminary studies in the lab indicate that 
the A transcripts (ones with the G allele) are expressed at lower levels than the B 
transcripts (Ng et al, unpublished data).  This may be due to the associated variation 
in TR length (perhaps fewer long transcripts are transcribed) and this is currently 
under investigation, making use, in part, of data collected in this study.  It is however 
possible to imagine that these various genetically determined variations as well as 
sequence variations in the TR array itself, act in different ways to alter susceptibility 
to H. pylori infection and colonisation.  In other words there may be differences in 
transport, variability in the binding of H. pylori to MUCl, differences in consequent 
signalling,  differences  in  the  associated  inflammatory  and  immune  responses.  At 
present not  all  of these variations  can  easily be  measured.  A  simple  PCR based 
method for examining TR sequence variation would certainly be helpful, so that a 
more in depth description of the TR variability could be obtained.
There  is  also  the  issue  of heterozygosity that has been  considered by the 
Portuguese group (Silva et al., 2001;Silva et al., 2003).  Short and long alleles can 
encode proteins of up to two-fold difference in length.  It is generally thought that 
these molecules  extend out  from the cell surface,  and this could mean,  say,  200- 
500nM according to  allele.  If binding of H. pylori is multivalent,  organisms may 
bind across molecules as well as to a single MUCl  molecule more in some people 
than others.
All this potential diversity, together with the fact that in small data sets there 
are likely to be a number of confounders, could account for our not replicating the 
previously observed association.
The small number of individuals in each group in both cohorts may have lead 
to  a  bias  in  the  results  either  by  generating  a  false  positive  or  false  negative 
association.  The  best  way  of decreasing  these  types  of errors  is  to  increase  the 
number of individuals, to at least a few hundred in each group.  The best way to 
achieve this would be to collect more samples by taking advantage of the wide range 
of  hospitals  affiliated  to  UCL  and  do  a  UCLH  (University  College  London 
Hospitals) multi- centre study, obtaining samples more quickly and still a 1 1  in the 
same geographical area- London.
With a larger study, multiple regression analysis could be performed to take 
into account several other factors that may be involved in disease susceptibility. On 
the one hand, these include external factors, such as the particular H. pylori strain(s)
172present  in  the  patients,  in  particular  the  virulence  factors  such  as  the  Cag 
pathogenicity  island,  the  VacA  locus  and  the  BabA2  adhesin,  since  the  disease 
outcome and progression depends greatly on the  strains that are present.  Another 
external factor that may be involved is the smoking habits of the individuals in the 
study.  On the other hand, we should also take into account other genetic loci (than 
the ones presented in this thesis) that are thought to alter H. pylori infectivity and 
disease consequences. These include the blood groups (e.g. Lewis b), that have been 
reported to be ligands to H. pylori or affect gastric disease susceptibility (Heneghan 
et al.,  1998), and the inflammatory cytokines,  such as IL-lp,  IL-1RN and TNF-a, 
that were shown to have genetic variants that are overrepresented in gastric disease 
(El Omar et al., 2000;E1 Omar et al., 2001;E1 Omar, 2001;Machado et al., 2003).
An additional problem is that the Southern Blot technique not only requires 
large amounts of good quality DNA (preferably blood extracted DNA) but also it is 
very  laborious  and  time  consuming.  To  get  around  this,  it  was  thought  to  be 
important  to  identify  single  nucleotide  polymorphisms  (SNPs)  that  would  act  as 
linked markers of the TR domain. However, none of the SNPs identified appeared to 
fulfil this role. In order to understand better how to proceed,  I have analysed the 
haplotypes again using the 7 SNP markers together with the CA microsatellite and 
TR in MUC1 using PHASE, but taking into account precise allele length. For this 
analysis, both cohorts (old and new cohort) were merged to increase sample size. The 
tandem repeat allele lengths were binned into 0.5kb classes, generating 12 alleles for 
the TR. With these 9 markers,  80 different haplotypes were predicted by PHASE. 
However, there are only 28 haplotypes based only on the SNPs, 5 of which (A, B, C, 
D and E) account for almost 90% of the chromosomes (figure 7.2).
To determine the relationship of the SNP haplotypes found, a phylogenetic 
tree was generated using Treeview software (version  1.6.6 uploaded in September 
2001)  (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html),  which  builds  trees 
based on their similarity using a parsimonious principle (figure 7.3).  Interestingly, 
the two most common haplotypes, A and B, are the exact opposite of each other. 
This phenomenon,  “yin yang haplotypes”,  was previously observed  for other loci 
(Zhang et al., 2003).
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Figure  12:  Schematic  representation  of MUC1  genomic  region  and  the  7  SNPs  selected  for the  haplotype 
analysis. Below the diagram, the 5 major SNP haplotypes are shown (A, B, C D E) in order of frequency (shown 
in brackets) with the letter representing each haplotype surrounded by a circle coloured according to the colours 
used for the haplotypes in figures 73 and 7.4.
The TR allele distribution in relation to the common SNP haplotypes can be 
seen in figure 7.4, both for the H. pylori gastritis and normal control groups. As can 
readily be seen, each of the common haplotypes, in particular haplotype A (the only 
one  carrying the  G  allele  from the  G3506A MUC1  SNP),  shows  a considerable 
diversity in TR allele length, suggesting that the SNP haplotypes are much older than 
the derived TR alleles on each background. In view of this analysis, it seems that 
further SNP testing is unlikely to be useful for the disease association studies, but 
that testing microsatellites with their higher mutation rate might give insight into the 
evolutionary origins of the haplotypes and might even prove useful for the disease 
association studies.
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Figure 73: Phylogenetic tree for the SNPs in MUC1 genomic region, generated using Treeview software. The 5 
major haplotypes are displayed in coloured boxes next to the haplotype name (letters in circles). The order of the 
SNPs is in agreement with their distribution (left to right) shown in figure 12.
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176After  completion  of  this  study  it  still  seems  possible  that  the  sequence 
variation of the tandem repeat array of MUC1  is the important factor in influencing 
gastric  disease.  One  way  forward might be  to  develop  a protocol  to  look  at the 
variant  repeats  using  sequence  specific  hybridisation  or  minisequencing,  though 
there would still be the need to separate the two alleles. It is possible that better DNA 
polymerases and protocols are now available for conducting these difficult long PCR 
reactions.
This  well  characterised  cohort,  although  small,  will  also  be  useful  for 
examining changes in MUC1 expression in relation to MUC1  gene haplotype and 
gastritis status, since biopsies and mRNA are available.
177APPENDIX 1
Distribution of TR alleles within the 5Kb to 5.5Kb range in the
Nigerian population
178Summary of the results:
Haplotypes Within 5-5.5kb
Possibly within 
5-5.5Kb
Outside
5-5.5Kb
AL 12 18 9 4
non A L 12 3
Raw data:
Individuals
code
Haplotypes predicted Haplotype
probability
TR size (Kb)
IND:  1 AS 12 GS 11 1 4.683
3.718
IND: 2 AS  12 AS 12 1 3.854
3.744
IND: 3 AS 12 AL 12 1 5.179
3.745
IND: 4 AL  12 AL 13 1 5.717
5.128
IND: 5 AS 12 AL 12 1 5.256
3.562
IND: 6 AS 12 AS 12 1 4.83
3.411
IND: 7 AL  12 AL 12 1 5.138
5.029
IND: 8 AS 12 GL 11 0.943 6.075
4.241
IND: 9 AS 13 GL 11 0.816 5.807
3.753
IND:  10 AS 12 GL 11 0.942 6.406
3.715
IND:  11 AL 12 GL 11 0.998 6.021
5.065
IND:  12 AS 12 AL 12 1 5.043
3.669
IND:  13 AL  12 GL 11 0.998 5.04
5.04
IND:  14 GL 11 GL 11 1 5.973
5.973
IND:  15 AS 12 AL 12 1 5.608
3.675
IND:  16 GL 11 GL 12 1 6.293
6.07
IND:  17 AS 12 AL  12 1 5.149
3.766
IND:  18 AS 12 GL 11 0.943 5.528
3.974Individuals
code
Haplotypes predicted Haplotype
probability
TR size (Kb)
180
52575759Individuals
code
Haplotypes predicted
Haplotype
probability
TR size (Kb)
IND: 42 GL 11 GL 11 1 6.14
6.14
IND: 43 AL  12 GL 11 0.998 6.055
6.055
IND: 44 GL 11 GL 11 1 6.14
6.14
IND: 45 AL 12 GL 11 0.998 6.313
5.282
IND: 46 AS 12 GL 11 0.943 6.073
3.725
IND: 47 AS 12 AS 12 1 3.759
3.602
IND: 48 GL 11 GL 11 1 6.347
6.072
IND: 49 AL 12 GL 11 0.998 5.988
5.025
IND: 50 GL 11 GL 11 1 6.105
6.105
IND: 51 AS 13 GL 11 0.832 5.538
3.775
IND: 52 AS 12 AS 12 1 3.617
3.617
IND: 53 AL  12 AL 12 1 5.309
5.172
IND: 54 AS 12 GS 11 1 4.867
4.172
IND: 55 AL 12 GL 11 0.998 6.311
5.173
IND: 56 AL  12 GL 11 0.998 5.958
5.638
IND: 57 AL 11 GL 11 1 6.143
6.143
IND: 58 GL 11 GL 11 1 5.987
5.987
IND: 59 AL  12 AL 12 1 5.151
5.151
IND: 60 AS 12 GL 11 0.943 6.142
4.513
Legend: TR size of the Nigerian individuals: The green boxes represent the A L 12 
alleles that are without doubt in the 5 to 5.5Kb range; the yellow boxes represent the 
A L  12  alleles that have 50% chance of being in the 5 to 5.5Kb range; the purple 
boxes represent the A L 12 alleles that are not binned in the 5-5.5Kb range. In the TR 
size column, the number in bold represent non-A L 12 alleles in the 5 to 5.5Kb range.
181APPENDIX 2
Raw data on the new gastritis cohort for the Northern European
individuals
182Survey
number
Categorisation MUCI  TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M186 FORMER HLO GASTRITIS 5.109 3.722 LS 12,12 AA AG TT CT AG AA AG
M187 NORMAL 6.415 4.931 LS 11,11 GG GG CC TT GG TT AA
M188 NORMAL 5.586 3.737 LS 12,13 AA AG TT CT AG AA GG
M189 NORMAL 3.723 3.723 SS 11,12 AG AG CT CT AG AT AG
Ml 90 FORMER HLO GASTRITIS 5.007 3.729 LS 11,12 AG AG CT CT AG AA AG
M191 FORMER HLO GASTRITIS 6.278 6.076 LL 11,11 GG GG CC TT GG TT AA
Ml 94 HLO GASTRITIS 6.24 3.665 LS 11,12 AG AG CT CT AG AT AG
Ml 95 NORMAL 5.551 3.695 LS 12,13 AA AG TT CT AG AA AG
M196 HLO GASTRITIS 6.293 3.057 LS 11,12 AG AG CT CT AG AT AG
Ml 99 NORMAL 6.065 4.181 LS 11,12 AG AG CT CT AG TT AA
M204 NORMAL 3.712 3.54 SS 12,12 AA AA TT CC AA AA GG
M205 FORMER HLO GASTRITIS 5.168 5.168 LL 11,12 AG GG CT TT GG AT AA
M206 HLO GASTRITIS 3.775 3.626 SS 11,12 AG AG CT n.d. AG AT AG
M207 NORMAL 5.146 3.682 LS 12,12 AA AG TT n.d. AG AA AG
M208 HLO GASTRITIS 5.144 3.693 LS 12,12 AA AG TT CT AG AA AG
M210 HLO GASTRITIS 6.01 4.192 LS 11,12 AG AA CT n.d. AG TT AA
M211 HLO GASTRITIS 3.705 3.524 SS 11,12 AG AG CT CT AG AT AG
M212 FORMER HLO GASTRITIS 3.695 3.695 SS 12,12 AA AA TT n.d. AA AA GG
M213 FORMER HLO GASTRITIS 5.086 3.604 LS 11,12 AG GG CC TT GG AT AA
M215 GASTRITIS NO HLO 5.846 3.675 LS 11,12 AG AG CT CT AG AT AG
M217 FORMER HLO GASTRITIS 5.878 3.192 LS 11,12 AG AG CT CT AG AT AG
M218 HLO GASTRITIS 5.308 3.564 LS 12,13 AA AG TT CT AG AA GG
M219 FORMER HLO GASTRITIS 6.169 6.169 LL 11,11 GG GG CC TT GG TT AA
M220 FORMER HLO GASTRITIS 5.106 3.613 LS 12,12 AA AG TT CT AG AA AG
M221 HLO GASTRITIS 6.281 3.658 LS 11,12 AG AG CT CT AG AT AG
M226 FORMER HLO GASTRITIS 6.299 6.064 LL 11,11 GG GG CC TT GG TT AA
M227 FORMER HLO GASTRITIS 6.121 3.591 LS 11,12 AG AG CT CT AG TT AA
M229 FORMER HLO GASTRITIS 6.981 6.12 LL 11,11 GG GG CC TT GG TT AA
M232 NORMAL 5.981 3.635 LS 11,12 AG AG CT CT AG AT AGSurvey
number
Categorisation MUCI  TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M233 NORMAL 6.322 3.685 LS 11,11 GG GG CC TT GG TT AA
M234 NORMAL 6.357 5.952 LL 11,11 GG GG CC TT GG TT AG
M235 FORMER HLO GASTRITIS 5.823 3.649 LS 11,12 AG AG CT CT AG AA GG
M237 FORMER HLO GASTRITIS 8.447 5.716 LL 11,11 GG GG CC TT GG TT AA
M238 FORMER HLO GASTRITIS 3.726 3.606 SS 11,12 AG AG CT CT AG AA GG
M239 FORMER HLO GASTRITIS 4.124 3.454 SS 12,12 AA AA TT CC AA AT AG
M240 FORMER HLO GASTRITIS 6.323 3.636 LS 11,12 AG AG CT CT AG AT AG
M241 FORMER HLO GASTRITIS 5.456 3.698 LS 12,13 AA AG TT CT AG AA GG
M242 HLO GASTRITIS 5.1 3.672 LS 12,12 AA AG CT CT AG AA AG
M246 NORMAL 5.707 3.679 LS 11,12 AG AG CT CT AG AT AG
M248 GASTRITIS NO HLO 3.726 3.682 SS 12,12 AA AA TT CC AA AT AG
M249 HLO GASTRITIS 4.087 3.68 SS 12,12 AA AG TT CT AG AA AG
M250 NORMAL 5.993 3.697 LS 11,12 AG AG CT CT AG AT AG
M253 FORMER HLO GASTRITIS 5.737 4.088 LS 11,12 AG GG CT TT GG AT AA
M254 FORMER HLO GASTRITIS 6.094 3.576 LS 11,11 GG GG CC TT GG TT AA
M255 FORMER HLO GASTRITIS 6.231 3.219 LS 11,12 AG AG CT CT AG AT AG
M264 FORMER HLO GASTRITIS 3.782 2.943 SS 11,12 AG AG CT CT AG AT AG
M265 FORMER HLO GASTRITIS 5.734 4.149 LS 11,12 AG GG CT TT GG AT AA
M267 FORMER HLO GASTRITIS 5.755 3.722 LS 11,12 AG AG CT CT AG AT AG
M269 GASTRITIS NO HLO 6.399 5.603 LL 11,11 GG GG CC TT GG AT AG
M273 NORMAL 6.307 3.684 LS 11,12 AG AG CT CT AG AT GG
M274 HLO GASTRITIS 5.197 3.432 LS 12,12 AA AG TT CT AG AA AG
M277 FORMER HLO GASTRITIS 5.385 3.674 LS 12,13 AA AG TT CT AG AA GG
M278 FORMER HLO GASTRITIS 6.076 3.667 LS 11,12 AG AG CT CT AG TT AA
M279 GASTRITIS NO HLO 6.112 5.369 LL 11,13 AG GG CT TT GG AT AG
M281 NORMAL 5.906 4.111 LS 11,12 AG AG CT CT AG TT AA
M282 HLO GASTRITIS 5.928 3.743 LS 11,11 GG GG CC TT GG TT AA
M284 NORMAL 6.004 4.069 LS 11,12 AG GG CT TT GG AT AASurvey
number
Categorisation MUCI TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M285 GASTRITIS NO HLO 5.945 3.626 LS 11,12 AG AG CT CT AG AT AG
M289 HLO GASTRITIS 6.279 6.088 LL 11,11 GG GG CC TT GG TT AA
M291 HLO GASTRITIS 5.212 5.212 LL 12,13 AA GG TT TT GG AA AG
M293 NORMAL 4.419 3.747 SS 11,11 GG GG CC TT GG TT AA
M294 FORMER HLO GASTRITIS 6.131 4.066 LS 11,12 AG GG CT TT GG AT AA
M295 FORMER HLO GASTRITIS 6.004 4.138 LS 11,12 AG GG CT TT GG AT AA
M2 96 GASTRITIS NO HLO 4.118 3.672 SS 12,13 AA AA TT CC AA AA GG
M297 GASTRITIS NO HLO 6.113 3.627 LS 11,12 AG AG CT CT AG AT AG
M298 NORMAL 6.306 5.398 LL 11,13 AG GG CT TT GG AA GG
M298A GASTRITIS NO HLO 6.222 4.781 LS 11,13 AG GG CT TT GG AT AG
M301 NORMAL 6.394 6.084 LL 11,11 GG GG CC TT GG TT AA
M3 03 GASTRITIS NO HLO 6.542 4.111 LS 11,12 AG GG CT TT GG AT AA
M312 NORMAL 6.196 5.975 LL 11,11 GG GG CC TT GG TT AA
M313 GASTRITIS NO HLO 6.196 3.005 LS 11,12 AG AG CT CT AG AT AG
M317 NORMAL 6.064 6.064 LL 11,11 GG GG CC TT GG TT AA
M318 GASTRIC CANCER 5.647 3.737 LS 12,13 AA AG TT CT AG AA GG
M320 NORMAL 6.257 5.704 LL 11,12 AG GG CC CT AG AT AG
M3 22 NORMAL 5.591 3.77 LS 12,13 AA AG TT CT AG AA GG
M3 23 NORMAL 6.491 3.689 LS 11,12 AG AG CT CT AG AT AG
M3 24 HLO GASTRITIS 5.647 5.317 LL 11,12 AG GG CT TT GG AT AA
M3 27 HLO GASTRITIS 6.162 5.913 LL 11,11 GG GG CC TT GG TT AG
M330 NORMAL 6.03 6.03 LL 11,11 GG GG CC TT GG TT AA
M334 HLO GASTRITIS 6.048 5.498 LL 11,13 AG GG CT TT GG AT AG
M335 NORMAL 6.252 3.648 LS 11,12 AG AG CT CT AG AT AG
M336 NORMAL 6.399 3.712 LS 11,12 AG AG CT CT AG AT AG
M338 HLO GASTRITIS 6.204 4.133 LS 11,12 AG GG CT TT GG AT AG
M339 NORMAL 5.432 3.801 LS 11,13 AG AG CT CT AG AT AG
M340 NORMAL 6.325 5.989 LL 11,11 GG GG CC TT GG TT AASurvey
number
Categorisation MUCI TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M341 NORMAL 6.292 3.733 LS 11,12 AG AG CT CT AG AT AG
M342 FORMER HLO GASTRITIS 6.408 6.408 LL 11,11 GG GG CC TT GG TT AA
M344 NORMAL 6.135 3.726 LS 11,12 AG AG CT CT AG AT AG
M345 FORMER HLO GASTRITIS 3.752 3.752 SS 12,13 AA AA TT CC AA AA GG
M346 HLO GASTRITIS 3.641 3.046 SS 12,12 AA AA TT CC AA AA GG
M347 NORMAL 3.742 3.742 SS 11,12 AG AG CT CT AG AT AG
M348 HLO GASTRITIS 5.843 2.902 LS 11,12 AG AG CT CT AG AT AG
M349 NORMAL 3.668 3.668 SS 12,12 AA AA TT CC GG AT GG
M3 50 NORMAL 7.365 4.14 LS 11,12 AG AG CT CT GG TT AG
M351 FORMER HLO GASTRITIS 5.741 4.055 LS 11,12 AG GG CT TT GG AT AA
M352 GASTRITIS NO HLO 4.071 3.661 SS 12,12 AA AG TT CT AG AA AG
M3 53 NORMAL 4.972 3.594 SS 12,12 AA AG TT CT AG AA AG
M3 54 FORMER HLO GASTRITIS 6.039 4.09 LS 11,13 AG AG CT CT AG AT AG
M355 NORMAL 4.157 3.675 SS 12,12 AA AA TT CC AA AT GG
M3 56 NORMAL 5.422 3.688 LS 12,13 AA AG TT CT AA AA AG
M3 57 HLO GASTRITIS 6.549 6.208 LL 11,11 GG GG CC TT GG TT AA
M3 58 NORMAL 6.526 5.502 LL 11,13 AG GG CT TT AG AT AA
M3 59 HLO GASTRITIS 6.142 3.824 LS 11,12 AG AG CT CT AG AT AG
M3 60 FORMER HLO GASTRITIS 7.983 3.421 LS 11,12 AG AG CT CT AG AT AG
M361 HLO GASTRITIS 3.75 3.75 SS 11,12 AG AG CT CT AG AT AG
M3 62 HLO GASTRITIS 5.908 3.165 LS 11,12 AG AA CT CT GG TT AG
M3 63 HLO GASTRITIS 6.306 3.788 LS 11,11 GG GG CC TT GG TT AA
M3 65 NORMAL 3.664 3.122 SS 11,12 AG AG CT CT AG AT AG
M3 67 FORMER HLO GASTRITIS 4.02 3.732 SS 12,12 AA AG TT CT AA AA AG
M3 68 NORMAL 5.951 5.103 LL 11,12 AG GG CT TT GG AT AA
M3 69 NORMAL 6.734 4.229 LS 11,12 AG AG CT CT GG TT AG
M371 FORMER HLO GASTRITIS 6.799 5.361 LL 12,13 AA AG TT CT AA AA AG
M3 73 GASTRITIS NO HLO 3.705 3.705 SS 12,12 AA AA TT CC AA AA GGSurvey
number
Categorisation MUCI  TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M3 74 NORMAL 3.689 3.689 SS 12,12 AA AA TT CC AA AA GG
M3 75 HLO GASTRITIS 6.122 5.058 LL 11,12 AG GG CT TT GG AT AA
M376 NORMAL 3.652 3.069 SS 12,12 AA AA TT CC AA AA GG
M377 NORMAL 6.144 3.717 LS 11,11 GG GG CC TT GG AT AA
M3 78 HLO GASTRITIS 6.332 6.332 LL 11,11 GG GG CC TT GG AT AA
M379 FORMER HLO GASTRITIS 3.763 3.763 SS 11,12 AG AA CT CT AG AT AG
M382 NORMAL 4.217 3.722 SS 12,13 AA AA TT CC AA AA GG
M383 FORMER HLO GASTRITIS 6.212 5.235 LL 11,13 AG GG CT TT GG AT AA
M3 84 HLO GASTRITIS 4.143 3.866 SS 12,12 AA AG TT CT AG AA AG
M385 FORMER HLO GASTRITIS 6.212 3.645 LS 11,11 GG GG CC TT GG TT AA
M3 86 GASTRITIS NO HLO 6.067 5.12 LL 11,12 AG GG CT TT GG AT AA
M387 NORMAL 6.251 3.79 LS 11,11 GG GG CC TT GG TT AA
M3 89 NORMAL 5.121 3.726 LS 12,12 AA AG TT CT GG AA AG
M3 90 GASTRITIS NO HLO 6.347 6.19 LL 11,11 GG GG CC TT GG TT AA
M391 FORMER HLO GASTRITIS 6.219 4.187 LS 11,13 AG AA CT CT AG AT AG
M3 92 NORMAL 5.872 3.708 LS 11,12 AG AA CT CT AG AT AG
M3 93 FORMER HLO GASTRITIS 6.363 3.57 LS 11,12 AG AA CT CT AG AT AG
M3 94 NORMAL 5.767 5.522 LL 11,13 AG GG CT TT AG AT AA
M3 95 GASTRITIS NO HLO 3.596 3.067 SS 12,12 AA AA TT CC AA AA GG
M3 96 NORMAL 6.25 6.099 LL 11,11 GG GG CC TT GG TT AA
M397 NORMAL 6.125 3.612 LS 11,12 AG AA CT CT AG AT AG
M3 98 HLO GASTRITIS 4.058 3.675 SS 11,12 AG GG CT TT GG AT AA
M3 99 HLO GASTRITIS 6.026 3.678 LS 11,12 AG AA CT CT AG AT AG
M400 NORMAL 3.894 3.789 SS 12,12 AA AA TT CC AA AA GG
M401 FORMER HLO GASTRITIS 4.264 3.76 SS 12,13 AA AA TT CC AG AT GG
M402 NORMAL 6.094 6.094 LL 11,11 GG GG CC TT GG TT AA
M403 FORMER HLO GASTRITIS 6.37 5.966 LL 11,11 GG GG CC TT GG TT AA
M404 FORMER HLO GASTRITIS 6.326 5.925 LL 11,11 GG GG CC TT GG TT AASurvey
number
Categorisation MUCI  TR size (Kb) TR size L/S CA repeat g/a SNP THBS3 PCR1 THBS3 PCR2 rs2070803 497 SNP KCP2 EFNA1
M406 NORMAL 4.279 3.804 SS 12,13 AA AA TT CC AA AA GG
M407 NORMAL 4.312 3.757 SS 12,13 AA AA TT CC AA AA GG
M408 NORMAL 6.023 5.267 LL 11,13 AG GG CT TT GG AT AA
M409 HLO GASTRITIS 6.122 5.974 LL 11,11 GG GG CC TT GG AT AA
M410 NORMAL 6.097 3.802 LS 11,12 AG AG CT CT AG AT AG
M411 NORMAL 6.167 3.815 LS 11,12 AG AG CT CT AG AT AG
M412 GASTRITIS NO HLO 8.822 6.371 LL 11,11 GG GG CC TT GG TT AA
M415 FORMER HLO GASTRITIS 5.685 3.8 LS 12,12 AG AG CT CC AA AA GG
M416 GASTRITIS NO HLO 6.294 6.294 LL 11,11 GG GG CC TT GG TT AA
M417 HLO GASTRITIS 3.055 2.931 SS 12,12 AA AA TT CC AA AA GG
M418 NORMAL 4.277 3.788 SS 12,13 AA AA TT CC AG AT AG
M419 NORMAL 3.848 3.73 SS 11,11 GG GG CC TT GG TT AA
M420 GASTRITIS NO HLO 6.358 3.863 LS 11,12 AG AG CT CT AG TT AGReferences
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